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Preface
This thesis is the result of my own work and includes nothing which is the outcome of
work done in collaboration except as declared in the Preface and specified in the text.
It is not substantially the same as any that I have submitted, or, is being concurrently
submitted for a degree or diploma or other qualification at the University of Cambridge or
any other University or similar institution except as declared in the Preface and specified in
the text. I further state that no substantial part of my thesis has already been submitted, or, is
being concurrently submitted for any such degree, diploma or other qualification at the
University of Cambridge or any other University or similar institution except as declared in
the Preface and specified in the text.
It does not exceed the prescribed word limit for the relevant Degree Committee.
Some laboratory work was performed under my academic supervision by undergraduate
students Joshua Cozens and Luke Vinter, and by masters student Tayla Gordon. This is
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Summary
Many Bacilli form dormant structures, spores, which routinely survive physical, chemical
and biological challenge. How do spores encapsulate their contents, and could it be possible
to mimic or adapt them to make better drug products?
Key spore component 2,6-dipicolinic acid (DPA) is necessary for protein stability, but
investigation of its role is confounded with that of water content. Tests replacing DPA with
chemical analogues were not successful, but led to the novel approach of doping spores with
extra DPA.
Various Bacillus species, in the main B. subtilis and B. thuringiensis, have been engineered to
produce, for the first time, fragments of a humanized monoclonal antibody: kindly provided
by Medimmune. It is possible to produce antibodies inside the spore core.
This work proposes for the first time that such therapeutic spores might lack an outer coat,
and demonstrates that antibody production continues. It is understood they continue to
resist most challenges including wet heat, which damages proteins, yet they become
susceptible to lysozyme. Such spores, further developed to lyse in presence of intestinal,
though not gastric fluid, may have use in oral delivery.
Cry1Ac of B. thuringiensis offers an alternative; large protein crystals are produced during
sporulation. Here, various fluorescent fusions that maintain fluorescence over months were
developed and investigated in detail. For the first time, fluorescent antibody crystals were
produced. In addition to drug delivery, these fusions offer a novel approach to crystallization
of intransigent proteins, for structural studies.
This work shows that it might be feasible to use spores as pharmaceutical formulations. A
number of challenges remain: from fabrication, through limits of current good
manufacturing practice, to engineering biology to protect the environment and commercial
interests. Bacterial spores have for the past century and a half been known for their
dormancy, and it’s about time engineers took advantage.
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CHO Chinese hamster ovary
CLE cortex lytic enzyme




DLS dynamic light scattering
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GALT gut associated lymphatic tissue
gDNA genomic DNA









KAM Klenow assembly method
LB lysogeny broth
LDS lithium dodecyl sulphate
L–ASA L–aspartate semi-aldehyde
mAb monoclonal antibody





NMR nuclear magnetic resonance




ORF open reading frame
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PA picolinic acid
PAGE polyacrylamide gel electrophoresis
PCR polymerase chain reaction
PD-L1 programmed death–ligand 1
PDB Protein Data Bank
PDM plasmid DNA medium







RBS ribosome binding sequence
RHAF Hadlaczky Alföldi Fodor
ROS reactive oxygen species
SASP small acid-soluble protein
SAXS small angle x-ray scattering
SC liquid suspension concentrate
scFv single chain variable fragment
SDS sodium dodecyl sulphate
SLS static light scattering
SM Sterlini-Mandelstam
SNB supplemented nutrient broth
SOB super optimal broth
SP spore photoproduct
SXO single crossover
TAE tris acetate EDTA
TBS tris-buffered saline
TEM transmission electron micrograph
TMB 3,3',5,5'-tetramethylbenzidine
tRNA transfer RNA
TSB tryptone soy broth
UC undercoat
UV ultraviolet
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YFP yellow fluorescent protein
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Nucleic acid codes






N aNy ✓ ✓ ✓ ✓ ✓
. none
K Keto ✓ ✓ ✓
Y pYrimidine ✓ ✓ ✓
S Strong ✓ ✓
W Weak ✓ ✓ ✓
R puRine ✓ ✓
M aMino ✓ ✓
B not
Adenine
✓ ✓ ✓ ✓
D not
Cytosine
✓ ✓ ✓ ✓
H not
Guanine
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Amino acid codes




D Asp Aspartic acid
















X — Unknown or other
Y Tyr Tyrosine
z Glx Glutamine/glutamate
Source: IUPAC-IUB Comm. on Biochem. Nomencl. (1968).




Ω Ohm Electrical resistance
bn billion
bp base pair Nucleotides
℃ degree centigrade Temperature
cfu colony forming unit Microbial viability











mol% percentage by mole Proportion
nt nucleotide Nucleotides
Pa Pascal Pressure
PSI pound per square inch Pressure
rpm revolution per minute Rate of rotation
s second Time
% v/v percentage by volume Proportion
% v/w volume percentage by total mass Proportion
% w/v mass percentage of total volume Proportion
% w/w percentage by mass Proportion
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Is it possible to use bacterial spores for drug delivery? Bacillus species form dormant
structures, which very effectively protect their contents from a range of physical and
chemical stresses — and this is an attractive feature of a biopharmaceutical formulation.
What follows is an exploration of this idea, from a study of the scientific literature
concerning its context, through patent literature on applications, laboratory investigation
into some of the possibilities, and a discussion of the gap between the outcome of such
research and having a finished product that could save lives.
Introduction
Chapter 1
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Bacilli and Clostridia differentiate into endospores to become the most robust biological
structures known (figure 1.1). They lie dormant for millennia, i.e. with no metabolic
activity, yet throughout that time they passively sense their environment. Within minutes of
the environment becoming hospitable, they germinate, once more becoming growing,
vegetative cells (Abel-Santos, 2012; Setlow, 2014).
The convention for naming proteins and genes is as follows: proteins begin with an upper
case letter and are typeset as the surrounding text; genes begin with a lower case letter and
are emphasised (e.g. Protein, gene).
Bacterial endospores1.1
Figure 1.1: Phase contrast micrographs of sporulating B. subtilis. (a) shows vegetative cells, 3 h after
inoculation; (b) shows a sporangium with forming forespores (4 h); (c) shows bright forespores (5 h); (d) shows
free spores and some debris (25 h) The bright regions of the spores have high refractive indices, indicating low
water content. Spores were produced using the synchronous resuspension technique. Scale bars are
5 µm × 1 µm.
a b
c d
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In a review of bacterial endospore coats, McKenney et al. (2012) described other dormant
bacterial ‘resting cells’. Metabacterium polyspora forms two (usually) and up to three spores per
cell. For Streptomyces, exospores form from a multinucleate cell at the tip of a hypha.
Myxococcus and some cyanobacteria form myxospores and heterocysts respectively, which
involve no cell division. The authors commented that though desiccation resistance is
common, resistances to other challenges vary. Like fungal spores and plant spores, these
various resting cells shall not be considered further.
Bacillus species are allochthonous. Much of their life cycle is spent as saprophytes, though
there remains much that is unknown about their behaviour in soil. The range of habitats of
sporeformers extends beyond just soil. A recent paper from a multidisciplinary team
reviewed, in part, the ecology of B. anthracis, reporting its ability to induce germination of
grass seeds by itself germinating nearby; this behaviour is typically shown by B. cereus, yet
the authors suspect B. anthracis has evolved to take advantage of the subsequent arrival of
grazers (Carlson et al., 2018). Bacillus species have been isolated from within walls of
buildings, and from rocks — both at Earth’s surface and up to 3 km below. It is not clear to
what extent this corresponds to cultures growing and sporulating within the rocks versus
spores filtering through the pores (Nicholson, 2002). The remainder of the life cycle often
includes passage through gastrointestinal systems of larger organisms. Bacillus species are
frequently found within mammalian gut flora, where sporulation is critical to development
of the GALT (gut associated lymphatic tissue) required for immune sampling (Tam et al.,
2006).
Spores’ resistance to typical sterilization techniques has inspired much research. John Tyndall
lends his name to one technique to kill bacterial spores. Tyndallization encourages spores to
germinate and uses heat to kill the subsequently-vulnerable vegetative cells (Gould, 2006).
The finest line on the industrial approach to spores must surely go to Grahame Warwick
Gould, who wrote:
‘Newer’ processes such as treatment with ionizing radiation (first proposed in
1905) and high hydrostatic pressure (first proposed in 1899) may be introduced if
consumer resistance and some remaining technical barriers could be overcome.
― Gould (2006)
Spores and humans1.1.1
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Some bacterial spores are a desirable presence, in agriculture. B. thuringiensis is widely used as
a biopesticide for its highly specific pathogenicity (Sansinenea, 2012), though its shelf life,
stability and ease of production and application no doubt played a role in its popularity. The
role extends beyond agriculture, to forestry and mosquito control. The toxic components
are the Cry and Cyt proteins (see section 1.3.3).
Spores as insecticides1.1.2
The ABE process is not the only example of sporeformers in industry. Bacillus spores have
themselves been used to test equipment and processes designed to disinfect or sterilize;
B. subtilis (and even the opportunistic pathogen B. cereus) is used as a probiotic; and the vital
agricultural role of B. thuringiensis is discussed. A comprehensive, and not quite dated, review
of Bacillus species as industrial fermenters is by Schallmey et al. (2004).
Duc et al. (2003) reported the first example of a spore as a vaccine delivery system, and that
work has continued, some as part of the doctoral thesis of Lin (2017) from the Christie
group. The pitch is straightforward: immune sampling in the gastrointestinal system,
predominantly at Peyer’s patches, identifies pathogens and raises an adaptive immune
response with greater efficacy against future mucosal infection than does injection. A spore
would both protect the antigens through the stomach and act as an adjuvant, enhancing the
immune response, once it reaches its destination.
Recently Martine Vandermarlière (2016) presented her work for amatsiQBiologicals on
production of recombinant spores. The specific focus was cGMP (current good
manufacturing practice): a framework for ensuring that the quality of a biopharmaceutical
product meets the requirements of regulators and patients. The company has been working
on a multidisciplinary project, aiming to use B. subtilis spores as a C. difficile vaccine,
CDVAX (Cutting, 2013).
Spores in industry1.1.3
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Therapeutic proteins, or biologics, can drastically improve health and quality of life of
patients with many diseases and conditions. They are often valuable because of their
multifunctional mechanisms (e.g. immuno-oncology, figure 1.2). However, there are difficult
formulation challenges: these proteins can be difficult to produce correctly, and maintain
their quality during formulation, transport and storage. It matters that the proteins have their
correct form, as damaged proteins vary in behaviour — from ineffective, to acutely harmful.
Therapeutic proteins1.2






Figure 1.2: Therapeutic binding proteins, such as antibodies, disrupt processes which cause disease. ① The
binding protein binds a target. ② The protein recruits an effector (such as a macrophage) or prevents other
molecules from binding the target. For example, in immuno-oncology, antibodies flag cancerous cells and the
ADCC (antibody dependent cell-mediated cytotoxicity) response marks them for phagocytosis, by
macrophages.
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The state of the art is as follows: mammalian cell lines produce proteins that are extracted,
purified, and concentrated as a solution that needs to be stored below 4℃. That’s often not
possible, and the protein must be lyophilized (freeze-dried) and reconstituted directly before
injection into a patient. This process is particularly complicated — and (importantly) it is
impossible to guarantee quality on reconstitution.
A mAb (monoclonal antibody) is a Y-shaped macromolecule, an immunoglobulin
(figure 1.3), which binds with one end (paratope) to specific targets (epitopes) on antigens:
typically pathogens or receptors. From a formulation perspective, they can be considered
amphoteric polyelectrolytes: globular proteins which can aggregate to cause inactivation
and immunogenicity (Arzenšek et al., 2012). The production complexities required to avoid
such an outcome is a major factor in the costs of mAbs (monoclonal antibody). Those costs
can be prohibitive. For example, the PD-L1 (programmed death–ligand 1) inhibitor
durvalumab (MedImmune) is estimated to cost $180 000 per patient per year, for a year of
fortnightly treatments (Optum Inc., 2017).
There are alternatives to mAbs. Antibody fragments such as scFvs (single chain variable
fragments) lack effector functions (such as for ADCC), making them a good choice for
interference with receptors. Newer alternatives, such as the camelid VHH antibodies’ single
domain variable fragments, nanobodies, are small enough for fast renal clearance (they are
∼25 kDa and the upper kidney threshold is ∼50 kDa, De Meyer et al., 2014, see figure 1.4).
These face many of the same production challenges, though, as full IgGs.
High production costs are in part a consequence of the industry standard, in which CHO
(Chinese hamster ovary) cells produce antibodies in fermentors. There is much research on
using bacteria as fermenters, instead.
Monoclonal antibodies1.2.1
The production of proteins, whether by bacteria or higher organisms, is termed expression.
Escherichia coli are the most common bacterial expression host, but others, in particular the
Gram-positive Bacilli, produce greater protein quantities, and with easier downstream
Bacterial production of therapeutic proteins1.2.2
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Figure 1.3: Cartoon representation of an IgG (immunoglobulin G). The light chain contains two domains, the heavy
chain four. The variable domains, Fv (two sets of two, one per branch), contain the paratope, which recognises the antigen
(epitope). The branch made from the light chain and corresponding CL and CH1 heavy chain domains is known as the
Fab domain. The branch made from the pairs of CH2 and CH3 heavy chain domains is known as the Fc domain, and it
is this which both binds Protein A and recruits effector functions.
processing (Terpe, 2006). Bacterial expression systems benefit from the fast, easy growth on
cheap substrates and relatively simple genetics of bacteria, as compared with eukaryotes (in
particular, mammalian cells).
For proteins expressed by E. coli, the chosen mechanisms usually deposit the product in the
cytoplasm (Terpe, 2006). The periplasmic space is an alternative, which is more suitable for
proteins requiring oxidized cysteines; osmotic shock or cell wall permeabilization then
release proteins from the periplasm.
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mammalian IgG camelid IgG
scFv scFv nanobody
Figure 1.4: Nanobodies are to camelid heavy chain antibodies as scFvs are to typical mammalian IgGs. The single
domain to the lower right is the VHH domain, the nanobody. Unlike for the individual variable domain fragments of
IgG, this single domain is sufficiently stable by itself for practical use.
Bacillus species offer an alternative. The Bacilli, being Gram-positive, secrete (extracellular)
protein directly into their medium, which usually suits industrial production better than the
periplasmic expression of E. coli (Schallmey et al., 2004), with titres of up to 1.5 gL⁻¹ in
B. megaterium (Biedendieck et al., 2011). An inherent advantage over E. coli is that Bacillus
species produce no lipopolysaccharide.
B. megaterium has been shown to produce a higher quantity of higher quality antibody
fragments than E. coli (Jordan et al., 2007); in the absence of lipopolysaccharide, such
proteins were also simpler to purify. Protein production brings this particular ‘big beast’ to
the fore (Biedendieck et al., 2011; Korneli et al., 2013). At 4 µm long, cells have a volume
100× that of E. coli; indeed single cell analysis is relatively straightforward as B. megaterium
cells are big enough for flow cytometry. The main factors that make B. megaterium a great
host for recombinant proteins include the ability to maintain plasmids without selection,
lack of (alkaline) proteases and endotoxin, high yields of intracellularly folded protein and
high protein export capability. B. subtilis is another important industrial Bacillus (Liu et al.,
2013).
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Bacteria as a whole are at a disadvantage when it comes to post-translational modification.
Even bacteria that glycosylate their proteins do so at different residues, and with different
moieties, to mammalian cells. With antibodies, one can customise the Fc domain to render
N-glycosylation unnecessary (Robinson et al., 2015).
Overall, the advantages in using bacteria, especially Bacillus species, for producing
therapeutic proteins are significant. Production is only part of the challenge, though;
downstream processing is just as important. The purpose of downstream processing is to
recover the protein from its source, and formulate it such that it can reach the patient in
good condition.
The main purpose of a biopharmaceutical formulation is to protect the therapeutic protein it
contains. Proteins are chains of amino acids, folded in three spatial dimensions to produce
highly specific shapes. This 3D conformation is mediated by interactions between residues,
and with the environment. Solvents, other proteins, co-solutes and interfaces can stabilize or
destabilize that structure. At low salt concentrations, electrostatic forces dominate all these
interactions, but at higher, physiologically relevant salt concentrations, short range non-
electrostatic ion forces (including polarizability) dominate behaviour. The effect is non-
linear, meaning conventional DLVO (Derjaguin Landau Verwey Overbeek) theory fails to
predict interactions, and like protein folding, protein-solvent-solute interactions are hard to
model (Boström et al., 2005).
These effects all pose challenges, for which formulation scientists have many techniques to
overcome.
Failings of formulations1.2.3
A drug product is more than just the API (active pharmaceutical ingredient) — for example,
a therapeutic protein. Fillers, buffers, antimicrobials and viscosity modifiers (e.g. binders &
disintegrants) make a product suitable for patients. These excipients must protect the API
during storage, transport and delivery, affecting neither pharmacokinetics nor efficacy. In
practice, these goals often contradict. Storage during transit imposes requirements on
stability, e.g. a limit on vibration as shear and cavitation enhance damage at interfaces
(Manning et al., 2010); consequently the producer will often freeze-dry the product for
How to stabilize a protein1.2.4
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reconstitution moments before delivery. There are harms associated with the large changes
of local environment on lyophilization and reconstitution (Manning et al., 2010), which the
drug manufacturer cannot always quantify; this loss of control over quality is a problem for
producers.
The most valuable APIs are the mAbs (see section 1.2.1). The hinge region is susceptible to
non-enzymatic, non–metal ion catalysed hydrolysis (Cordoba et al., 2005). Glutamate is a
common N-terminal residue on the light chain; pyroglutamic acid forms from nucleophilic
attack of the N-terminal amine on the side chain carbonyl. This degradation increases
during storage. Tryptophan photooxidation has been shown to reduce immunoglobulin
activity, as does disulphide scrambling of cysteine residues. Oxidation in general is
particularly problematic as it has been known to destabilize immunoglobulin conformations
and enhance aggregation (Manning et al., 2010). Such outcomes can occur without
oxidation — antibodies adsorb on plastic, complicating processing, and aggregate
destructively on freeze-thaw. In addition, the importance of the problem of reversible self-
association is increasing in line with prevalence of sub-cutaneous formulations. These
require a mass of antibody greater than 100 mg in a volume smaller than 2 ml,
i.e. > 50 mg ml⁻¹ (Dobson et al., 2016) and so excipients which can prevent such degradation
are in high demand. Arginine and glutamate allow proteins to remain soluble at
concentrations an order of magnitude above their previous solubility limit (Golovanov et al.,
2004).
It is illustrative to consider how formulation scientists measure protein quality. A number of
techniques assess antibody structure; DLS (Dynamic Light Scattering), SLS (static light
scattering), DSC (differential scanning calorimetry), VPO (vapour phase osmometry) and
SAXS (small angle x-ray scattering) are preferred (C. F. van der Walle, personal
communications, 2016). The (high throughput) scattering techniques investigate
aggregation; when the aggregation properties of the correctly folded antibodies are known
one can infer the nature and variation in structure of those proteins measured. With VPO
one infers a change in water activity, also determined by antibody structure, and DSC
identifies energies of interactions as it scans the temperature range (Arzenšek et al., 2012;
Boström et al., 2005; Schneider et al., 2011).
Quantifying protein quality1.2.5
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With these techniques, formulation scientists can measure the quality of proteins they have
produced, and thus infer the consequences for a whole drug product itself. These
measurements and inference techniques do not all transfer beyond the established
formulation techniques; they certainly do not transfer across to using spores to formulate
therapeutics. In order to understand the ways in which a spore-based biopharmaceutical
may differ, one must consider the biology of the spores themselves.
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The morphology and behaviour of spores has fascinated researchers for over a century. As
one example, the model organism B. subtilis is particularly well studied, and its genome well
characterized (Losick, 2015). Though there are significant differences across the genera,
much has been conserved. This section shall review features of spore-forming bacteria, and
their spores, that are relevant to designing therapeutic formulations.
Spore biology1.3
Prokaryotes, especially bacteria, and especially B. subtilis, are highly amenable to genome
editing. It is straightforward to introduce mutations — insertions, deletions, combinations
thereof — by transforming cells with suitable DNA (linear or as circular plasmids). Many
mutations rely on native promoters, which, when bound by σ factors (e.g. the vegetative cell
cycle factor σA), lead to transcription of the attached operons. There are also heterologous
promoters: most importantly the inducible promoters, which cause transcription in the
presence of a specific chemical (the inducer). Harwood & Cutting (1990) have provided a
list of techniques for working with Bacillus species.
Such biotechnological work, like much work that uses B. subtilis as a model organism,
typically considers the vegetative cell cycle exclusively.
Sporeformers in biotechnology1.3.1
Sporulation is the process by which vegetative cells differentiate to become endospores.
Germination is the opposite: the process by which spores resume a vegetative life cycle.
All endospores formed by species in the genera Bacillus and Clostridium have the same
minimum structure of core, inner membrane, cortex, and coat (figure 1.5). The core
contains the genome, half the spore’s proteins, the ribosomes, tRNAs, a pool of 3-PGA and,
complexed with Ca²⁺ and other divalent ions, 2,6-DPA (dipicolinic acid) (figure 1.6). The
critical biological macromolecules are protected; a spore must preserve in its core all the
functional components it needs to once again become a vegetative cell (Bassi et al., 2012).
The sporulation-germination cycle1.3.2
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Figure 1.5: The structure of a Bacillus megaterium spore. The TEM (transmission electron micrograph) on the left is a
B. megaterium spore (Source: G. Christie, personal communications, 2013–2019). The expanded diagram (derived
from the diagram of mature spores of B. thuringiensis, Bechtel & Bulla, 1976) shows the layers of the spore, from inside
to out (left to right). Abbreviations in the diagram: CO, core; IM, inner membrane; PW, primordial cell wall; C, cortex; OM,
outer membrane; IMC, incorporated mother cell cytoplasm; LC, lamellar spore coat; OC, outer spore coat; E, exosporium.
The scale bar is 100 nm.
Figure 1.6: The chemical structure of DPA (2,6-dipicolinic acid).
Sporulation
Sporulation is the process by which cells, anticipating unsustainable conditions, use the last
of their free energy to form these dormant survival structures. For B. subtilis and
B. megaterium, this takes roughly twelve hours. The layers of the spore structure are
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synthesized by both forespore and mother cell, which communicate via channels (Camp &
Losick, 2009). The properties of the environment significantly affect the properties of the
spores produced (Xu Zhou et al., 2017).
The sporulation process is shown in figure 1.7; see figure 1.1 for phase contrast micrographs
of this process in B. subtilis. Sporulation is initiated through nutrient stress, at a sufficient
population density, and at the appropriate point in the vegetative cell cycle (Errington,
1993). Cells aggregate as a sporangium. Spo0A and σH promote transcription of the initial
sporulation genes. The early mother cell sporulation genes are controlled by σE; as the
forespore begins to form, the genes there are controlled by σF. The engulfed forespore
begins to see σG-dependent transcription. This includes the SASPs (small acid-soluble
proteins), and GRs (germinant receptors). Synthesis of the cortex, and then the coat, begin
during these stages. Finally, σK controls expression in the late mother cell. At this point,
DPA is synthesized, in the mother cell, and transported into the forespore. The forespore,
having acquired the properties of the mature spore, is released from the mother cell.
The forespore begins its process of isolating from the mother cell at stage I and
compartmentalizes fully by stage III, a point at which it is neither fully formed nor contains
sufficient nutrients to complete sporulation. As a result there must be some mechanism by
which free energy is supplied from the mother cell, and so Camp & Losick (2009) proposed
what they called the feeding tube model. Subsequent work has indicated genes and channels
which might be involved but it is not yet clear how to use this research to increase forespore
protein productivity (Camp et al., 2011; Crawshaw et al., 2014)
The various stages are illustrated too for B. thuringiensis by Young & Fitz-James (1959),
reproduced here as figure 1.8. These species produce crystal proteins (see section 1.3.3) in
the mother cell. There are binding sites for both the mother cell σE and σK factors in the
promoter of cry1Aa, from B. thuringiensis HD-1 (Adams et al., 1991).
Crops of spores — even when strictly isogenic, and produced under the same conditions —
are heterogeneous (Setlow et al., 2012). In addition to potential microenvironments and
quorum effects, stochastic variation is significant, especially when there may only be one or
two molecules of mRNA per gene within a sporulating cell. GRs make a good example; the
number of receptors for a specific nutrient in mature spores may vary three to four times,
which can have a dramatic effect where there are only tens of receptors present in the first
place. As a result, even in identical environments, spore populations will show
heterogeneity.
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Figure 1.7: A summary schematic of the sporulation stages. 0, vegetative cells, σH active; 0–I, σE active II, cell
separated by septum, σF; III, engulfment of pre-spore, σG in forespore; IV, cortex synthesis begins; V, coat synthesis
begins, σK in mother cell; VI, maturation, acquisition of resistance properties; VII, release. The genomic DNA is shown
at each stage until stage VI, where the dashed outline of the spore core is shown in its place. Original image from Piggot
& Coote (1976).
Figure 1.8: A schematic of the sporulation process for B. thuringiensis subsp. alesti. Cells proceed from A–M, and the
numbers to the lower right of each spore correspond to hours following inoculation at 30℃. The chromosome divides,
resulting chromatids condense and then separate into the forespore (left) and mother cell. A bipyramidal crystal initially
forms at the forespore (H). The result is a phase bright spore, with a loose-fitting exosporium, and a protein crystal.
Reproduced from Young & Fitz-James (1959), who knew this strain as B. cereus var. alesti.
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Some spores — typically 1 to 3% (Ghosh et al., 2009) — are just hardier, in that they show
greater resistance to heat and less sensitivity to germinants. Spores demonstrating the latter,
termed superdormant, will resist Tyndallization-type approaches (see section 1.1.1; though
these spores are still viable — they germinate in response to dodecylamine and Ca-DPA).
For example, while spores of B. anthracis resist antibiotics that easily kill B. anthracis cells,
heterogeneity within the spore population means that treatment must be timed to ensure
cells are exposed to a lethal, rather than a selective, dose. Properties of the spores which vary
include size (± 25%), composition, staining behaviour, water content, requirement for heat
activation and germination response (Setlow et al., 2012).
The heterogeneity extends beyond variation within a spore population. Not all cells in a
population will sporulate, and some spores will germinate immediately. In the laboratory,
spores must usually be washed free of nutrients, cell debris (sporangia) and any remaining
vegetative cells (Church et al., 1954), before analysis.
Germination
Though spores resist many challenges, under specific conditions they give up their resistance
and germinate, resuming the vegetative cycle. For B. subtilis and B. megaterium, germination
and outgrowth together take close to three hours; the initial phase darkening (hydration)
lags the addition of nutrients (termed germinants) by 5–25 min and then takes just 30 s to
complete (Abel-Santos, 2012; Setlow et al., 2012). A variety of factors can induce
germination, through a number of routes (table 1.1, sourced from Setlow, 2014; Shah et al.,
2008). In germination, the IM permeability increases. The stores of H⁺, K⁺ and Na⁺ are
released, then all Ca-DPA. The cortex lyses, and over a matter of minutes the water content
of the spore core rises from 25–55% w/w to 80% w/w (c.f. 75–80% w/w for vegetative cells,
Abel-Santos, 2012).
Spores commit to germination — they still germinate after germinant removal. Even pulses
of germinants, individually insufficient to trigger germination, have an additive effect
(Setlow, 2016). Commitment is when the act of blocking GRs (e.g. with competitive
inhibition, or acidification) no longer prevents germination; this step precedes Ca-DPA
release by minutes. Setlow (2014) suggests that it is the IM that changes, on commitment.
Heat, too, reversibly promotes GR-dependent germination — this is termed heat activation.
The next step is the aforementioned release of DPA. SpoVA appears to form a Ca-DPA IM
channel. SpoVAC is mechanosensitive (Velásquez et al., 2014); SpoVAEa and SpoVAD are
IM associated, likely on the outer IM surface; and SpoVAD binds DPA (Setlow, 2014). In
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Table 1.1: Factors that induce germination, and their mechanisms. Abbreviations: GR
(germinant receptor), CLE (cortex lytic enzyme).
Factor Mechanism
Nutrients GR activation
150–250 MPa hydrostatic pressure GR activation
Ca-DPA CwlJ, a CLE
Dodecylamine SpoVA channel
500–1000 MPa hydrostatic pressure SpoVA channel
Peptidoglycan fragments PrkC, a Ser/Thr protein kinase
principle a channel, such as this, could permit other small molecules, but likely candidates
AMP (adenosine monophosphate), Pᵢ (inorganic phosphate) and 3-PGA (phosphoglyceric
acid) remain in the spore during early germination. The mechanism by which the channel
operates remains a research problem.
Another mystery concerns the behaviour of the CLEs (cortex lytic enzymes), which degrade
the cortex following DPA release. The Bacillus enzyme CwlJ is activated by Ca-DPA,
though this mechanism too is unknown (Paidhungat et al., 2001). It is neither clear whether
a direct chemical reaction causes the activation, nor how activation is suppressed during
spore maturation. The precise mechanism of the other CLE in Bacillus, the lytic glycosylase
SleB, remains a mystery too, despite the publication of crystal structures for several Bacilli
(Setlow, 2014).
What follows cortex lysis are rehydration of the core, resumption of enzymatic activity —
including ATP (adenosine triphosphate) synthesis and degradation of the SASPs (small acid-
soluble proteins) — and finally, outgrowth of the new vegetative cell (Moir, 2003).
⁂
The sporulation-germination cycle as a whole allows sporeformers to survive challenging
local conditions, through dormancy, and resume their vegetative state when conditions are
more favourable. From an evolutionary perspective, this behaviour has allowed spore-
forming species to survive existential threats.
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The highly specific, insecticidal component of crystalliferous strains of B. thuringiensis is the
Cry crystal protein. This inclusion is formed in the mother cell and usually released from the
sporangium in a ratio of one crystal per spore (Sansinenea, 2012) although they can form
within the exosporium (Zhu et al., 2011) or even as an alternative to the spore (Deng et al.,
2014). Agaisse & Lereclus (1996) review the key factors enhancing crystal production. The
full length crystal structure of Cry1Ac (figure 1.9), produced by B. thuringiensis subsp.
kurstaki HD-73, was published by Evdokimov et al. (2014).
Crystal proteins1.3.3
Figure 1.9: The annotated crystal structure of Cry1Ac. The majority of interactions are between residues in
the protoxin domains, IV–VII. The toxic core (the N-terminus) has the insecticidal properties. Only recently
have researchers solved the full structure, in part as previous research focussed exclusively on the toxin.
Technically, the crystals are of a cysteine poor variant, developed to overcome the ‘pernicious’ aggregation of
the native protein. (Reproduced from Evdokimov et al., 2014).
Highly specific toxicity
Cry toxins bind highly (species) specific–receptors, (hetero-)oligomerize, change
conformation to penetrate the epithelial plasma membrane, and then insert — opening a
non-selective ion channel and killing gut cells (Pardo-López et al., 2013). The three-domain
Cry toxins are highly specific, affecting neither vertebrates (including humans) nor plants.
There are two-varieties: 65 kDa and 130 kDa; the latter has a C-terminus that gut proteases
cleave. (In the case of engineered, Cry-containing Bt-corn, plant enzymes perform this role).
The active toxin is ∼600 residues, preceded by a 20–60 amino acid N-terminal fragment
(possibly a signal peptide) and the overall structure is highly conserved. Knowles & Ellar
(1987) propose the toxins form a non-selective ion channel, leading to osmotic death.
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Indeed the Cry toxins hetero-oligomerize to form a membrane penetrating structure (the
“umbrella model”, Pardo-López et al., 2013); this typically depends on cadherin protein on
the gut epithelium of sensitive organisms. Not all Cry variants behave like this. Cry4Ba can
be proteolytically activated to a pore-forming structure in vitro, without cadherin receptors,
and Cry1A can be engineered to oligomerize similarly (Soberón et al., 2007). Furthermore,
Cry proteins and the other group of (non-crystal) toxins, the Cyt proteins, are synergistic:
mechanistically, Cyt1Ac has been shown to induce oligomerization of Cry11Aa (Pardo-
López et al., 2013).
Vegetative cells of B. thuringiensis strains, like B. cereus, can produce β-exotoxin (Sansinenea,
2012). This chemical analogue of adenine, a heat-stable neurotoxin, can interfere with RNA
synthesis across species. In one study, five out of every six crystal-toxin producing strains
also produced β-exotoxin (Perani et al., 1998). For a strain to be commercially viable in
North America and Europe, it must not produce β-exotoxin (Glare & O’Callaghan, 2000;
via Palma et al., 2014). Similarly, B. thuringiensis can produce enterotoxin and there have
been reports of food poisoning in humans (Bishop et al., 1999; Johler et al., 2018). Many
cases, thought to be caused by B. cereus, may have been thus misdiagnosed.
High expression
Agaisse & Lereclus (1995) posed a question in the title of their paper: How does Bacillus
thuringiensis produce so much insecticidal crystal protein? Crystal proteins make up to
20–30 wt% (dry basis) of some spore strains (Agaisse & Lereclus, 1996). The factors which
encourage such high expression have utility beyond these species and these proteins. The
high yields mean producing Cry proteins industrially, at scale, is relatively straightforward.
Downstream processing
Following fermentation, the crude B. thuringiensis liquor is concentrated in an evaporator,
disc-stack centrifuge or ultrafiltration unit. The resulting slurry is typically formulated as an
SC (liquid suspension concentrate) e.g. Vectobac® 600L (Valent Biosciences Corporation)
or, following spray-drying, as a WP (wettable powder) e.g. DiPel® WP (Valent), WG
(wettable granule) e.g. DiPel® 2X DF (Valent) or OF (oil flowable) liquid/emulsion
e.g. Thuricide® 48LV (Bonide) (Brar et al., 2006; Bryant, 1994). Choice depends on
delivery method: for aerial delivery high concentration OF formulations reduce evaporation;
dry formulations reduce transport costs and have longer shelf lives; WG formulations are
often easiest to process in the field. Recent advances include encapsulation, helpful for
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aquatic use, and direct waste-water sludge formulation (Brar et al., 2006). Industrial
preparations of B. thuringiensis crystals usually contain spores too, partly as it is not cost
effective to purify the mixtures and partly as there is a synergistic effect, possibly due to
spores germinating during transit through the larval gut (Crickmore, 2006). One
consequence is that though there are established, industrial scale processes for B. thuringiensis
production, they do not extend to crystal purification.
⁂
The crystalliferous strains of B. thuringiensis occupy a remarkable evolutionary niche, of
which only farmers have so far taken advantage. The factors which make such spores a
useful insecticide also make for capable expression systems. Not all of that utility is due to
the crystals; the resistance of spores of B. thuringiensis to challenges in their environments is
important, too.
Clearly, spores do not give up their dormancy simply.
― Setlow (2014)
Bacterial spores, in their dormant state, resist: a) the denaturing effects of wet heat; b) DNA
damage caused by dry heat, desiccation, freeze-drying, ionizing radiation and UV light; c)
oxidation due to dry heat and chemical attack; d) physical disruption due to pressure
(positive and vacuum) or shear; and e) other chemical and biochemical damage from acids,
bases, ionophores, organic solvents, radicals and enzymes (Aronson, 2012; Pedraza-Reyes et
al., 2012).
The spore’s remarkable properties are due to its unique structure (see figure 1.5). For many
species the outer layer is the hydrophobic, flexible exosporium that provides an outer barrier
(especially to ionophores) and can help the spore adhere to hydrophobic surfaces (Aronson,
2012; Xu Zhou et al., 2017). In B. anthracis it is the exosporium which holds the superoxide
dismutase and arginase needed for spores to survive inside macrophage lysozomes (Abel-
Santos, 2012; Mock & Fouet, 2001). However, the exosporium structure is highly porous,
and so for most resistance properties, the structural basis begins with the coat.
Spore survival1.3.4
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A proteinaceous coat
The coat is a ‘reactive armour’ (Bassi et al., 2012) comprising at least 70 proteins (McKenney
& Eichenberger, 2012). Together, these provide structure, flexibility, strength and, critically,
porosity to small molecules (in particular: water and germinants, including DPA,
2,6-dipicolinic acid). The variation in coat composition among (and even within) species is
enormous, yet the main structural features — the distinct lamellar inner coat, and ability to
change shape in response to water activity — are highly conserved (Aronson, 2012).
A few proteins, termed morphogenetic, are critical for structural integrity: SpoIVA (anchor),
SafA (inner coat), CotE (outer coat), SpoVM and SpoVID (encasement, McKenney et al.,
2012). For example, Zheng et al. (1988) first investigated the effects of the ∆cotE mutation on
B. subtilis. Such spores are heat resistant, germination impaired and optically refractile, yet
also lysozyme sensitive — lysozyme exposure leads to a >95% drop in viability. It is clear
from TEMs (transmission electron micrographs) that indeed the outer structure does not
form (figure 1.10). CotA–C are absent from such spores, too, though their genes cotA–C
expressed normally. From this the authors inferred CotE anchors the outer coat to the inner,
and subsequent work by Bauer et al. (2001) further elucidated the mechanism.
The coat electrically insulates the inner layers. This is particularly important for the stability
of the core because of its interaction with the cortex.
Figure 1.10: Transmission electron micrographs, comparing the outer layers of ΔcotE mutant spores (right)
derived from wild type B. subtilis PY-17 (left). The coat mutant lacks the (electron dense) outer coat and
crust, and so its inner coat is exposed to the environment. Labels: Ex (exosporium), typically called the crust
for B. subtilis; OC (outer coat); IC (inner coat); UC (undercoat); Ctx (cortex). The scale bar is 100 nm.
(Source: Zheng et al., 1988).
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The cortex
The cortex is a crosslinked peptidoglycan wall, similar to the cell walls of vegetative cells,
but 50 % of what in peptidoglycan would be N-acetylmuramic acid is missing the
pentapeptide side chain, and is therefore muramic acid δ-lactam (Abel-Santos, 2012).
During sporulation, the cortex grows at its inner surface, compressing the core (Algie,
1980). CLEs (cortex lytic enzymess), break down the cortex at germination, coinciding with
the point at which germinating spores turn from phase bright to phase dark (Gould, 1969).
Peptidoglycan usually provides rigidity in bacteria, containing and constraining the
membrane within, and in spores this constraining role is vital. The cortex peptidoglycan’s
negative charge attracts positive counter ions leading to an osmotic potential equivalent to
2MPa (Bassi et al., 2012), and this too is important for stability of the core, discussed below.
The inner membrane
The IM (inner membrane), the layer just inside the cortex, is the main barrier to small
molecules — in particular, DPA. Its lipid composition matches that of the plasma membrane,
but its structure does not. At the end of sporulation, the volume contained by the IM halves
and the membrane becomes a semi-solid gel. This volume then doubles by the start of
cortex hydrolysis (during germination) and the membrane’s physical properties revert to
those of a plasma membrane (Setlow, 2014). There is no new membrane made as part of this
process — indeed, ATP production does not start until later (Bassi et al., 2012); this suggests
the structure changes dynamically.
Vepachedu & Setlow (2007) proposed that some release of DPA was linked to the SpoVA
proteins, with the rest due to the increase in IM permeability on germination. A step change
in permeability of the membrane could surely not be due to the (admittedly large) changes
in lipid arrangement; how would these small molecule concentrations reach such high levels
on sporulation if the membrane were this permeable before the core dehydrates? More
recent results, supporting the notion that SpoVA proteins form a mechanosensitive channel,
imply the release associated with changes in the membrane is actually via the SpoVA
channel itself (Velásquez et al., 2014).
The IM is the final barrier to the spore core.
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The spore core
The core contains all the requirements for germination and the beginning of outgrowth of
germinating spores. There has been some debate on whether it is in a glassy state (an
amorphous near-solid) or that of a gel (e.g. Ablett et al., 1999; Bradbury et al., 1981). The
preponderance of evidence leans towards the latter: that the core is a water permeable
matrix, containing all the key macromolecules required by germinating spores (Sunde et al.,
2009).
Since the 1960s, researchers have known that most water in spores is mobile (97 %, from
D₂O exchange, Bassi et al., 2012), and more recently NMR studies have confirmed this
(Kaieda et al., 2013; Leuschner & Lillford, 2000; Sunde et al., 2009). There have been
conflicting results on the relative hydration of the cortex and core; the NMR study by
Bradbury et al. (1981) found no difference, but later laser-diffractometry experiments by
Ulanowski et al. (1987) found 0.6 gml⁻¹ water in the cortex but just 0.3 gml⁻¹ in the core.
Not only is this water exchanged with the environment, the quantity of water in an
individual spore will change depending on the environment’s humidity (Westphal et al.,
2003). The true values will thus vary as governed by the osmotic potentials of the spore and
cortex.
The composition of dry spores includes 5–15% w/w 2,6-DPA (Murrell, 1969); the dry cores
comprise 20% w/w (Setlow et al., 2006). Accounting for the water content in non-dried
spores, this corresponds to 2 mol%, or 0.8 M (which is just lower than the limit of Ca-DPA
solubility in a binary mixture with water, approximately 1 M). Colorimetric assays of spore
extracts suggest DPA appears in a 1:1 stoichiometric relationship with Ca²⁺ ions in the spore
core (Murrell, 1969); calcium ions and DPA released from spores during germination
maintain such a stoichiometry, too (Vepachedu & Setlow, 2007).
Indeed, lyophilized B. cereus showed Raman peaks corresponding to the symmetric
breathing vibration of Ca²⁺-DPA (1021–1015 cm⁻¹), rather than H₂-DPA (1002–998 cm⁻¹),
suggesting the Ca²⁺ salt is the dominant form in vivo (Shibata et al., 1986). This does not rule
out DPA in complex with other, non-Ca²⁺ cations, as those other dipicolinate salts would
show similar peaks. In particular, other divalent and monovalent metal ions, and free amino
acids are prevalent, and likely complexed with DPA, in the core.
Based on work with B. megaterium, Murrell (1969) suggested the most prevalent free amino
acids in Bacilli were arginine, histidine and glutamate. More recently, NMR (nuclear
magnetic resonance) has confirmed this, indicating significant quantities of arginine,
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glutamate and two other small molecules in the extracted cores of Bacillus subtilis (Magge et
al., 2008). Glutamate makes up 20–100 µmol (g dry spores)⁻¹ (0.3–1.5% w/w) and Vepachedu
& Setlow (2007) found 90 % was released with the DPA on dodecylamine-induced
germination (with most of the free arginine released in parallel). The formation of
DPA-glutamate and DPA-arginine complexes in vivo is consistent with the parallel release
hypothesis.
It is possible to estimate some values important to the physics of the core. Assuming
Ca²⁺-DPA is solvated but does not quite dissociate, for a 2 mol% ideal binary mixture of
Ca²⁺-DPA and water, the mole fraction of the latter is 0.98. The osmotic pressure of this
greatly simplified system is given by the following equation, in which R is the molar gas
constant in kJ kmol⁻¹ K, T is temperature in K, V̲ the molar volume of water in m³ kmol⁻¹, γ
the (dimensionless) activity coefficient and x the (dimensionless) molar fraction:
This rough calculation suggests the osmotic pressure of the core is of the order of 2–3 MPa,
compared with reported values of 0.02–0.2 MPa for vegetative cells (Cayley et al., 2000;
Deng et al., 2011). Indeed, Bassi et al. (2012) reported an osmotic pressure of 2 MPa, and the
simplified calculation above is consistent with the proposition that the behaviour of DPA
dominates that property. This means the cortex and core are in osmotic equilibrium, despite
the core’s far lower water content, and thus the cortex plays a vital role in the latter’s
stability. Furthermore, one can infer that the osmotic pressure is also a store of free energy,
used to power the germinating cell.
Independently, Algie (1980) published a near-identical calculation, based on water activity
rather than DPA concentration, which produced an identical result. This result was taken
further, treating the cortex as a pressure vessel. The overall outcome is consistent with the
core being dehydrated by reverse osmosis, as the pressure in the core increases with cortical
growth. Further evidence comes from DSC (differential scanning calorimetry); Tiburski et
al. (2014) showed that water in the spore core undergoes its vaporization transition at 200℃,
rather than 100℃ for surface water, indicating the high pressure state therein.
⁂
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The spore structure in this way creates (and maintains) the optimum environment in which
to stabilize proteins. The core preserves the critical biological molecules at high osmotic
pressure: genome, enzymes, ribosome system and an energy store. The cortex maintains the
osmotic pressure, the coat protects the cortex from chemical attack, and an exosporium or
crust protects the coat. Together, they keep the spore stable in a high energy state, so as
soon as germination begins, the spore can become a vegetative cell as quickly as possible. It
may be possible to mimic some of that state, without that full surrounding structure — and
for this, DPA looks like a particularly interesting place to begin.
Spores must stabilize their core proteins to resist wet heat (Pedraza-Reyes et al., 2012). The
magnitude of this resistance depends to a great extent on the water activity of the spores;
manipulation of water activity suffices to overcome the 10⁴ times difference in survival
between different species (Murrell & Scott, 1966). The contraction of the spore, associated
with a reduced water content, has been shown to correlate with resistance to wet heat
(Algie, 1983). While DPA’s role in heat resistance has been reported for 60 years (Church &
Halvorson, 1959; Murrell, 1969), there is still no widely accepted mechanism for its action
(Setlow, 2014). Both factors are related; water activity is a function of water and solute
composition, and the solute is dominated (as described above) by DPA (Algie, 1984; Sunde
et al., 2009).
DPA is ubiquitous among spore-formers. Most possess the DPA synthetase enzyme to
produce it by reducing DHDPA (dihydrodipicolinic acid); indeed, this enzyme is highly
conserved across sporeformers. Taxonomic analyses (and both in vivo and in vitro
experiment) suggest that before this enzyme evolved, ancestors of Bacilli and Clostridia co-
opted the electron transfer flavoprotein EtfA in its place (Orsburn et al., 2010).
Protein stability in spore cores1.3.5
Heat resistance
Heat is damaging to cells as it damages proteins: directly, through thermal denaturation, and
indirectly, through acceleration of kinetics (Manning et al., 2010). There are a number of
mechanisms, through which DPA might increase spores’ heat resistance; many stabilize the
proteins against thermal denaturation.
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One such mechanism is the role of DPA in the low water content of the spore core. In the
core, water preferentially hydrates non-protein molecules, so proteins generally have only a
single layer of water molecules around them. Low water content means fewer ROSs
(reactive oxygen species), and less oxidative damage (Bassi et al., 2012).
Bradbury et al. (1981) proposed a model in which dehydration alone is not enough to
provide the resistance; Ca-DPA itself acts as a support. This support restricts the movement
of macromolecules; restricting movement in this way is a reliable method of enhancing
protein stability (Bhardwaj et al., 2016). There is a mechanism by which DPA may form a
support. Electron density is delocalized over the whole DPA molecule. Guanidinium and
arginine show similar properties, and in low water environments they stack (Schneider et al.,
2011). It seems likely that DPA behaves similarly.
Another such mechanism is chelation of metal ions, preventing metal-catalysed oxidation.
Calcium, potassium, magnesium and manganese species are the most prevalent ionic metal
species in the spore core, followed by iron, aluminium, sodium, phosphorous and copper
(Bassi et al., 2012).
Finally, DPA may also interact more directly with proteins. Such behaviour has been
demonstrated beyond spores. Tris(DPA)lanthanide, a DPA complex, has been shown to co-
crystallize with proteins, acting as a crystallographic phasing agent (Pompidor et al., 2008a).
The carboxylate groups in the complex interacted specifically with arginine residues of hen
egg white lysozyme, in both solid and liquid phases, producing a new crystal form
(figure 1.11). Such specific interactions may help stabilize proteins in the spore core, in the
manner described by Bhardwaj et al. (2016).
UV resistance
When it comes to UV resistance, DPA too is an important component, along with SASPs
(small acid-soluble proteins). UV damages spores mostly through damage to DNA.
UV radiation causes more DNA damage in spores containing DPA than mutants without
(Paidhungat et al., 2000). Nucleotides form 5-thyminyl-5,6-dihydrothymine (i.e. SP, spore
photoproduct), rather than lactams. Unlike the latter, however, the former reaction product
is reliably repaired on germination (Pedraza-Reyes et al., 2012). As a consequence, UV
damage is reversible. The gel structure of the core also restricts DNA motion so when the
spore germinates, breaks are easier to repair.
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Figure 1.11: A DPA (2,6-dipicolinic acid)–lanthanide complex interacts specifically with arginine residues in hen egg
white lysozyme. DPA chelates the lanthanide ions, keeping them from the surface of the protein in a way that might be
relevant to the way proteins are stabilized in spores. Image produced using Pymol, from PDB entry 2PC2 (Pompidor et
al., 2008b).
DNA extracted from spores differs in many properties from that of vegetative cells, mainly
due to the presence of DPA. This has practical effects; Setlow et al. (2006) inferred from the
change in DNA’s UV photochemistry that DPA must be close enough to DNA for electron
transfer to take place. Separately, and consistent with that hypothesis, DPA-derivatives have
been shown to bind tightly to DNA. For example, a number of dipicolinate tris-arenes, such
as methoxy-substituted 4,4’-dinitrodipicolinalinide have been shown to provide a
hydrophobic DNA coat and thereby improve plasmid transformation efficiency in E. coli
(Atkins et al., 2012). In binding DNA in this manner, DPA may stabilize DNA like it might
proteins: through specific interactions.
Finally, UV also creates DNA-damaging radicals such as superoxide. The reduced water
content reduces the likelihood of superoxide-creation events occurring, and DPA in turn
reduces such radical-associated damage when they do.
The UV protection mechanism in vivo may be a combination of all three effects: SP
formation, direct binding to DNA and dehydration.
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Spores lacking DPA
From this correlation of DPA with reduced water content, one might infer there is a
mechanism linking the two. Together, these spore resistance properties suggest DPA forms
a water-solvated matrix, stabilizes proteins in an inactive but thermostable form, and
excludes water from beyond proteins’ first hydration shell. One way to test this hypothesis is
to consider what happens when spores lack DPA.
DPA is produced via the DAP (diaminopimelic acid) pathway. DapA converts L–ASA
(L–aspartate semi-aldehyde) and pyruvate to HTDA (4-hydroxy-tetrahydro-dipicolinic
acid), which spontaneously dehydrates to DHDPA (dihydrodipicolinic acid). Then, in
Bacillus and most Clostridia, the DPA synthetase enzyme SpoVF converts this to DPA
(Orsburn et al., 2010). The DPA is taken up into the spore via the SpoVA channel.
This provides two approaches to make spores that lack DPA via genetics, and physical
methods lead to a third. Knocking out the spoVF operon in B. subtilis means the mother cell
cannot produce DPA. Paidhungat et al. (2000) tried this (based on the work of Balassa et al.,
1979), but the spores produced were phase dark, indicating they had autogerminated; they
lacked stability. The researchers then deleted the three main germinant receptors (with
which a spore detects nutrients, if an environment is suitable for germination), leading to
stable spores. Later, Magge et al. (2008) produced the ∆spoVF ∆sleB mutant, able to produce
neither DPA nor the semi-redundant CLE SleB; these spores were also stable. Indeed, DPA
was later shown to prevent SleB activation in an unknown way (Kaieda et al., 2013). As
expected, the mutants of Magge et al. (2008) showed reduced resistance to wet heat,
indicating reduced protein stability. However, in these mutant strains, DPA channels still
function, meaning any DPA in the mother cell would be taken into the forespore.
As described in section 1.3.2, SpoVA proteins form a gated channel, through which DPA is
actively transported into the forespore during sporulation, and then, on germination,
released (Velásquez et al., 2014; Vepachedu & Setlow, 2007). Magge et al. (2008) produced
B. subtilis mutants with a ∆sleB ∆spoVA genotype, which lack this gated channel. They could
neither transport DPA against an enormous chemical potential gradient into the forespore,
nor transport it with the chemical potential gradient out of the germinating spore. These
spores were ‘extremely stable’ — evidence that the SpoVA channel is critical for ion or water
release during germination, too. Paredes-Sabja et al. (2008) replicated this finding, that
∆spoVA spores are stable, in Clostridium perfringens.
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For the ∆spoVF mutants of Magge et al. (2008), supplementing the sporulation medium with
DPA led to DPA replete spores, which did contain DPA. The concentrations of DPA, and
resistances to wet heat, oxidation and some ionophores followed the order: DPA-less spores
< DPA-replete spores < WT spores. However, the water content of these spores varies; the
level of dehydration followed the same order, and most of the wet heat resistance (and
oxidation resistance) was probably due to varying water content.
It is also possible to physically remove DPA from spores. Margosch et al. (2004) exposed
spores to up to 800 MPa in a 15 ml pressure vessel; 500 MPa will germinate spores in a way
that bypasses their biological germination mechanism (Setlow, 2014) and which almost
certainly activates the mechanosensitive (Velásquez et al., 2014) SpoVA channel. After 2 min,
the B. subtilis spores had lost almost all (96 %) their DPA. They then heat shocked the spores,
and for comparison a) heat shocked spores lacking DPA, and b) pressure and heat shocked
DPA-replete spores. Spores missing DPA were significantly more sensitive to heat than
those containing it, no matter why the spores contained or did not contain DPA. That said,
the pressurised spores did not germinate on loss of DPA as the pressure damaged the CLEs,
located outside the core (Margosch et al., 2004).
Control of DPA must be very tight during uptake into the forespore, as the proteins in the
IM must do a lot of work against the potential gradient inherent in building the 2 MPa
osmotic pressure. Li et al. (2012) showed that in the B. subtilis SpoVA complex, the SpoVAD
subunit specifically interacts with 2,6-DPA, but not the 2,3-, 2,5-, or 3,5- isomers. A highly
conserved Cys-110 residue forms part of their suspected binding site, and based on docking
simulations the authors suggested Asp-234 and Ser-277 recognise the acid groups at the 2
and 6 positions (see figure 1.12). However, one implication of DPA’s interactions with
proteins may be that standard in silico models do not correctly model it as a ligand. It would
be interesting to see how the SpoVA channel differs in B. megaterium. The channel is made
from fewer distinct subunits (six as opposed to seven), and the germinant receptor behaviour
is more complex (Gupta et al., 2013).
⁂
This section has shown how spore-forming bacteria use their differentiated spore form as a
means to survive harsh environments — at individual, and species levels. This can be a
nuisance, when such bacteria are an undesirable presence. It is also a useful capability from a
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Figure 1.12: SpoVAD forms a gated DPA channel in B. subtilis. This channel is highly specific and is required for the
forespore to fill with DPA at the end of sporulation. The crystal structure shown here, as a cutaway into the channel
itself, is a single dimer subunit. The Cys-110 (magenta), Asp-234 and Ser-277 (orange) residues, which make the
putative channel entrance, are highlighted. Image produced using Pymol, from PDB entry 3LM6 (Forouhar et al., 2010).
biotechnological perspective. The very conditions which challenge spore survival also
challenge many therapeutic protein products, and that similarity has informed the goals of
the work reported here.
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If spores have such remarkable protein-stabilizing properties, why not use spores themselves
to deliver mAbs? Formulation scientists have a problem of proteins suffering irreversible
damage; meanwhile, Bacilli and Clostridia — through the factors described in section 1.3.4 —
package the proteins in their core, enabling them to resist the same challenges. Could
mimicking the mechanisms of these spore-formers solve this formulation challenge?
As a delivery vehicle, spores are suitable for oral delivery, wherein therapeutic proteins they
release are transported across the gut epithelium. Beyond that, Bacillus spores can travel
around a body; the invasiveness of B. anthracis spores is certainly an extreme example, but the
non-pathogenic Bacilli offer similar behaviour that might make them convenient hosts for
delivering therapeutic proteins.
Spores as delivery vehicles1.4
Many of the protein damage mechanisms (discussed in section 1.2.3) require the protein to
be in a hydrated local environment, whether in liquid solution or solid state. Even when the
bulk environment is frozen, cold denaturation can happen if locally the protein is hydrated
and below the thermodynamic cut-off temperature; for example, oxidation in freeze-dried
formulations increases with increasing moisture content (Manning et al., 2010).
Stabilizing proteins against the challenges of harsh or rapidly changing environmental
conditions is a fundamental biological problem and organisms have independently evolved
many solutions. Plants, seeds, pollen and fungal spores all stabilize their proteins against
enormous changes in salt concentrations, fast temperature changes and radiation. In these
systems, the local protein environment is a glass: an amorphous near-solid.
Spores are different, and hold proteins (and ions) immobilised in a water permeable matrix
(Bassi et al., 2012). Producing such a water-poor environment is tricky. Decreasing the
water concentration increases salt concentrations, making salting in and chaotropic
denaturation more likely. Spore cores avoid this. Not only would an understanding of the
mechanisms involved be a valuable contribution to microbiology, it would also help those
who design techniques to stabilize proteins in pharmaceutical formulations.
Spores protect their protein contents1.4.1
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Despite preliminary results of Bradbury et al. (1981), showing DPA could stabilize proteins
with respect to heat, it appears there has, until now, been no subsequent research. Arginine
and glutamate, abundant in the spore core, show synergy in stabilizing proteins (Schneider
et al., 2011); it is only since the start of this project that anybody has investigated DPA, too,
for this role in vitro (Batalha et al., 2017).
Given the decades of research on Cry protein, why have so few researchers considered them
for non-agricultural purposes? One factor must surely be the context in which much of this
research has been conducted. Tautologically, the one thing all agriculture researchers have
in common is that they are researching agriculture. Indeed, the work presented by Nair et al.
(2015) was inspired by a serendipitous discovery (that fusions crystallized) while trying to
improve imaging contrast to that end. Furthermore, and in contrast to much bacterial spore
research, a good proportion of Cry research has been conducted in industry, rather than
academia, and it may be the case that these ideas have been tested and reported within
relevant companies, but not published. There has been work at this boundary between fields
before (e.g. Pigott et al., 2008), yet it has focused on improving specificity of the toxin rather
than converting the protein for pharmaceutical use.
Crystallizing mAbs from commercial formulations leads to stable, bioactive samples, suitable
for subcutaneous administration (Yang et al., 2003). Volume restrictions mean that
subcutaneous mAb formulations have a minimum concentration of 50 mg ml⁻¹. However,
this high concentration causes formulation problems (see section 1.2.3). Cry crystal
suspensions can easily reach that minimum concentration limit.
Another somewhat novel proposition concerns yet another field of research. Cry fusions
offer a novel screening method for crystallogenesis. Much protein structural work relies on
crystallization, yet many proteins of interest — in particular: membrane proteins, in general,
or in the context of spores, coat proteins — have proved impervious to attempts to produce
crystals. In a recent review, Giegé (2017) describes both the challenge of crystallogenesis and
its reward. For example, the author refers to work in which Ting et al. (2016) determine the
crystal structure of a membrane anchored serine peptidase, using crystals of that protein as a
fusion with MBP (maltose binding protein). Giegé (2017) does mention, in passing, the
work of Nair et al. (2015) — yet only in the context of drug delivery. It is striking in a
review on the future of crystallogenesis the author does not propose the use of Cry fusions
Spores can produce vast quantities of protein1.4.2
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for structural studies. While Cry crystals are not suitable for traditional X-ray
crystallographic study, techniques such as Cryo-EM can produce structures. Indeed, there
has been much interest in in vivo crystallization more generally (Adalat et al., 2017;
Koopmann et al., 2012; Schönherr et al., 2018), including work by Sawaya et al. (2014) on
producing a 2.9Å crystal structure by injecting Cry3A-producing vegetative B. thuringiensis
cells into an X-ray free-electron laser beam.
Given the above, what work has been done on using spores as delivery vehicles for
therapeutic proteins? The prior art is sparse and not substantially developed, and covers coat
fusions, forespore core expression, and Cry protein fusions; work has taken place on the
former two in the Christie lab — see the theses of Lin (2017) and Mohamed (2015)
respectively — though it is the latter two which are most relevant and shall be reviewed,
briefly, below.
There has also been work on anaerobic spores, as a cancer treatment. Clostridium species
have been used to deliver cytokines and enzymes to xenograft tumours in mice (Umer et al.,
2012). These bacteria are strict anaerobes, so only germinate and grow in the absence of
oxygen. Tumours are hypoxic, so following ingestion, a) spores spread throughout the
body, and b) germinate in tumours. c) The cells produce and secrete antibody fragments,
which d) kill cancerous cells (strictly, all cells in the hypoxic zone), and then e) a short course
of antibiotics kill the bacteria. For example, Groot et al. (2007) engineered Clostridium novyi-
NT to produce a 15 kDa single chain camelid antibody raised against hypoxia inducible
factor 1α, which maintains tumour oxygen levels. The authors showed the purified
antibodies bind their target, and their stated goal was a deliverable spore, but there has been
no published progress from the research group, since.
Finally, there is some work on surface display that is especially relevant because of its
relation to Cry proteins. Du et al. (2005) anchored GFP and an scFv to the coats of
acrystalliferous B. thuringiensis using N-terminal fusions of Cry1Ac.
Prior art1.4.3
Cry fusions
The academic literature contains very little on Cry protein fusions in a non-agricultural
context. In the only real example, Nair et al. (2015) produced GFP and mCherry fusions of
Cry3Aa and proposed they could be used to deliver therapeutics. Indeed, they showed
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uptake by macrophages, conferment of gastric protection on fused luciferase, and migration
through mouse lymph nodes. However, it is vegetative B. thuringiensis, not spores, that
natively produces Cry3Aa, and the researchers used that vegetative machinery to produce
their crystals.
There are a wide range of patents concerned with B. thuringiensis but few related to potential
therapeutic use. It is instructive to consider differences between the applications for these
patents and the remaining claims in the grants. Though the applications are often very
broad, most of these claims do not survive review. For example, in granting Côté et al.
(2008) for parasporin, an anti-cancer Cry variant (Mizuki et al., 1999, first reports; and
reviewed, Ohba et al., 2009), the application was stripped of claims for all DNA sequences,
the strain, all but two of the amino acid sequences, and their modulation method. The result
is substantial freedom to operate, at the possible cost of difficulty in acquiring a patent on
related work should that be desired.
The only directly relevant patent applications cover some of the work presented by Nair et
al. (2015; these are Chan et al., 2010; Chan & Nair, 2013). With the caveats of the above
paragraph, the application by Chan et al. (2010) looks fairly unrestrictive. The claims cover
“a protein crystal formed by a plurality of a fusion polypeptide, the fusion polypeptide
comprising a Cry protein, or a crystal-forming fragment thereof, fused to a heterologous
polypeptide” in various contexts, specifically: in a cell; as an isolated crystal; chemically
crosslinked; as a fusion with “an immunogenic antigen” (i.e. a vaccine), “imageable agent”,
“fluorescent protein”, “blood substitute”, or “therapeutic enzyme”; as DNA encoding a Cry
fusion; and as a spore of a strain that contains such DNA. Not all combinations are
represented. Bizarrely, they also claim for standard lab methods used to isolate such crystals.
Claim 9 offers the restriction of Cry from “Cry1Aa, Cry1Ab, Cry2Aa, Cry3Aa, Cry4Aa,
Cry4Ba, Cry11Aa, Cry11Ba, and Cry19Aa, their homologs [sic], or a crystal forming
fragment thereof.” It is not clear why they do not explicitly reference Cry1Ac; from a patent
search it doesn’t appear to be covered under a similar patent, and there does not appear to be
any Cry1Ac-specific prior art. There is still much room to operate, not least because many
of the steps needed to produce a commercial formulation across the entire platform of Cry
fusions have yet to be published, and, judging from the dearth of published preliminary
requirements, are yet to be invented. Chan & Nair (2013) extended the earlier application to
a worldwide patent and merged a few others; the above thoughts continue to apply.
Furthermore it has now been over seven years since the first patent was filed; Google Patents
reports that the application has been abandoned. Most importantly, though, there is no claim
or reference made to therapeutic, non-enzyme proteins.
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The final patent application to consider is that of Soto et al. (2014), on Cry proteins (not
parasporin) that feature anti-cancer properties, similar to that of Aggarwal & Rodriguez-
Padilla (1999), recently expired. These inventors too claim standard lab practices without
refinement, and the remaining claims are notably vague.
Expression of proteins in forespores
Work on expression of heterologous proteins by sporulating cells is less established, still.
Following the work of Webb et al. (1995), Mohamed (2015) tested sporulation specific
promoters PsspB and PsspD, demonstrating their relative levels of expression using a lacZ
fusion (PsspB expressed greater quantities of protein) and then using PsspB to drive
transcription of genes encoding human growth hormone, single chain insulin and an scFv
against lysozyme.
From a densitometric analysis of a western blot, Mohamed (2015) inferred spores produced
therapeutic proteins under PsspB at yields from 5 µg (mg spores)⁻¹ for GFP-fused single chain
insulin, down to 0.8 µg (mg spores)⁻¹ for a GFP-fused scFv. Quoting doses of
1.4–2.1 mg day⁻¹ (from Walsh, 2005, for insulin), and for a human child of 1.3 mg day⁻¹
human growth hormone — these correspond to 0.3–0.4 g spores and 0.5 g respectively —
Mohamed (2015) deduced that “the level of protein production within the spore is high
enough to allow for a reasonable amount of spores to constitute a dose.” ‘Reasonable’ in this
context probably means a single tablet or capsule. However, this calculation did not account
for the bioavailability of such a drug delivered orally, which for a protein therapeutic is often
below 10% (Morishita et al., 2006; Sarmento et al., 2007). The dose would have to increase
by a factor of 5 to 1.5–2 (g spore) day⁻¹ (assuming 50% bioavailability for the reported dose
on which the calculation is based, Søeborg et al., 2012). Beyond that, there is more to a
pharmaceutical product than the active ingredient; even a minimal formulation which
simply suspends the spores in fluid would contribute to an increased total dose size.
Furthermore, as Walsh (2005) points out, insulin has acute and chronic dosage requirements;
if 1.5–2 (g spore) day⁻¹ does suffice for the chronic dose, acute doses are likely to be much
higher. These problems are not insurmountable, but they do mean there is much work to do
before a promising yield in the lab can become a commercial product.
What about the anti–hen egg white lysozyme scFv reported by Mohamed (2015)? For
comparison, Durvalumab, the PD-L1 inhibitor recently indicated for bladder cancer, is
delivered intravenously as 10 mg kg⁻¹ once every two weeks, often for a year (Optum Inc.,
2017). For a 70 kg patient, that means the equivalent of 50 mg day⁻¹ — and that is just the
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antibody. If the full antibody were produced to the same mass as the scFv fusion, that would
correspond to 60 (g spore) day⁻¹ (i.e. a small drink). Add in the aforementioned potential for
poor bioavailability and it becomes clear that the protein yields reported by Mohamed
(2015) will not suffice.
Finally, this prior work has only involved B. subtilis. B. megaterium and B. thuringiensis express
complex proteins at high yields and might provide a better option than B. subtilis.
Remaining milestones
In attempting to design a bacterial spore–based biologic, a number of important milestones
have not been reached. Nobody has yet produced fragments of a human or humanized
antibody in sporulating cells. Nobody has yet produced whole antibodies in sporulating
cells. It follows that nobody has demonstrated function or quality of these proteins; indeed,
the formulation quality is absent from any related work in these organisms. These all form
unanswered questions, some of which form the goals of this project.
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There is much scope to explore concerning production of heterologous proteins by
sporulating bacteria, and this thesis will examine just a fraction of those possibilities. What
follows is a feasibility study, asking the question ‘are sporulating bacteria capable of
producing therapeutic proteins, in therapeutically useful quantities?’ There are three parts:
1. investigation of the mechanisms that enhance protein stability in spores,
2. design and optimisation of protein expression systems in spores, and
3. proof-of-principle production of a deliverable formulation which allows a controlled
dose of proteins to be released in its environment.
How do spores stabilize the proteins in their cores? Much is known on the composition of
the environment, but little on mechanisms — in particular, those involving DPA. Nobody
has adequately controlled for water content of DPA-less spores when investigating their
properties. Do chemical analogues provide an alternative mechanism by which to
investigate this, and if so, what does such work reveal?
Building on previous work in the Christie group, is it possible to use established spore
systems to produce novel, more complicated molecules? How does expression vary with
different expression machinery, in different strains, or in different species? Is it then possible
to evaluate such molecules using the tools of formulation science? How do they compare by
these quality factors to antibodies produced in CHO cells?
What else might be needed as part of a deliverable formulation? This will certainly depend
on the magnitude of expression; is a formulation even feasible? And if so, what is needed to
progress from that to a finished product? Of particular interest is a mechanism by which
proteins encapsulated within spores are released at the appropriate time and place.
The risk of this whole endeavour is high. Many standard techniques, in evaluating protein
quality for therapeutic considerations, are yet to be established for spores. The very resilience
of sporeformers that is so desirable also makes collaboration with pharmaceutical experts
tricky; they will not allow spores near any of their equipment. Despite that, there is plenty
of space in which to work; few researchers are currently investigating these questions, and
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What follows is a report on the course of research, inspired by the context in this chapter.
The long term goal — a spore-based pharmaceutical formulation — has been the driving
force behind the research focus and direction. Following the descriptions of the methods
used throughout this project in the next chapter, chapter 2, are a trio of chapters; each uses a
separate route to investigate whether it is possible to develop biopharmaceutical products
based on bacterial spores.
The first of these, chapter 3, describes an investigation of the role of DPA (dipicolinic acid)
in the stability of spores, with a view to mimicking aspects of the environment in the spore
core. The work of Magge et al. (2008) and Li et al. (2012) is extended to B. megaterium,
showing similarities and differences, and is extended with a new selection of chemical
analogues. This chapter presents a technique to investigate DPA-enhanced, in addition to
DPA-depleted spores, by supplementing the sporulating medium. The work presented here
has inspired one line of research from an industrial collaborator (published by Batalha et al.,
2017) and contributed to another publication from the Christie group (Xu Zhou et al.,
2017). Strains engineered as part of the work reported in chapter 3 have been sent to
collaborators for further study.
Work on the opposite approach is reported in chapter 4; rather than designing a formulation
that mimics the conditions within the spore core, this approach would see the B. subtilis
spore core used itself, as a spore-based package. Specifically, the chapter reports the
production of heterologous, therapeutic proteins in forespores. This chapter reports for the
first time the production of a variety of humanized antibody fragments by sporulating cells,
and the production of camelid antibody fragments in sporulating B. subtilis. A ∆cotE mutant
strain is reported; it can be disrupted using chemical, rather than mechanical means, and thus
offers both a route to scale extraction of core contents and to release payloads in vivo.
The challenge of low protein yields is addressed in chapter 5. This chapter considers, as an
alternative to production in the spore core, a novel way of producing therapeutic proteins in
sporulating cells, using B. thuringiensis Cry proteins. A set of fluorescent Cry fusions have
been created as a platform for subsequent engineering. The platform has been demonstrated
to work, producing fusions to humanized antibody fragments. This work has been taken
forward by a number of researchers: both within the Christie group and beyond.
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Finally, in chapter 6 I review the achievements of this project, in the context of the academic
literature and commercial opportunities. The chapter presents some direction for future
work, both to directly answer some of the questions raised by the work reported here, and
to take this project forwards towards the goal of a spore-based therapeutic product.
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Sterile stock solutions were filtered using a 0.22 µm Millex syringe filter (Merck Millipore).
Unless otherwise noted: chemicals were supplied by Sigma-Aldrich, enzymes by New
England BioLabs, and dried, complex media by Melford.
Materials & Equipment2.1
Antibiotics are listed in table 2.1, with the exception of 5-FU (fluorouracil). Cassettes were
discussed by Guérout-Fleury et al. (1995). This was prepared as a 50 mM stock, for use
(37.5 µM) as 3 in 4000 dilution (e.g. 75 µl in 100 ml, or 300 µl in 400 ml). This required
6.58 mg ml⁻¹ 5-FU.
For 25 mol% DMSO (dimethyl sulfoxide) in water (corresponding to 60% w/w and 57% v/v)
a mix of (final) volume fraction 0.59 DMSO and 0.45 water was used. If the mix is prepared
and then the 5-FU is added, dissolution is slow. Direct addition of the 5-FU to the DMSO,
before slowly adding water, helped. Note the DMSO and water generate heat on mixing. If
diluting 5-FU in DMSO, note also the latter has a specific gravity of 1.10.
Antibiotics2.1.1














Carbenicillin bla 100 50–100
Kanamycin kan 100 10–50 5 50
Tetracycline tet 10 5–10 10 100
Chloramphenicol cat 25 25–170 5 20
Erythromycin erm 10 ― 1 10
Lincomycin erm 25 ― 25 100
Spectinomycin spc 50 50 100 200
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The rabbit polyclonal Anti–6× His tag® antibody (HRP) ab1187 (AbCam), lot no.
GR214185-2, was used at a 1 in 4000 dilution.
Antibodies2.1.2
DNA ladders were the Quick-Load 2-Log ladder (NEB) and Hyperladder 1kb (Bioline).
Protein ladders were Novex® Sharp Pre-stained Protein Standard (Thermo Scientific)




Plasmids in this thesis begin pDBT and the suffix is coded according to the following scheme.
• The first character of the code corresponds to the base vector (table 2.2).
• Subsequent characters correspond to variants of that base vector (such as those in
table 2.3).
• Any plasmid ending in 0 is a vector designed to take an insert.
• A lower case character ends the code, and corresponds to a particular insert; there is
typically a mnemonic.
• A question mark at any position corresponds to a series of plasmids sharing a common
feature, where the plasmids differ at the single ? character.
• An asterisk at any position corresponds to a series of plasmids sharing common features
or lineage, and differing in the * position.
A full list of plasmids, constructed as part of this work, is in table 2.4.
Strains2.1.5
Strains sourced from others
Strains not constructed in this thesis are listed in table 2.5.
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Modifications in this work
Parent
Source
1 Library pGEM-3Z Deletion of BsaI sites and










pHT315 Deletion of BsaI sites and








7 B. subtilis pSS Deletion of BsaI sites BGSC
(Shi et al.,
2013)
Strains engineered in this thesis
The strains constructed as a part of this project are named according to a similar schema to
that presented in section 2.1.4. Strains are named for the base strain and the suffix of the
plasmid used to transform them, separated by a ‘∷’. Where there is no ambiguity, subsequent
strains would keep only the final suffix of their parent strain.
For example, B. subtilis 168 transformed using pDBT611h would become 168∷611h. By
contrast, B. subtilis 168∷690 transformed using pDBT71e would become 690∷71e, as the
preceding ‘168∷’ may be elided without ambiguity.
The full lists of strains, which have been constructed as a part of this project, are presented in
tables 2.6–2.8.
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Table 2.3: Further plasmids used, but not designed, as part of this work.
Name
here
Parent plasmid Description Source
pDBT6* pDG1662-PsspB-
SCI-GFP
pDG1662 with inserted coding sequences
under control of PsspB
Mohamed
(2015)













— pMA-NIP109-Lc Library vector containing the NIP109 light
chain, codon optimised for B. subtilis
Medimmune
— pMA-NIP109-Hc Library vector containing the NIP109 heavy
chain, codon optimised for B. subtilis
Medimmune
Table 2.6: B. megaterium strains, engineered to test behaviour of DPA. Genes tet, spc and kan confer
tetracycline, spectinomycin and kanamycin resistance, respectively.
Strain Genotype Description
1551∷21s+ spoVF∷tet∷spc SXO (single crossover) DPA synthetase mutant
1462∷21s sleB∷kan spoVF∷spc DXO (double crossover) double mutant
Laboratory equipment is listed in table 2.9.
Equipment2.1.6
Unless noted, buffers were autoclaved before storage.
Buffers2.1.7
TE-1
TE-1 buffer is 10 mM Tris-HCl, 1 mM EDTA (ethylenediaminetetraacetic acid), at pH 8.
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120 With kanamycin, not carbenecillin, cassette





1540 VHH GFm4 nanobody













3160 cry1Ac operon, with σG recognition site in promoter
31610 mCherry, on cry1Ac operon with σG recognition site in promoter
31710 cry1Ac m
31720 cry1Ac Cm
610 NIP109 plasmids; on PsspB, for expression in spore core during sporulation
6110 AL11-GFP-His fusion
611h NIP109 Heavy chain
611l NIP109 Light chain
611s NIP109 scFv (L→H, 7-mer linker)
611t NIP109 scFv (L→H, 18-mer linker)
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611u NIP109 scFv (H→L, 7-mer linker)
6160 His fusion
616h NIP109 Heavy chain
616l NIP109 Light chain
616s NIP109 scFv (L→H, 7-mer linker)
616t NIP109 scFv (L→H, 18-mer linker)





6540 VHH GFP4 nanobody
651m VHH GFP4 chromobody
690 To (attempt to) generate supercompetent strain
69c To generate 5-FU- and chloramphenicol-resistant strain
69d To generate 5-FU- and chloramphenicol-resistant supercompetent strain
71e Delete cotE, introduce spectinomycin resistance and 5-FU sensitivity





is 50 mM phosphate buffer (pH 7.5), 1 mM MgSO₄, 10% w/v glycerol
and 2 mM PMSF (phenylmethylsulfonyl fluoride).
Spore breakage
buffer
is 50 mM Tris-HCl (pH 7.5), 0.5 mM EDTA and 1 mM PMSF.
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Table 2.5: Background strains, used in this thesis.
Species Name Description Source
B. subtilis 168 With fixed
trpC locus
Prof. Peter Setlow (University of
Connecticut Health Center, USA)
B. megaterium QM B1551 Wild type Prof. Patricia S. Vary (Northern Illinois
University, USA)
B. megaterium PS1462 ∆sleB∷kan
Kmr
Prof. Peter Setlow (University of
Connecticut Health Center, USA)




E. coli DH5α Cloning
strain
New England Biolabs
E. coli Turbo Cloning
strain
New England Biolabs (C2984)
B. cereus ATCC
14579
Wild type Toril Lindbäck (Norwegian University of
Life Science, Ås, )







is phosphate buffered saline (20 mM phosphate buffer pH 7.4, 500 mM
NaCl) with 20 mM imidazole.
His-elution
buffer
is phosphate buffered saline (20 mM phosphate buffer pH 7.4, 500 mM
NaCl) with 500 mM imidazole.
Both were filter-sterilized and stored in the dark, at 4℃.
Transforming buffer
Transforming buffer, for preparation of highly competent E. coli, is presented in table 2.10.
T-base
T-base, used in preparation of chemically competent B. subtilis (see section 2.3.5) comprises
the ingredients listed in table 2.11.
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Table 2.7: B. subtilis strains, with coat mutation or for antibody expression. Genes bla, spc and cat are carbenicillin,
spectinomycin and chloramphenicol antibiotic resistance cassettes, respectively.
Strain Genotype Description
168∷616l amyE∷cat NIP109 Light chain
168∷616h amyE∷cat NIP109 Heavy chain
168∷616s amyE∷cat NIP109 scFv
168∷616t amyE∷cat NIP109 scFv
168∷616u amyE∷cat NIP109 scFv
168∷611l amyE∷cat NIP109 Light chain (GFP)
168∷611h amyE∷cat NIP109 Heavy chain (GFP)
168∷611s amyE∷cat NIP109 scFv (GFP)
168∷611t amyE∷cat NIP109 scFv (GFP)
168∷611u amyE∷cat NIP109 scFv (GFP)
168∷6510 amyE∷cat BcII10 nanobody
168∷651m amyE∷cat BcII10 chromobody
168∷6520 amyE∷cat TEM02 nanobody
168∷6530 amyE∷cat TEM13 nanobody
168∷6540 amyE∷cat VHHGFP4 nanobody
168∷654m amyE∷cat VHHGFP4 chromobody
168∷690 upp∷comK (Para) Inducibly supercompetent counter-selectable strain
168∷69c upp∷cat 5-FU validation strain
168∷69d +cat∷comK (Para) Progenitor of 168∷690
690∷71e upp∷comK cotE∷spc Coat deficient mutant
690∷611h upp∷comK
amyE∷cat
NIP109 Light chain (GFP), WT coat
690∷611l upp∷comK
amyE∷cat
NIP109 Heavy chain (GFP), WT coat
690∷611s upp∷comK
amyE∷cat
NIP109 scFv (GFP), WT coat
71e∷611h upp∷comK cotE∷spc
amyE∷cat
NIP109 Light chain (GFP), coat deficient
71e∷611l upp∷comK cotE∷spc
amyE∷cat
NIP109 Heavy chain (GFP), coat deficient
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Table 2.7: B. subtilis strains, with coat mutation or for antibody expression. Genes bla, spc and cat are carbenicillin,




NIP109 scFv (GFP), coat deficient
Table 2.10: Transforming buffer (E. coli). The first three
ingredients were combined in water and adjusted to
pH 6.7 with potassium hydroxide, KOH, before addition
of the MnCl₂.
Component Mass / g L⁻¹
PIPES 3.0
Calcium chloride (CaCl₂) 2.2
Potassium chloride (KCl) 18.6
Manganese chloride (MnCl₂) 10.9
Table 2.11: T-base buffer (B. subtilis). Ingredients were dissolved in water and autoclaved.
Ingredient Final concentration / g L⁻¹
Ammonium sulphate ((NH₄)₂SO₄) 2.0
Potassium phosphate, dibasic (K₂HPO₄·3H₂O) 18.3
Potassium phosphate, monobasic (KH₂PO₄) 6.0
Trisodium citrate (Na₃C₆H₅O₇·2H₂O) 1.0
…table cont’d
Electroporation buffer
Solution A (electrocompetence variant) is a cell wall–weakening treatment used to




is described in table 2.12.
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Table 2.8: Strains, for work with cry1Ac operon. Genes bla and erm are carbenicillin
and erythromycin/lincomycin antibiotic resistance cassettes, respectively. The mnemonic
is L, T, P, m for the leader, toxic core, protoxin and mCherry sequences, then l for light
chain, h for heavy chain and s for scFv.
Strain Species Genotype Description
Turbo∷310 E. coli +bla LTP assembly
Turbo∷3110 E. coli +bla Lm assembly
Turbo∷3120 E. coli +bla LmP assembly
Turbo∷3130 E. coli +bla LPm assembly
Turbo∷3140 E. coli +bla LTm assembly
Turbo∷3150 E. coli +bla LTPm assembly
Turbo∷31710 E. coli +bla m assembly
Turbo∷31720 E. coli +bla mP assembly
HD-73∷30 B. thuringiensis +erm Empty vector
HD-73∷310 B. thuringiensis +erm LTP
HD-73∷3110 B. thuringiensis +erm Lm
HD-73∷3120 B. thuringiensis +erm LmP
HD-73∷312h B. thuringiensis +erm LmPh (NIP109)
HD-73∷312s B. thuringiensis +erm LmPs (NIP109)
HD-73∷3130 B. thuringiensis +erm LPm
HD-73∷313l B. thuringiensis +erm LPml (NIP109)
HD-73∷313h B. thuringiensis +erm LPmh (NIP109)
HD-73∷313s B. thuringiensis +erm LPms (NIP109)
HD-73∷3140 B. thuringiensis +erm LTm
HD-73∷3150 B. thuringiensis +erm LTPm
HD-73∷31710 B. thuringiensis +erm m
HD-73∷31720 B. thuringiensis +erm mP
690∷3130 B. subtilis +erm LPm
690∷3140 B. subtilis +erm LTm
690∷3160 B. subtilis +erm LTP
690∷31610 B. subtilis +erm m
14579∷3130 B. cereus +erm LPm
14579∷3140 B. cereus +erm LTm
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Table 2.8: Strains, for work with cry1Ac operon. Genes bla and erm are carbenicillin
and erythromycin/lincomycin antibiotic resistance cassettes, respectively. The mnemonic
is L, T, P, m for the leader, toxic core, protoxin and mCherry sequences, then l for light
chain, h for heavy chain and s for scFv.
Strain Species Genotype Description
YBT-020∷3130 B. thuringiensis +erm LPm
YBT-020∷3140 B. thuringiensis +erm LTm
Table 2.12: Electroporation buffer (B. cereus family). The ingredients were combined, adjusted to pH 7.0 and filter
sterilized.
Component Final Concentration / mM
Sucrose 250
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid) 1






is 20 mM Tris-HCl (pH 7.6) with 150 mM NaCl; the
TBST variant also comprises 0.1% v/w Tween-20, and its
TBST-BSA variant also contains 5% w/w BSA (bovine serum albumin).
Transfer buffer is 10% v/v NuPAGE 20× Transfer buffer (Thermo Scientific), 0.1% v/v
NuPAGE antioxidant (Thermo Scientific) and 10% v/v Methanol.
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Table 2.9: Laboratory equipment. The original list was compiled by Mohamed (2015).
Instrument Purpose Supplier
FastGene blue light LED illuminator Agarose gel
electrophoresis
Geneflow
Gel electrophoresis tanks Agarose gel
electrophoresis
BioRad
UVItec gel documentation system Agarose gel
electrophoresis
UVitec
Herasafe class II biological safety cabinet Aseptic operation Hereaus
Mars class II biological safety cabinet Aseptic operation Scanlaf
Microflow advanced biosafety cabinet
Class-II
Aseptic operation Bioquell
Incubators Cell culture New Brunswick
Scientific
WhirliMixer vortex Cell culture Fisons
FastPrep F120-B10101 Cell disruption Thermo Scientific
MC cell disruptor Cell disruption Constant Systems
5810R centrifuge, with A-4-62 swing
rotor
Centrifugation Eppendorf
Sorvall LYNX 400 super-speed
centrifuge
Centrifugation Thermo Scientific
ND-100 NanoDrop spectrophotometer DNA quantification Thermo Scientific
Gene Pulsar Electroporation BioRad







Wallac Envision 2104 Multiplate Reader Optical measurements Perkin-Elmer
BX51 microscope Optical microscopy Olympus
BX53 microscope (with UV source) Optical microscopy Olympus
Retiga 2000R cooled CCD Optical microscopy QImaging
DNA engine DYA thermal cycler PCR BioRad
Trans-Blot Semi Dry Transfer Cell Western blot BioRad
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Table 2.9: Laboratory equipment. The original list was compiled by Mohamed (2015).
Instrument Purpose Supplier
3D rocking platform PAGE Jencons Stuart
Scientific
Bolt Mini Gel Tank PAGE Life technologies
G-Box gel documentation system PAGE Syngene
PowerPac 200 power supply PAGE BioRad





Buffer QG, used to dissolve agarose gels, comprises 5.5 M guanidine thiocyanate
and 20 mM Tris-HCl, at pH 6.6.
Buffer P1, the resuspension buffer for minipreps, comprises 50 mM Tris-HCl,
10 mM EDTA and 100 μgml⁻¹ RNaseA, at pH 8.0.
Buffer P2, the miniprep lysis buffer, comprises 200 mM NaOH and 1% w/v SDS
(sodium dodecyl sulphate).
Buffer N3, the miniprep neutralisation buffer, comprises 4.2 M guanidinium
hydrochloride and 0.9 M potassium acetate, at pH 4.8.
Buffer PB, the binding buffer for minipreps and PCR clean-ups, comprises 5M
guanidinium hydrochloride and 30% v/v isopropanol.
Buffer AE is the elution buffer for gDNA (genomic DNA) extractions. It is
composed of 10 mM Tris-HCl and 0.5 mM EDTA, at pH 9.0.
Buffer PE is the elution buffer for miniprep and PCR clean-ups. It is composed
of 10 mM Tris-HCl and 80% v/v ethanol, at pH 7.5.
Proprietary buffers
Buffers AW1 and AW2 are proprietary Qiagen buffers. Buffer AW1 is a guanidinium
hydrochloride based wash buffer; buffer AW2 is a wash buffer based on sodium azide
(Himmelreich & Werner, 2014).
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Media were autoclaved at 121℃ for 15 min.





was prepared as described by Harwood & Cutting (1990).




was prepared as described by Harwood & Cutting (1990).
Composition: 20 gL⁻¹ tryptone, 0.5 gL⁻¹ NaCl, 5 gL⁻¹ yeast extract,
magnesium sulphate (MgSO₄) 2.4 gL⁻¹, potassium chloride (KCl)
0.186 gL⁻¹, pH 7.0.
TSB (Tryptone
Soy Broth)
was prepared using Tryptone Soy Broth CM0129 (Oxoid).
Composition: 17.0 gL⁻¹ casein (pancreatic digest), 3.0 gL⁻¹ soy bean
meal (papaic digest), 5.0 gL⁻¹ NaCl, potassium phosphate dibasic
(K₂HPO₄) 2.5 gL⁻¹, glucose 2.5 gL⁻¹, pH 7.3.
PDM (Plasmid
DNA Medium)
was presented by Danquah & Forde (2007) as an effective and cost-
effective medium for plasmid production. The optimized variant,
PDMR (PDM,
ratio optimized),
uses a C/N ratio of 2.8. The recipe is provided in table 2.13 (base) and
table 2.14 (supplement).
Table 2.13: Base for PDMR (PDM, ratio optimized), with
C:N ratio of 2.8:1. All listed ingredients were combined,
then autoclaved.
Component Mass / g L⁻¹
Water 910   
Yeast extract Y1333 (Melford) 4.4 
Tryptone LP0021 (Oxoid) 8.0 
Ammonium chloride (NH₄Cl) 5.5 
Magnesium sulphate (MgSO₄) 0.26
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Table 2.14: Supplement for PDMR, added before use. Components were prepared as individual stocks, then
combined into a master mix.
Component Stock concentration Volume / ml L⁻¹
Glucose 50% w/v 20
Disodium phosphate (Na₂HPO₄) 1M 48





broth was prepared (table 2.15, as described by McCool & Cannon,
2001).
SpC & SpII are required for producing chemically competent B. subtilis. Table 2.16
describes the recipes. Media were made fresh from the listed stocks, on




was prepared as a 2× stock in TSB, as described in table 2.17. To use,
the stock was mixed with TSB in a 1:1 ratio
Table 2.15: Composition of RHAF (Hadlaczky Alföldi Fodor) broth (B. megaterium). The pH was
adjusted to 7.5 using concentrated HCl before addition of magnesium chloride.




Ammonium chloride (NH₄Cl) 19    1    
Sodium sulphate (Na₂SO₄) 2    0.3  
Mono-potassium phosphate (KH₂PO₄) 1.0  0.14 
Sodium chloride (NaCl) 1.0  0.058
Potassium chloride (KCl) 0.50 0.035
Yeast Extract 5    
Tryptone 5    
Magnesium Chloride (MgCl₂·6H₂O) 23.0 4.68 
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Table 2.16: Recipes for SpC and SpII media (B. subtilis). The individual ingredients were prepared as stocks (in 30 ml









D-glucose 50% w/v  0.30 2
Yeast extract 10% w/v 0.60 2
Magnesium sulphate trihydrate
(MgSO₄·3H₂O)
1.2% w/v 0.45 14
Casamino acids 1.0% w/v 0.75 2
Calcium chloride (CaCl₂) 0.1 M ‒    1
Total 30.0  200
Table 2.17: Electroporation recovery medium.
Component Stock Concentration / mM
Sucrose 250
Magnesium chloride (MgCl₂) 5
Magnesium sulphate (MgSO₄) 5




was prepared (table 2.18, as described by Harwood & Cutting, 1990).
Table 2.18: Composition of SNB, supplemented nutrient broth (B. megaterium).
Component Concentration / mM Mass / g L⁻¹
Difco nutrient broth 8.0   
Glucose 5.55  1.0   
Potassium chloride (KCl) 13.4   1.0   
Manganese chloride (MnCl₂) 0.02  0.004 
Ferrous sulphate (FeSO₄) 0.001 0.0003
Magnesium sulphate (MgSO₄·7H₂O) 1.0   0.2465
Calcium chloride (CaCl₂) 1.0   0.147 
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2×SG, the modified Schaeffer’s media, was prepared according to Harwood &
Cutting (1990). To 1 kg water were added 16.0 g Difco nutrient broth,
2.0 g KCl, 0.5 g MgSO₄·7H₂O, and 17.0 g technical agar (Melford).
The pH was adjusted to 7.0 and the resulting medium (of specific
gravity 1.04) autoclaved. Before use, this was supplemented with the
volumes of the stock solutions listed in table 2.19.
2×SGR was prepared according to Warriner & Waites (1999), having
demonstrated an increase in spore titre versus 2×SG (on switching half
of the glucose for ribose).
CCY (casein
casein yeast)
medium (Stewart et al., 1981) required the ingredients in table 2.20:
combined, adjusted to pH ∼ 7.5 with 1 M KOH (though this was often
unnecessary) and autoclaved. The CCY salts master mix described in
table 2.21 was added as a supplement at 0.1% v/v, before use.
Table 2.19: Supplements for 2×SG and 2×SGR medium (B. subtilis). Stocks were filter sterilized, then










Calcium nitrate (Ca(NO₃)₂) 1.0 M 1.0 1.0
Manganese chloride
(MnCl₂)
0.1 M 1.0 1.0
Iron (II) sulphate (FeSO₄) 1mM 1.0 1.0
Glucose 50% w/v 2.0 1.0
Ribose 42% w/v ‒ 1.0
Table 2.21: CCY salts, to supplement base medium. The master mix was
stored at 4℃.
Component Stock concentration / mM
Magnesium chloride (MgCl₂) 500
Manganese chloride (MnCl₂) 10
Iron (III) chloride (FeCl₃) 50
Zinc chloride (ZnCl₂) 50
Calcium chloride (CaCl₂) 200
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Table 2.20: Base CCY (casein casein yeast) medium (B. cereus family).
Component Final concentration / mM Mass / g L⁻¹
Water ‒     1000   
Enzymatic casein hydrolysate ‒     1   
Acid casein hydrolysate ‒     1   
Yeast extract ‒     0.4 
Potassium phosphate, monobasic (KH₂PO₄) 13    1.77
Potassium phosphate, dibasic (K₂HPO₄) 26    4.53
Glutamine 0.27 0.04
Glycerol 0.6 
SM medium for sporulation by resuspension
This recipe for SM (Sterlini-Mandelstam) medium was published as a technical resource, by
Nicholson & Setlow (1990).
Growth
medium




was prepared fresh on the day of use, according to table 2.23.
CH I + II is described in table 2.24.
Table 2.22: SM (Sterlini-Mandelstam) growth
medium.
Component Volume / ml (100 ml)⁻¹
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Table 2.23: SM (Sterlini-Mandelstam) resuspension
medium.





Table 2.24: CH I + II, for SM (Sterlini-Mandelstam) medium (B. subtilis).
Glutamic acid was dissolved, using 10 M NaOH to adjust the pH to 7. The
combined solution was autoclaved.
Component Mass / g (940 ml)⁻¹




Potassium phosphate, monobasic (KH₂PO₄) 1.36  
Ammonium chloride (NH₄Cl) 1.34  
Sodium sulphate (Na₂SO₄) 0.11  
Ammonium nitrate (NH₄NO₃) 0.10  
Iron (III) chloride (FeCl₃·6H₂O) 0.0010
CH III comprises magnesium sulphate (MgSO₄·7H₂O, 1.98 gL⁻¹) and calcium
chloride (CaCl₂(aq) 10% w/v, 4 ml L⁻¹): combined and autoclaved.
CH IV is manganese sulphate (MnSO₄·4H₂O, 1.1 gml⁻¹), autoclaved.
CH V is L-tryptophan (2 mg ml⁻¹), filter-sterilized.
Sporulation salts are Solution A (SM variant, 1 ml L⁻¹) and Solution B (10 ml L⁻¹),
combined with 989 ml L⁻¹ water.




comprises iron (III) chloride (FeCl₃·6H₂O, 0.89 gL⁻¹), magnesium
chloride (MgCl₂·6H₂O, 8.30 gL⁻¹) and manganese chloride
(MnCl₂·4H₂O, 19.79 gL⁻¹): combined, autoclaved and stored at 4℃.
Solution B comprises ammonium chloride (NH₄Cl, 53.5 gL⁻¹), sodium sulphate
(Na₂SO₄, 10.6 gL⁻¹), potassium phosphate, monobasic (KH₂PO₄,
6.8 gL⁻¹) and ammonium nitrate (NH₄NO₃, 9.7 gL⁻¹): combined,
balanced with 2 M NaOH to pH 7.0 and stored at 4℃.
Solution C is L-glutamic acid, 5% w/v, adjusted to pH 7.0 with 10 M NaOH and
autoclaved.
Solution D is calcium chloride (CaCl₂) 0.1 M, autoclaved.
Solution E is magnesium sulphate (MgSO₄·7H₂O) 1 M, autoclaved.
Spore-forming bacteria as pharmaceutical factories Methods · 2
87
Basic microbiology2.2
Cells were routinely cultured in LB at 37℃ (E. coli, B. subtilis, B. thuringiensis YBT-020) or
30℃ (B. megaterium, B. cereus, B. thuringiensis HD-73), shaken in an orbital shaker at




To measure growth, liquid cultures were tested for optical absorption at 600 nm. These data
are reported here as OD₆₀₀ values, as is common in the literature on bacterial spores.
Agar plates
Solid media were set using High Gel strength technical agar (Melford). Broth containing
agar was autoclaved (see section 2.1.8) and either stored in a 50℃ water bath until use or, if
allowed to cool to room temperature, melted in a microwave then cooled to 50℃ in the
same water bath. Antibiotics were added only once the agar bottle temperature had
equilibrated.
Plates (90 mm) were filled with ∼20 ml molten agar medium, swirled to displace bubbles, and
allowed to set (∼10 min).
Gradient plates were poured in two stages. Plates were set to rest with one edge on the
horizontal surface and the diametrically opposite edge on the lid. Molten agar (10 ml)
containing no antibiotic were added, with care taken to ensure wetting of the entire base of
the plate. When set, the plates were placed horizontally, and agar containing the maximum
antibiotic concentration poured atop the existing wedge.
Gradient plate analysis2.2.2
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Validating 5-fluorouracil
With the positive control strain, 168∷69c, and negative control WT strain, B. subtilis 168,
LB cultures (10 ml) were inoculated and shaken at 37℃ and 225 rpm for 5 h. Samples
(100 µl) of each were spread on LB agar gradient plates, containing 5-fluorouracil from
0–50 µM (see section 2.2.1). The plates were incubated overnight at 37℃.
The NNPP (neural network promoter prediction) technique, as described by Reese (2001),
was performed to identify potential promoters, using the NNPP
(http://www.fruitfly.org/seq_tools/promoter.html) tool.
Promoter analysis2.2.3
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Cloning2.3
Sequences were designed with assistance of Snapgene (GSL Biotech LLC) or Benchling
(Benchling, Inc.). Codon optimization was performed, where relevant, using the GeneArt®




Primers were supplied by Sigma-Aldrich as dried ≥25 nmol pellets. Following resuspension
to a 100 µM stock in TE-1 buffer, and subsequent dilution with water to a working solution
of 10 µM, they were stored at -20℃.
High fidelity PCR
All PCRs (polymerase chain reactions) performed to construct fragments for subsequent
cloning or sequencing used Q5 polymerase (New England Biolabs UK), in the form of the
2×Master mix. Reactions proceeded consistent with the manufacturer’s protocols, briefly:
30 s melt at 98℃; 25–35 cycles of 98℃ for 5 s, an optimized annealing temperature for 10 s,
then a period, dependent on product size, at 72℃; and a final extension for 2 min at 72℃.
Where possible, primers were designed to anneal to the template at 60℃. However, for
overlap assemblies, primers were typically designed to anneal to PCR products at a higher
temperature, often 68℃ or 72℃, and the reaction proceeded with two stages of cycles; the
first for 5 cycles annealing at 60℃ and then a further 30 cycles at the higher temperature.
Such a process was designed to reduce mispriming and encourage the formation of a single
product band.
Templates for high fidelity PCR were plasmids: typically 1 µl at concentration 1ngµl⁻¹ was
used per reaction; or gDNA: typically 1µl at ∼100 ngµl⁻¹ per reaction.
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Genomic DNA extraction
From various Bacilli, gDNA (genomic DNA) was extracted using a QIAamp DNA mini kit
(QIAGEN) according to the manufacturer’s protocol, modified by Mohamed (2015).
Overnight culture (600 µl) was mechanically disrupted, as per section 2.7.1 (but with 20 s
pulses and no final dilution). Of the supernatant, 200 µl were combined with 20 µl
proteinase K, pulsed on a vortex, briefly, incubated for 10 min at 37℃, then mixed with
200 µl absolute ethanol and pulsed on a vortex for 15 s, until homogeneous. The sample was
applied to the provided spin columns and centrifuged, each time in a clean collection tube:
twice for 1 min at 6 000 g, then 3 min and 1 min at 20 000 g, and a final spin for 1min at
6000 g. Each was separated by addition of 500 µl AW1 buffer, 500 µl AW2 buffer, nothing,
then 500 µl AE buffer, incubated for 3–4 minutes before the final spin.
GeneArt® Strings™
DNA synthesized by Life Technologies/ThermoFisher was delivered dried, in centrifuge
tubes. The pellet was resuspended to 50 ngµl⁻¹ with TE-1 and the resulting solution used as
(cleaned-up) PCR product in subsequent assembly reactions.
While the GeneArt® gene synthesis service guarantees that their product is monoclonal and
correct, their Strings™ service offers no such guarantee; however the latter is both 10 % of
the cost and has a quicker turnaround (5–7 days, versus a fortnight).
PCR clean-up
PCR products were purified using the QIAquick Gel Extraction Kit (Qiagen), according to
the manufacturer’s protocol for either the gel extraction or the PCR clean-up.
Klenow extension
Where necessary, DNA was extended (with random bases) using the large (Klenow)
fragment of DNA Polymerase I (NEB). Gel extracted oligomers were combined with 1µl
dNTPs (deoxy-nucleoside triphosphate) and 1 µl Klenow polymerase for 30 min at 37℃.
The product was purified using gel extraction or PCR clean-up.
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DNA fragments were assembled into whole plasmids using Gibson assembly (Gibson et al.,
2010, 2009) or, later, the simpler and less expensive KAM (Klenow Assembly Method),
developed in-house by David Bailey (Bailey & Mohamed, 2018). The former was performed
with 2×Gibson assembly master mix (New England Biolabs) following the manufacturer’s
protocol.
KAM is similar to Gibson assembly, but dispenses with the polymerase and ligase, while
swapping the 5’→3’ exonuclease for a 3’→5’ variant: the Klenow fragment of E. coli DNA
polymerase I. Linear double-stranded DNA is digested from the 3’ ends, exposing 5’
overhangs. Homologous sequences anneal reversibly and, following transformation of
chemically competent cells (typically E. coli), the native DNA repair mechanisms complete
the plasmid assembly. Fragments designed for Gibson assembly are also compatible with
KAM. KAM was used routinely for five- or six-fragment assemblies, and even showed
success with assemblies of eight fragments.
Golden gate cloning, using standard (eukaryotic) parts, offered an alternative (Engler et al.,
2008; Patron et al., 2015). A 9× golden gate buffer was prepared with 1 volume ATP
(adenosine triphosphate) solution (100 mM, pH 7 with KOH; optionally stored at -80℃)
and 9 volumes of Cutsmart buffer (NEB). A 2× master mix was prepared with 22% v/v 9×
golden gate buffer, 10% v/v BsaI (NEB), 10% v/v T7 ligase (NEB) and 58% v/v water, and
stored in 20 µl aliquots at -20℃. Reactions (5 µl) used 2.5 µl master mix with 200 ng of each
plasmid.
Assembly2.3.3
Assemblies were verified by colony PCR, restriction digest, and Sanger sequencing.
Verification of constructs2.3.4
Colony PCR
For simple constructs, direct colony PCR is an effective screening method. A PCR reaction
was set up, using, as template, 1 µl of:
• a bacterial colony diluted in 20–50 µl water (for B. subtilis, B. cereus, B. thuringiensis and
E. coli), or
• a 50 µl sample of liquid culture, boiled for 10 min (B. megaterium).
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Primers were chosen such that the correct genotype would produce a band of known size,
typically shorter than 1.5 kb. It was often possible to multiplex the reaction, such that an
incorrect genotype would also produce a band, but at a different size, thereby indicating that
the reaction had worked but the template was incorrect; where that was the case, this has
been done.
The reactions used the taq enzyme, either as a) Reddymix (Thermo Scientific), b) OneTaq
2× master mix (New England Biolabs), c) 2×Taq master mix (New England Biolabs),
supplemented with 1 part in 80 160× (4%) Orange G dye (Sigma-Aldrich), or d) a in-house
produced taq master mix of the same composition, and reactions followed the manufacturers’
protocols, where available.
For the home-made taq the protocol was as per Reddymix: a 2 min melt at 95℃; 30–35
cycles of 25 s at 95℃, 35 s at 50℃, 1 min kb⁻¹ at 72℃; 5 min extension at 72℃; and storage
at 4℃. Master mixes contained loading dye and glycerol, for subsequent agarose gel
electrophoresis.
Reaction products were loaded (typically 7 µl) on a 1 wt% TAE (tris acetate EDTA)–agarose
gel containing 0.05% v/v ethidium bromide (Sigma Aldrich). Electrophoresis was conducted
at 5–10 Vcm⁻¹ for 35–75 min. A CCD (charge-coupled device) collected light from the gel
under UV transillumination, and KY-Link (JVC) recorded images (table 2.9).
Agarose gel images were routinely processed using the linear functions of GraphicsMagick
(GraphicsMagick Group); they were typically inverted for printing.
Restriction digest
Restriction digests have utility when screening constructed plasmids, as they give a reliable
indication of whether a construct has assembled correctly.
Typically, 500 µg of plasmid DNA would be digested in a 5 µl reaction containing 0.5 µl
10×buffer, ≤0.5 µl enzyme, topped up to 5 µl with deionized water. Where this was not
possible, due to a low miniprep yield for example, the digest would be designed to ensure
maximum DNA, a total volume as close to 5µl as possible, and no more than 10% v/v of the
restriction enzyme.
The other routine use of restriction digest follows a high-fidelity PCR from a plasmid
template. The 4 bp cutter DpnI (New England Biolabs; GA*|TC — the star indicates
methylation) digests adeno-methylated DNA. Added to crude PCR product, with the aim of
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reducing false positives following subsequent cloning, it digests only the template.
Typically, a 40 µl PCR product would be incubated at 37℃: either with 1.0 µl of enzyme for
2h, or overnight with 0.5 µl.
Sanger sequencing
Sanger sequencing was ordered as a service from either
• Department of Biochemistry, University of Cambridge; or
• Genewiz (formerly Beckmann-Coulter genomics).
Transformation2.3.5
E. coli
Chemically competent cells were produced using a protocol, reported by D. M. D. Bailey
(personal communications, 2013–2019). E. coli were streaked on LB-agar and incubated at
37℃ overnight. Large colonies (3–12) were transferred into 250 ml SOB (super optimal
broth) and incubated at room temperature and 225 rpm, until the culture reached OD₆₀₀
0.6–0.75. For E. coli DH5α, this took up to five days; E. coli Turbo cultures attained this
optical density with growth overnight. The culture was cooled on ice for 10 min, then
pelleted twice in a pre-chilled centrifuge at 2 500 g, for 10 min: respectively 1) resuspending
in 80 ml ice cold transforming buffer and incubating on ice) for 10 min, then 2)
resuspending in 20 ml ice cold transforming buffer. After addition of DMSO to 7% v/v and
incubation for 10 min on ice, aliquots of 50 µl were flash frozen in liquid nitrogen and stored
at -80℃.
Transformation of E. coli was via the protocol provided by New England Biolabs. Aliquots
(50 µl) were thawed on ice, mixed with a 5 µl assembly mix or 1µl 100 ngµl⁻¹ plasmid and
iced for 30 min. Following a 30 s heat shock at 42℃ and 5 min recovery on ice, 200 µl warm
SOB were added and cells were shaken at 37℃ for ½–1½ h (more than 1 h, if not
subsequently selecting on carbenicillin).
B. subtilis
Chemically competent B. subtilis subsp. subtilis 168 were prepared and transformed using the
procedure from Harwood & Cutting (1990), as modified by Mohamed (2015).
2 · Methods Spore-forming bacteria as pharmaceutical factories
94
Pre-warmed SpC medium (20 ml) was inoculated from an overnight culture in LB to an
OD₆₀₀ of 0.5, then shaken at 37℃ and 225 rpm, until stationary phase (identified as no
change in OD₆₀₀ over 30 min), usually 3½ h. Pre-warmed SpII (200 ml) was then inoculated
with 2 ml of this culture, and shaken at 37℃ and 120 rpm, for 90 min. The sample was
pelleted at 8 000 g for 5 min, then resuspended in 18 ml of the supernatant. After addition of
2ml sterile glycerol, the suspension was divided into 200 µl aliquots (or multiples thereof),
flash frozen, in liquid nitrogen, and stored at -80℃.
Supercompetent strains (B. subtilis 168∷690–derived)
Shi et al. (2013) generated a B. subtilis 168–derived supercompetent strain, which they
claimed transforms efficiently, is suitable for counter-selection, and can quickly recycle
markers. Strain B. subtilis 168∷690, and its derivatives, were handled in a similar manner to
that of Shi et al. (2013).
Overnight cultures of B. subtilis in LB were diluted 10×, grown to OD₆₀₀ ∼ 1, then shaken
with 0.4% w/v arabinose for 2h. Of the resulting mixture, 100 µl were incubated with
∼150 ng plasmid DNA, followed by 90 min shaking at 37℃. The whole mixture was spread
on LB plates containing appropriate antibiotic, before incubation at 37℃ overnight.
Colonies were selected the following morning.
Induced competent cells could be frozen for later use. After shaking with arabinose, DMSO
was added as a cryoprotectant, to 7% v/v. Aliquots were flash frozen in liquid nitrogen.
For a negative control, water would be added to the competent cells, at the same volume as
that of plasmid solution in the experimental samples.
B. megaterium
Transformation was via the PEG-mediated protoplast protocol of McCool & Cannon
(2001).
A confluent B. megaterium lawn on an LB-agar plate was suspended in 3 ml RHAF. A 25 ml
RHAF culture, in a 250 ml bottom-baffled flask, was inoculated with 200 µl of the
suspension, then incubated (37℃, 225 rpm) until the OD₆₀₀ reached 0.6, not exceeding 0.7
(typically 2 h). The culture was pelleted, four times, at 1 250 g and 4℃ for 7 min: respectively
1) resuspending in 2 ml RHAF broth; 2) resuspending in 1.8 ml RHAF broth and 200 µl
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lysozyme (12 mg ml⁻¹ in RHAF), then mixing gently and incubating at room temperature
for 10 min; 3) resuspending in 2 ml RHAF broth; and 4) resuspending in 1 ml RHAF broth.
Protoplasts were stored on ice immediately.
Protoplasts (200 µl) were transferred to a 50 ml centrifuge tube, with 10 µl plasmid (1 µg) and
gently mixed. A 30 % w/v PEG/RHAF solution (200 µl) was aspirated around the side of the
tube, without mixing. The tube was gently mixed, then immediately incubated in a 37℃
water bath, for 4–5 min. At this point 3ml RHAF was added, and the culture immediately
pelleted at 1 250 g and 4℃ for 7 min. The supernatant was fully discarded (with the tube
tipped upside down and lid changed) before the pellet was resuspended, gently, in 1 ml
RHAF. The tube was incubated at 30℃ and 175 rpm for 3 h, after which samples (200 µl)
were spread on selective RHAF plates. Plates were incubated at 30℃ overnight.
B. thuringiensis
Electrocompetent B. thuringiensis subsp. kurstaki HD-73 and B. thuringiensis subsp. finitimus
YBT-020 were prepared and transformed according to Lereclus et al. (1989).
Electrocompetent cells were prepared from an overnight culture, in LB. A 100 ml culture of
TSB was inoculated with 1ml of this overnight sample, then incubated at 37℃ and 225 rpm
until the OD₆₀₀ reached 0.5. (Note, 0.65 was acceptable, 0.8 was not.) The culture was split
in two and pelleted at 3000 g, for 7 min, four times: 1) resuspending in 35 ml Solution A
(electrocompetence variant), 2) resuspending in 35 ml said Solution A and resting on ice for
15 min, 3) resuspending in 35 ml electroporation buffer, and 4) resuspending in 1 ml
electroporation buffer. This volume was split among 50 µl aliquots, flash frozen in liquid
nitrogen, then stored at -80℃.
For electroporation, 500 ng of plasmid were added to a thawed 50 µl aliquot of
electrocompetent cells. The mixture was tapped to mix, incubated on ice for at least 5min,
then transferred to an electroporation cuvette, which had itself been rinsed with water,
dried, and cooled on ice. A 2 kV electric field was applied, at 200 Ω and 25 µF, and the cells
were immediately diluted with 1 ml of recovery medium. This culture was incubated at
30℃ and 225 rpm for 2–3 h, before being spread (200 µl) on LB plates containing selective
antibiotics.
B. cereus
The transformation protocol for B. cereus ATCC 14579 was as for B. thuringiensis.
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Plasmid pUCTV2 (and the derived pDBT2* plasmids) carry a Bacillus origin of replication that is
temperature sensitive: oriT. Strains transformed with such a plasmid will maintain the
plasmid at 30℃ or 37℃, but find it cured after growth at 42℃. Incubating such strains at
the latter temperature on LB containing an antibiotic, the resistance marker to which is
borne by the pDBT2* plasmid, will select for strains which integrate the plasmid into the
genome via a SXO (single crossover) event (see figure 2.1). Colonies were thus propagated,
to generate such a Campbell-type insertion mutation.
To isolate a DXO (double crossover) strain, the SXO colonies were re-plated on LB
(without antibiotic) twice per day, five days per week over a three week period, and
incubated for this time at 42℃. The pDBT2* plasmids bear two antibiotic resistance cassettes:
one on the backbone, one in the insert. Following every evening plating, each colony was










Figure 2.1: Allelic exchange via Campbell-type homologous crossover between the vector and target genome.
The plasmid matches a region upstream of the target with a region upstream of its replacement, and vice versa
for the downstream region. The first crossover event is the SXO (single crossover), known as a Campbell type
insertion, which can happen at one of two sites: producing one of two genotypes, as indicated. The upper path
shows the desired variants; this crosses over at the upstream region of homology. The single DNA strand that
results can cross over itself at either region of homology; the desired event is a crossover at the downstream
region.
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subcultured on a trio of LB agar plates: one without antibiotic (the propagation plate), the
others containing respectively antibiotics corresponding to the insert marker and the
backbone. Strains which grew on the insert plate, yet did not grow on the backbone plate,
were selected from the propagation plate. Candidate DXO strains were grown in 5 ml liquid
LB, with antibiotic, overnight at 30℃ and shaken at 225 rpm. These overnight cultures
were used for colony PCR verification.
Plasmids were extracted from 3–10 ml liquid cultures using the QIAprep Spin Miniprep Kit
(QIAGEN) according to its manufacturer’s protocol, from either overnight or (for E. coli
Turbo strains) day cultures. Options within the protocol were chosen to maximize yield and
correctness, specifically: incubating for the maximum time with wash buffers, and eluting
with elution buffer, warmed to 70℃.
Plasmid extraction2.3.7
The restriction enzyme I-SceI (New England Biolabs) cuts at the 18 bp recognition sequence
TAGGG|ATAA_CAGGGTAAT leaving the 4 bp ATAA overhang. This sequence is not present
within the B. subtilis 168 genome.
The plasmid pBKJ223 features the i-SceI gene coding for the enzyme, and has been used with
success in the Christie lab for markerless cloning in association with the pMAD vector in
B. cereus ATCC 14579 (Ghosh et al., 2018). Janes & Stibitz (2006) constructed the former
from B. amyloliquefaciens genomic DNA and the i-SceI sequence obtained from plasmid
pUC19RP12 (Pósfai et al., 1999).
Shi et al. (2013) produced pEBS-cop1 containing the i-SceI gene and a temperature sensitive
Bacillus ori, meaning the plasmid is cured by growth at 37℃. Here, double strand breaks
were induced in the B. subtilis genome using this plasmid.
A 2–10 ml LB culture of B. subtilis, transformed to erythromycin/lincomycinr with pEBS-
cop1, was grown overnight at 30℃ (or 37℃) and 225 rpm, then diluted 10× in (typically
10 ml) fresh LB. These day cultures were shaken at 30℃ (or 37℃) and 225 rpm until the
OD₆₀₀ reached 1.0, at which point they were induced with 10% w/v D-xylose (Sigma
Aldrich), to a final concentration of 1% w/v xylose. Shaking was continued at 30℃ and
225 rpm for a minimum of 6 h.
I-SceI digestion2.3.8
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Of this mixture, 100 µl were spread on 5-FU plates and incubated at 37℃ for 24 h. Colonies
were checked for chloramphenicol sensitivity on LB-chloramphenicol plates at 37℃, then
verified by colony PCR across the excised region. Correct clones were cured of pEBS-cop1
by growing on LB plates, without antibiotic, overnight at 50℃: as per the protocol of Shi et
al. (2013).





Two fragments of the B. megaterium QM B1551 genome (corresponding to sections of
spoVFA and spoVFB) and one from the p7Z6 plasmid (corresponding to the zeocin
resistance gene ble) were amplified by PCR using primers in table 2.25. These fragments
were assembled into pUCTV2, which had been digested with EcoRI-HF (NEB UK), using
Gibson assembly. To avoid excision of the ble gene due to recombination at lox sites during
cloning with E. coli DH5α, this antibiotic resistance cassette was switched for spc
(spectinomycin resistance) from HindIII-HF (NEB UK)-cut, Klenow-extended pDG1726.
Inverse PCR was used to create a backbone free of the remaining ble operon, into which the
spc fragment was ligated (figure 3.1). Competent E. coli DH5α transformed this plasmid;
colonies which grew on LB-spectinomycin plates were cultured for miniprep.
Table 2.25: PCR primers, to construct plasmid pDBT21s.
Label Template Sequence
y001 spoVFA 5’ cagctatgaccatgattacgaattcGCGACGAAATATCAGATAGAGGAGC
y004 spoVFA 3’ tccaatggaaaaggttgggaattcCTGTTTATCTTCAAGCGCTGCG
y007 p7Z6 GGGTTTGCAACCTTTCTATCTTTCTttcgagctcggtacccgggg
y008 spoVFA 3’ cggtagaatcgtcgacctgcaggTAATTTGGGAGCAGAAGTGTTACCG
y009 p7Z6 CGGTAACACTTCTGCTCCCAAATTAcctgcaggtcgacgattctaccg
y010 spoVFA 5’ ccccgggtaccgagctcgaaAGAAAGATAGAAAGGTTGCAAACCC
Strains 1551∷21s+ and 1462∷21s
B. megaterium QM B1551 and B. megaterium PS1462 were transformed to dual
tetracycline–spectinomycin resistance, via PEG–mediated protoplast transformation.
Transformants were subsequently incubated on LB-spectinomycin at 42℃ to induce a SXO
(single crossover) mutation (see section 2.3.6). The location of integration into the
chromosome was verified by PCR. The amplified region was from 100 bp upstream (in the
genome) of the upstream homology in pDBT21s, to a region only present in the vector; the
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PCR was designed to produce defined bands only if a SXO had occurred. Single crossover
strains were named for the final, DXO strain, but with a suffix: + for integration at the
upstream region of homology, - for downstream.
The SXO strains were subsequently cultured to isolate DXO (double crossover) mutants, as
described in section 2.3.6. Vegetative strains based on the PS1462 background differ from
those based on QM B1551 only in having a kanamycinr phenotype. Candidate DXO strains
were screened by PCR for loss of QM B1551 plasmid 7, pBM700 (Manetsberger, 2015).
Table 2.8 includes all B. thuringiensis strains constructed in this work.










































Figure 2.2: Map of plasmid pDBT30, based on pHT315. The BsaI deletions and added Receptor elements
enable Golden Gate cloning with standard parts. Antibiotic cassettes are erm (erythromycin) and bla
(carbenicillin); the E. coli and Bacillus origins are ori and ori1030’ respectively.
Cry1Ac sub-unit fusions
Library plasmid pDBT12d was constructed using KAM from plasmid pDBT10 (pGEM-3Z) and
B. thuringiensis subsp. kurstaki HD-73 gDNA. Sequences, corresponding to cry1Ac variants
detailed in table 5.1, were subsequently amplified from pDBT12d, assembled using KAM, and
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Table 2.26: PCR primers, to construct plasmid pDBT30. Primers y149 and y150 were used to delete
the BsaI site from bla in other plasmids, too.
Label Template Sequence
y149 pHT315 bla -BsaI gtgagcgtggttctcgcggtatcattgcag
y150 pHT315 bla -BsaI accgcgagaaccacgctcaccggc
y151 pHT315 ori3010 -BsaI caatctcaattcgagtcctcggcatctaagccag
y152 pHT315 ori3010 -BsaI gatgccgaggactcgaattgagattggttgcat
y156 pHT315 +BsaI attcggtctcactccactggccgtcgttttaca
y157 pHT315 +BsaI ggccagtggagtgagaccgaattcgagctcggtaccc
y158 pGEM-3Z tacgccagcgtgagaccaagcttgcatgcctgca
y159 pGEM-3Z ttggtctcacgctggcgtaatcatggtcatagct
used to transform E. coli Turbo cells to carbenicillin resistance. PDMR-carbenicillin cultures
(10 ml) were inoculated with individual colonies, resulting from each transformation.
Primers are listed in Table 2.27.
The various pDBT31* plasmids were used to transform electrocompetent B. thuringiensis
HD-73 to erythromycin/lincomycin resistance, with successful transformants subsequently
induced to sporulate in 5 ml CCY medium. The resulting cultures were pelleted and
resuspended in sterile deionized water to 500 µl total volume, for microscopy.
Additionally, with pDBT3130 and pDBT3140, B. thuringiensis subsp. finitimus YBT-020 were
transformed to erythromycin/lincomycin resistance and subsequently induced to sporulate
in 5 ml CCY (B. cereus group).
Antibody fusions
Table 2.28 lists primers used to construct plasmids for antibody triple fusions. The plasmids
in table 5.3 were assembled as the sub-unit fusions. E. coli cloning strains were checked for
the red hue, associated with mCherry on the cry1Ac expression system. B. thuringiensis subsp.
kurstaki HD-73 were transformed and selected as before, with spores produced as 5 ml CCY
cultures, then concentrated to 500 µl for microscopy.
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Table 2.27: PCR primers, to construct cry1Ac-mCherry plasmids. The mCherry fragments were amplified from
pDBT654m.
Label Template Sequence
y073 pDBT10, pDBT30 tctagagtcgacctgcaggc
y074 pDBT10, pDBT30 ggatccccgggtaccgagctcgaat
y177 cry1Ac operon tccggtctcaggagagaacgtgagggctgg
y178 cry1Ac operon ctctagaggtctctagcgcagaaccttttctacatactttctagg
y252 pDBT30 aggttctgcgctggcgtaatcatgg
y253 pDBT30 gttctctccactggccgtcgttttaca
y254 cry1Ac 5’ ggccagtggagagaacgtgagggc
y255 cry1Ac 3’ gccagcgcagaaccttttctacatactttctagg
y256 cry1Ac 6×His ccaccatcattagtctcatgcaaactcaggt
y257 cry1Ac 6×His atgagactaatgatggtggtgatgatgttcctccataaggagtaattcca
y258 mCherry ggaggaacggggtgtgagcaagg
y259 mCherry tgagactaatgatggtggtgatgatgcttgtacagctcg
y260 cry1Ac protoxin caccccgttcctccataaggagtaattcca
y261 cry1Ac leader tcacaccccgtggggtgtaaccagtttct
y262 mCherry ttacaccccacggggtgtgagcaagg
y263 mCherry ttgcagtcttgtacagctcgtccatg
y264 cry1Ac protoxin tgtacaagactgcaacactcgagg
y265 cry1Ac 5’ acaccccgcataagttacctccatctcttttattaaga
y266 mCherry aacttatgcggggtgtgagcaagg
y268 cry1Ac protoxin caccccaactgcaacactcgagg
y269 cry1Ac leader gtgttgcagttggggtgtaaccagtttct
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Table 2.28: PCR primers, to construct cry1Ac-NIP109 plasmids.
Label Template Sequence
y333 NIP109 light chain aactggttacaccccagatattcaaatgacacaatcaccg
y334 NIP109 light chain cctcgagtgttgcagtgcattcgcctctattaaatgatttt
y335 NIP109 light chain tactccttatggaggaagatattcaaatgacacaatcaccg
y336 NIP109 light chain tgagactaatgatggtggtgatgatggcattcgcctctattaaatgattt
y337 NIP109 heavy chain actggttacaccccacaagttaatctgagagaatcaggc
y338 NIP109 heavy chain gcctcgagtgttgcagttttgccagggctcagtg
y339 NIP109 heavy chain actccttatggaggaacaagttaatctgagagaatcaggc
y340 NIP109 heavy chain gcatgagactaatgatggtggtgatgatgtttgccagg
y341 NIP109 scFv gcctcgagtgttgcagttgatgaaactgtaaccagtgtgaacc
y342 NIP109 scFv tgagactaatgatggtggtgatgatgtgatgaaactgt
Table 2.8 lists the B. cereus strains constructed in this work. With pDBT3130 and pDBT3140,
B. cereus ATCC 14579 were transformed to erythromycin/lincomycin resistance and
subsequently induced to sporulate in 5 ml CCY medium.
B. cereus2.4.3
Tables 2.7, 2.8 list the strains engineered for chapter 4 and chapter 5 respectively.
B. subtilis2.4.4
Antibodies
MedImmune (Cambridge, UK) generously provided coding sequences for the NIP109
antibody as a pair of plasmids, codon optimized for expression by Bacillus subtilis. One of the
pair (pMA-NIP109-Lc) bears the light chain; the heavy chain is within the other (pMA-
NIP109-Hc). Listing A1.1 lists the peptide sequences used for antibody fusions.
Fragments as GeneArt® Strings™ (ThermoFisher), with and without GFP fusions, were
inserted into the vector pDBT60. This plasmid contains the SASP promoter, PsspB, which
features a σG binding site (Connors et al., 1986; Mohamed, 2015). The vector backbone was
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amplified as two fragments (see table 2.29 for primers), and assembled with the Strings™
using KAM. Competent E. coli DH5α were transformed to carbenicillin resistance with the
ligation mix.
Each vector was used to transform transform chemically competent B. subtilis subsp. subtilis
168 to chloramphenicol resistance, and clones, selected on LB-chloramphenicol plates, were
isolated for subsequent study. The strains were named in the same manner as previously: e.g.
the strain transformed with plasmid pDBT611s became 168∷611s. Figure 4.1 shows a sample
plasmids.







DNA sequences corresponding to the nanobodies in table 4.2 were designed, codon
optimized for B. subtilis, and subsequently synthesized as GeneArt® Strings™
(ThermoFisher). Fragments were assembled, using KAM, into pGEM-3Z for the library
plasmids pDBT15*. The presence of coding sequences for anti–β-lactamase nanobodies had
no effect on carbenicillin selection, for E. coli DH5α used for assembly. This nanobody work
was performed by undergraduate research students Joshua Cozens and Luke Vinter. Primers
are in table 2.30.
Nanobody coding sequences were assembled similarly into pDBT60-derived vectors for
expression during sporulation, on the PsspB promoter. This includes the VHHGFP4
chromobody (pDBT654m). With these plasmids, aliquots of chemically competent
B. subtilis 168 were transformed to chloramphenicol resistance. Strains 168∷65?0, confirmed
by colony PCR to contain the correct insertion at the amyE locus, were cultured and
induced to sporulate. This nanobody work was performed by undergraduate research
students Joshua Cozens and Luke Vinter, and masters student Tayla Gordon.
Additionally, Tayla Gordon cloned a chromobody with bcII10 and mCherry, to make
pDBT651m (and B. subtilis strain 168∷651m).
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Table 2.30: PCR primers, to construct nanobody plasmids. Primers tg_02 and tg_03 were designed by Tayla Gordon.
Label Template Sequence
y073 pDBT10, pDBT30 tctagagtcgacctgcaggc
y074 pDBT10, pDBT30 ggatccccgggtaccgagctcgaat
y108 nanobody 5’ taaaggaggaaggatccatgGACCAAGTTCAACTGGTTG
y109 nanobody 5’ ggggacgttaatgatggtggtgatgatgTGATGAAACTGTAACTTGTGTG
y110 nanobody 5’ ttgaatttctTGATGAAACTGTAACTTGTGTG
y111 chromobody linker agtttcatcaAGAAATTCAATCAGCTCACTG




y120 chromobody linker GTCAACAGTTCCGAGAGCAAGAGATCCG
y121 chromobody linker TTGCTCTCGGAACTGTTGACGGAATTGAC
y122 pDBT60 (with His-
tag)
catcatcaccaccatcatTAAGAATTCTCATG
y123 nanobody 3’ AGAATTCTTAatgatggtggtgatgatgtgatgaaactgtaacttgtgtg
y133 nanobody 5’ ataaaaaggagattttacacATGCAAGTTCAACTGGTTG
y134 nanobody 3’ GAGAATTCTTAATGATGGTGGTGATGATGTGATGAAACTG
tg_02 chromobody 3’ GCCACCTCCGCCTGAACCGCCTCCACCtgatgaaactgtaacttgtgtgc
tg_03 mCherry GGAGGTGGCTCTGGCGGTGGCGGATCGcggggtgtgagcaagggcg
Inducibly (super-)competent B. subtilis
Table 2.31 lists primers used to construct inducibly supercompetent B. subtilis.
Plasmid pDBT69c was assembled using KAM and checked by restriction digest with PstI.
Following transformation of chemically competent B. subtilis 168, three candidate 168∷69c
colonies showed the correct band.
For plasmid pDBT69d, fragments were assembled using KAM (see section 2.3.3); transformed
colonies of E. coli Turbo cells were selected on LB-carbenicillin plates. Plasmids were
verified with SspI SacI double digest and Sanger sequencing of the indel region. Chemically
competent B. subtilis 168 were transformed to chloramphenicolr with pDBT69d, and selected
on LB plates containing chloramphenicol.
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Table 2.31: PCR primers, to construct pDBT69? plasmids.
Label Template Sequence
y180 pDBT60 TCTTGACACTCCTTATTTGATTTTTTGAAGACT
y181 upp 5’ TAAGGAGTGTCAAGAgcgcttacttcatggtggat





y187 upp 3’ aaactgaatgaataatgaacattctgtggagacgt









y211 upp 5’ cccgccgggcataagc
Candidate supercompetent strains were transformed with pEBS-cop1 to erythromycin/
lincomycinr via induced competence, and colonies were cultured at 30℃. Markers were
then excised by activating the xylose-inducible i-sceI gene, as described in section 2.3.8.
Strains were selected on LB agar plates (selection plates) containing 38 µM 5-FU. Colonies
were propagated on LB–5-FU at 37℃ (propagation plates) and cured (cure plates) at 50℃,
on LB agar. At the same time, the same colonies were challenged on agar plates containing
chloramphenicol or erythromycin/lincomycin, at 37℃, for the desired phenotype (
chloramphenicols 5-FUr erythromycin/lincomycins). Candidate strains were challenged
with antibiotic both before and after a sporulation-germination cycle. The resulting strain
was labelled 168∷690.
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∆cotE mutants
Plasmids pDBT72e, pDBT12u and pDBT71e, were designed to introduce the ∆cotE mutation into
B. subtilis (see figure 2.3). Table 2.32 lists the primers. First, pDBT72e was assembled, from pSS
and B. subtilis gDNA (genomic DNA). The template for amplification of the spectinomycin
resistance cassette, spc, was pDG1662. Library plasmid pDBT12u, with an improved cassette,
was assembled with spc, upp from B. subtilis gDNA and pDBT130. This cassette was then used,
with B. subtilis gDNA and pSS, to assemble pDBT71e. E. coli Turbo transformants of pDBT71e
were selected on carbenicillin, then patched onto LB medium containing spectinomycin.
Plasmid pDBT71e was used to transform B. subtilis 168∷690 to spectinomycin resistance, via
arabinose-induced chemical competence. The resulting strain was transformed using pEBS-


















































Figure 2.3: Plasmid pDBT71e, constructed to delete cotE from B. subtilis. The two regions flanking the
spc–upp cassette match those flanking the cotE sequence in the genome. On recombination, by double
crossover, these two regions of homology would excise the native gene, replacing it with the paired selection-
counter-selection cassette, and thereby introducing the twin spectinomycinr 5-FUs phenotype. The I-SceI site
lies between two regions of homology from the 3’ end of cotE; following digestion, recombination at these loci
will excise the selection and counter-selection cassettes.
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y232 cotE 5’ acctgcaggcatgCgcttgaagagattcctgttatcc
y233 cotE 5’ aaaagtgataaaagaatgatatgataaagtttatacgcggctga
y234 pDBT70 cassette cattcttttatcactttttgtttatgTCGAACTCGAGCCATGG
y235 pDBT70 cassette ATTACCCTGTTATCCCTAACTTTAC
y236 cotE 3’ TAGGGATAACAGGGTAATatatcattcttttatcactttttgtttatgt
y237 cotE 3’ GTAGATCTCTTAAGTcggctttcggatcttcc
y247 pDBT130 agagcagctacacgcGGTAagagacctctagagtcgacct
y248 pDBT130 ATTACCCTGTTATCCCTAAAGCtgagaccggatccccg
y250 spc (pDG1662) GACGTAAAGTaagcttggagtatggccactaatactaagt
y251 pDBT72e aagcttACTTTACGTCTCCACAGAATGt
y267 spc (pDG1662) TAGGGATAACAGGGTAATGCATATGATCAGATCTTAAGGCC
y270 pDBT70 ggtgaagcttCCGTACTTAAGAGATCTACTAGTCATATGTGA
y271 pDBT70 aagcCTCCgcctgcaggtcgact
y272 cotE 5’ gcaggcGGAGgcttgaagagattcctgttatcc
y275 cotE 3’ cgcGGTAtaaaaaagggactaggggagac
y276 cotE 3’ GTACGGaagcttcaccgccgtctctgc
Cry1Ac
With pDBT3130 and pDBT3140, B. subtilis subsp. subtilis 168∷690 were transformed to
erythromycin/lincomycin resistance and subsequently induced to sporulate on 2×SG plates.
Plasmids pDBT316* were constructed, containing the full length cry1Ac gene (pDBT3160, c.f.
pDBT310) and just mCherry (pDBT31610, c.f. pDBT31710) respectively. These plasmids
substituted the B. subtilis σG promoter for the B. thuringiensis cry1Ac sequence table 2.33.
They were used to transform B. subtilis 168∷690 to erythromycin/lincomycin resistance.
Clones were induced to sporulate by nutrient exhaustion (see section 2.5.1), before
examination by phase contrast and fluorescence microscopy. Table 2.33 shows the
promoters native to cry1Ac, versus the σG alternative, from B. subtilis.
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Spore-specific microbiology2.5
For B. subtilis, two methods were used (Nicholson & Setlow, 1990).
1. Sporulation by resuspension, a synchronized approach, yields a small quantity of spores
with moderate work.
2. Sporulation by nutrient exhaustion on 140 mm plates with 2×SG media induces
unsynchronized sporulation, with minimal work.
B. megaterium and B. cereus/B. thuringiensis were induced to sporulate by nutrient exhaustion
in SNB (supplemented nutrient broth) and CCY (casein casein yeast) medium, respectively
(Nicholson & Setlow, 1990). After ∼12 h, these cells depleted the broth of nutrients, and start
to sporulate. After a further ∼24 h, the broth contained almost all spores, with few to no
vegetative cells.
Sporulation media contained no antibiotic.
Sporulation2.5.1
Sporulation by resuspension (B. subtilis)
SM growth media (5 ml) were inoculated and incubated at 37℃ and 225 rpm overnight.
The cultures were diluted with warm growth medium to OD₆₀₀ of ∼0.1, then incubated at
the same conditions until the OD₆₀₀ had reached 0.5–0.8. After pelleting at 8000 g and room
temperature, for 5min, cells were resuspended with warm resuspension medium, to the
same volumes (and in the same vessels) as the previous growth phase; the time of
resuspension was recorded as time t₀. Samples were incubated as before, and sampled at
various times.
Sporulation by nutrient exhaustion (B. subtilis)
Overnight culture in LB (600 µl) were spread on a 140 mm 2×SG, or 2×SGR, plate. Plates
were wrapped loosely in polythene and incubated at 37℃ for 5 days.
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Sporulation by nutrient exhaustion (B. megaterium)
Cultures were inoculated in liquid volumes 400 ml in a 2 L bottom baffled volumetric flask
(of true volume 2.5 L), or 2 ml in a 50 ml conical-bottomed centrifuge tube (true volume
55 ml), and shaken at 30℃ and 225 rpm, for up to two days; true volumes indicate the gas
volumes in each vessel, important for aeration.
Media, supplemented with DPA (dipicolinic acid), were prepared by adding DPA and
NaOH in a 2:1 molar ratio, i.e. a mass of 0.48 (g NaOH) (g DPA)⁻¹.
For most analyses, spores must be washed free of nutrients, cell debris (sporangia) and any
remaining vegetative cells. Typically in the Christie laboratory this is done with water (as
per Church et al., 1954). A more effective approach uses an aqueous two-phase system to
split the washing into two phases:
1. separating spores from vegetative cells and sporangia, and
2. diluting any remaining soluble components of the sporulation medium.
Spore washing2.5.2
B. subtilis
Spores were recovered from 2×SG plates with a sterile spreader and ∼22.5 ml water, and
transferred to a 50 ml Nalgene® centrifuge tube.
System W (PEG-1000 and 3 M buffered potassium phosphate: Sacks, 1969) separated
B. subtilis spore suspensions from plates into a PEG rich upper phase containing spores, and a
salt-rich lower phase; cells migrated to the interface. Progressive decanting, pelleting and
recycling of the upper phase (Delafield et al., 1968) was used to extract spores until that phase
became relatively transparent (typically two cycles). The spores were then washed once with
water, before transfer to centrifuge tubes for storage. The yield was noticeably greater than
for the traditional water washing technique (this has not been tested quantitatively, here).
Note that with PEG-6000, the upper phase of the System W master mix solidified at room
temperature, complicating processing. The spore preparations had huge variation in ratio
between the two phases. This was avoided by switching to PEG-1000.
2 · Methods Spore-forming bacteria as pharmaceutical factories
112
Finally, ball milling was occasionally used to diminish clumps, where it was not desirable to
add a surfactant. Glass beads, of 1 mm diameter, were added to a 15 ml centrifuge tube
containing the spore sample. The tube was pulsed on a vortex until clumps were sufficiently
diminished, as measured with phase contrast microscopy.
B. megaterium
B. megaterium spores were washed with water to >99% spores, as measured by phase contrast
microscopy (Gupta et al., 2013).
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All optical microscopy was performed on a BX53 Upright Microscope (Olympus) fitted
with a 10× eyepiece and one of the objective lenses listed in table 2.34. This microscope was
fitted with a Retiga 2000R CCD (QImaging) and operated using the software suite
QCapture Pro (QImaging).
Transmission electron microscopy was performed on samples prepared by Sina Schack;
images were taken by her at CAIC (Cambridge Advanced Imaging Centre) with assistance
of Dr. Katrin Mueller and Lyn Carter.
Microscopy2.6
Table 2.34: Lenses and corresponding magnifications, for optical microscopy. Lenses supplied by
Nikon Instruments, Inc.
Objective magnification Overall magnification Interface
10× 100× Air
40× 400× Air
100× 1000× Type F immersion oil
Samples (2 µl) of culture were transferred by micropipette to a ground glass slide (VWR) and
covered with a coverslip. For one or two samples per slide, 22 mm × 22 mm coverslips would
be used; with three samples each had a smaller coverslip (18 mm × 18 mm) instead. Spores or
cells on agar plates were scraped with a micropipette tip loaded with 2 µl water, then rinsed
with that water onto the slide.
Slide preparation2.6.1
Agar pad
Spores were fixed using an agar pad: 600 µl of 2% w/w agarose, aspirated quickly onto a slide
and immediately sandwiched with another slide, to set.
Phase images paired with fluorescence images were typically taken with the same filter as
the fluorescent images, to avoid the stage shifting on changing filter.
Phase contrast2.6.2
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Samples were illuminated with a mercury lamp, through blue or green filters (see table 2.35).
Whereas for GFP fluorescence the filters were adjusted from phase contrast to collect more
light, this was not done for mCherry fluorescence. Sets of GFP micrographs were
normalized.
Fluorescence2.6.3
Table 2.35: Fluorophores, used in fluorescence microscopy.
Fluorophor Excitation / nm Emission / nm Filter
GFP (green fluorescent protein) 488 510 Blue
mCherry 587 610 Green
Images were prepared with FiJi (ImageJ), GraphicsMagick (GraphicsMagick Group) and
Inkscape (Software Freedom Conservancy).
Many micrographs are presented here as triples of phase contrast image on the left,
fluorescence on the right, and an overlay in the middle. The overlays were created using the
composite -compose Over function of GraphicsMagick. The fluorescence micrographs are
all presented as negatives, with dark regions corresponding to greater intensity.
Polyacrylamide gels were recorded as monochromatic images, and are presented in false
colour.
Image processing2.6.4
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Protein processing2.7
Spores were mechanically disrupted using a FastPrep FP120 Cell Disrupter (Thermo
Scientific) based on the protocol established by Mohamed (2015). A spore pellet of
equivalent OD₆₀₀ 5 (i.e. if resuspended in 5 ml if would have had an OD₆₀₀ of 1) was
resuspended in 400 µl disruption buffer and supplemented with 2µl ml⁻¹ 1 M PMSFEtOH. The
suspension was transferred to lysing tubes: either a) Lysing Matrix B 2 ml tubes (MP
Biomedicals), or b) those same tubes containing 0.1 µm zirconia (i.e. the in-house version);
and beaten in the disrupter 2–3 times at speed 6 for 30 s, separated by 5 min coolings on ice.
The disruption was confirmed with phase contrast microscopy. The supernatant, typically
650 µl after dilution with 500 µl buffer and pulses on a vortex, was recovered to a
microcentrifuge tube.
Spore disruption2.7.1
The extracts from cell or spore disruption contained the total protein content of the cell or
spore core. To isolate the soluble fraction, a portion of the liquid recovered from disruption
was pelleted at top speed in a microcentrifuge. The resulting supernatant contained the
soluble protein fraction.
Isolation of soluble protein fraction2.7.2
Polyacrylamide gel electrophoresis was performed using NuPAGE reagents and either
NuPAGE 4% Bis-Tris Mini protein gels or RunBlue SDS Protein Gels 4–12%, per the
manufacturers’ instructions. Either 20× MES, 2-(N-morpholino)ethanesulphonic acid
(Thermo Scientific) or 20× MOPS, 3-(N-morpholino)propanesulphonic acid (Thermo
Scientific) buffer was diluted to either 800 ml or 400 ml for the Xcell SureLock™ Mini-cell
electrophoresis tanks (Thermo Scientific) or Bolt™ Mini gel tank (Thermo Scientific),
respectively. NuPAGE antioxidant (Thermo Scientific) was added (500 µl) to the 200 ml of
buffer at the well side of the gel, with the remaining buffer in the other compartment of the
chamber. Of each sample buffer–containing sample, 90% v/v (typically 18 µl) were mixed
with 10% v/v (2 µl) NuPAGE sample reducing agent and loaded into each well. Novex®
Sharp Pre-stained Protein Standard (Thermo Scientific) (5 µl) were loaded as a ladder for
SDS-PAGE2.7.3
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subsequent Coomassie staining, and 2 µl MagickMark™ XP Western Protein standard
(Thermo Scientific) were used if the gel were destined for western blot. Sample buffer was
loaded into any empty wells to reduce smiling.
Electrophoresis was conducted with a PowerPac 200 power supply (Bio-Rad) for 35 min at
200 V (MES) or 50 min at 200 V (MOPS).
Sample denaturation for PAGE
Samples of total or soluble protein were mixed in a 13:5 volumetric ratio of protein sample,
to 4× NuPAGE LDS (lithium dodecyl sulphate) sample buffer, typically 52 µl protein sample
with 20 µl sample buffer. Mixtures were incubated at 70℃ for 10 min (standard conditions).
The resulting samples were either placed on ice and used immediately for PAGE, stored for
up to a week at 4℃, or stored long term at -20℃.
In the modified conditions, after addition of LDS (lithium dodecyl sulphate) sample buffer,
samples were boiled for 5min rather than incubated for 10 min at 70℃ (Thomas & Ellar,
1983).
Coomassie stain visualisation
Gels were released from their frames, rinsed with sterile water, then shaken for 2 h in a
140 mm Petri dish containing 50 ml Quick Coomassie stain (Generon). The Coomassie was
then recovered, while the stained gels were rinsed again in sterile water, then returned to the
Petri dish and shaken in 50 ml sterile water for at least 4 h, typically overnight. Gels were
stored for up to a week in 20% v/v ethanol.
Images were taken using either the G-Box gel documentation system (Syngene) or the main
camera of a OnePlus One (OnePlus) with an Exmor IMX214 CMOS (Sony
Semiconductor).
Western blot
Blots were performed as Mohamed (2015), with the only difference being use of Amersham
Hybond LFP 0.2 PVDF (polyvinylidene difluoride) membranes (GE Healthcare).
Membranes were wetted in methanol (30 s), rinsed in water and then soaked in transfer
buffer (5 min). A semi-dry blotting stack was built with the membrane and transfer
buffer–equilibrated polyacrylamide gel sandwiched between two sets of equilibrated
blotting paper. The blotter was operated at 15 V for 20 min, and the membrane blocked
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with TBST-BSA (either for 2 h at room temperature on a 3D rocking platform, or at 4℃
overnight). Membranes were labelled with 2.5–10 µl antibody in 10 ml TBST-BSA for an
hour; if not using a conjugate, secondary labelling took 30 min. Gels were sometimes fixed
with TMB (3,3',5,5'-tetramethylbenzidine), using Pierce 1-Step™ Ultra TMB-Blotting
Solution (ThermoFisher)
Blots images were taken using either the enhanced chemiluminescence option on the G-Box
gel documentation system (Syngene) or (where fixed with TMB) the main camera of a
OnePlus One (OnePlus) with an Exmor IMX214 CMOS (Sony Semiconductor).
Proteins were purified, either using an ÄKTA Pure (General Electric), with the supplied
UNICONV software and protocols optimized by Al Riyami (2017), or using Ni-NTA Spin
columns (Qiagen), according to the manufacturer’s protocols. On the ÄKTA, the
HisTrap™ HP (GE Life Sciences) and HisTrap™ FF crude (GE Life Sciences) columns
were used.
Purification2.7.4
Buffer exchange was conducted by repeated concentration and dilution using Amicon®
Centrifugal Filter Units (Merck Millipore), based on the protocol optimized by Al Riyami
(2017). Columns were washed with water, then equilibrated and centrifuged with room
temperature buffer for 15 min. All centrifugation steps were performed at 3 220 g and room
temperature. Up to 4ml of sample were then transferred to the membrane, before
centrifugation for (initially) 20 min and until the solution was at the desired concentration.
New buffers were added to the columns, and the centrifugation repeated as necessary. The
samples were then diluted with the new buffers, and these retentates recovered by aspiration.
Buffer exchange2.7.5
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Spore assays2.8
Spores’ DPA concentrations were measured by colorimetric assay (Janssen et al., 1958;
Nicholson & Setlow, 1990; Rotman & Fields, 1968). Spores grown in 2 ml culture were
centrifuged, resuspended in 1 ml water, boiled for 20 min, then iced for 15 min. Samples
(400 µl) were diluted in equal volumes of water, to which 200 µl assay reagent (L-cysteine,
FeSO₄ and (NH₄)₂SO₄ in pH 4.6 acetate buffer) were added. These samples and assays of
known DPA concentration (for a calibration curve) were measured for absorption at 440 nm
in a Lambda 19 photospectrometer (PerkinElmer) with a 1 cm path length (Nicholson &
Setlow, 1990), or measures of 100 µl were analysed in 96-well plates using a Wallac Envision
2104 Multiplate Reader (PerkinElmer).
Concentrations were calculated based on standard curves, taken contemporaneously with
the readings. The standard curves were consistent among the runs of the experiments
(figure A1.1). Results were normalized to the levels of DPA measured for the WT strain,
within each batch.
DPA assay2.8.1
Spores were washed with 1 M NaCl and water, then 1 ml of spores with OD₆₀₀ of 1 were
pelleted and resuspended in 1 ml 50 mM Tris-HCl (pH 7.2). Experimental samples contained
50 µgml⁻¹ lysozyme. Samples were placed on a rolling platform overnight at 4℃.
Lysozyme susceptibility2.8.2
A protocol based on that of Church & Halvorson (1959) was followed. Spores at OD₆₀₀ of 1
were incubated at various temperatures for 20 min, then plated on LB to estimate the loss of
viability.
Wet heat susceptibility2.8.3
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Spores were serially diluted, by a factor of ten each time, over six orders of magnitude,
before plating on LB agar (Nicholson & Setlow, 1990). The plating arrangement of Miles et
al. (1938) was followed: 10 µl drops of each dilutions were plated, in triplicate. The plates
were incubated at 30℃ for 12 h, after which the number of colonies were counted.
Counts were analysed using Bayesian inference techniques (Clough et al., 2005; Comoglio
et al., 2013; Hedges, 2002; Niemelä, 2003). In particular, the R library presented by
Comoglio et al. (2013) was used to process the serial dilution counts. The relative viability of
the spores is directly proportional to the dilution-adjusted number of colonies (for example,
3 colonies at 10⁴ dilution is the same viability as 30 colonies at 10³ dilution, but with less
statistical power). Viabilities are presented as the maximum likelihood estimators for the
population count, with errors corresponding to the 95% credible intervals.
Judgements as to whether samples could be said to be drawn from different populations
were informed by BEST (Bayesian estimation [that] supersedes the *t*-test); strictly this
should be modified for Poisson experiments such as colony counts, but as probability
distributions from samples are adequately described by the t-distribution, the existing
framework suffices (Kruschke, 2013).
Spore viability count2.8.4
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The effects of dipicolinic acid on
spores
Chapter 3
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Although DPA (2,6-dipicolinic acid) is known to contribute to spores’ heat resistance, the
precise mechanism by which it does this is unknown (Setlow, 2014). Given that wet heat
damages proteins, in preventing that damage, DPA must be protecting the proteins in the
spore core. If it does so in the spore core, why not in a pharmaceutical formulation?
An important factor in protein damage is water. At a molecular level, proteins in water are
free to alter their configurations; given excessive kinetic energy, they are free to alter their
configurations irreversibly, and thereby denature. In addition, water can be ionized,
producing superoxide radicals, which directly degrade proteins. Water is thus critical to the
heat susceptibility, and therefore heat resistance, of spores. It is possible that the sole effect of
DPA on this heat resistance is through stabilization of low water environments; it is also
possible that DPA protects proteins through direct interaction. One might expect that spores
lacking DPA would suffer more damage than WT (wild type) spores, when challenged with
heat. Indeed, this is almost always the case (Balassa et al., 1979; Magge et al., 2008;
Paidhungat et al., 2000). However, nobody has yet produced spores, modified to have no
DPA, yet with no change in their water content. Most experiments in spores therefore
cannot differentiate between absence of DPA and presence of water.
DPA has proved capable of improving such products’ stability (Batalha et al., 2017), but
without elucidating the mechanism, constraints of formulation robustness and intellectual
property preclude its use. DPA does not act in isolation, and there are likely to be other
spore components which prove useful to formulation scientists.
To separate the effects of DPA from those of water, one must remove or replace the DPA at
a fixed water composition, This in turn requires spores for which the DPA composition of
the core can be controlled, and either chemical or physical ways to control water content.
Assays of wet-heat sensitivity conflict with the latter, so the need here is for spores which
can be doped to contain chemical replacements for DPA in their cores.
There is precedent for this. In B. subtilis, Magge et al. (2008) demonstrated that inactivating
the spoVF operon results in spores lacking DPA. This operon encodes a pair of DPA
synthetases: spoVFA and spoVFB. Sporulating cells of strains which lack this operon will
scavenge DPA from their environment, and the resulting spores, termed DPA-replete,
Introduction3.1
3 · The effects of dipicolinic acid on spores Spore-forming bacteria as pharmaceutical factories
122
behave much like WT variants. Is this behaviour is seen in other Bacilli, too? B. megaterium’s
genome includes homologues of the aforementioned genes from B. subtilis, and this chapter
demonstrates that the operon operates similarly.
As for doping spores, Li et al. (2012) repeated the uptake experiments using position isomers
of DPA instead, finding none of those chemical analogues present in the core. Importantly,
the authors reported that SpoVA, the DPA uptake channel in B. subtilis, relies on specific
residues at the channel entrance. With this additional knowledge, they might have chosen
the chemical analogues based on interactions with these residues, rather than similarity of
chemical formula. The work presented here does just that.
Finally, while prior work on changing DPA composition has sought to deplete or restore
DPA, and alternative is to enhance its level. One might expect such to offer a different
relationship between DPA and water content and thereby help identify any DPA-specific
effects.
The outcome of the work presented in this chapter is an extension of understanding of DPA
uptake, and a platform for further investigation of DPA uptake behaviour in B. megaterium.
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Results & discussion3.2
The bicistronic WT putative–DPA synthetase operon comprises the upstream spoVFA and
downstream spoVFB genes, named for their homologues in B. subtilis. Mutant B. megaterium
strains were constructed, for which this operon had been disrupted, using the plasmid
pDBT21s (figure 3.1). Table 3.1 lists all the B. megaterium strains; section 2.4.1 describes the
construction of mutants.
The pDBT21s plasmid could integrate into the chromosome via a Campbell-type mechanism
at one of two points, and so produce one of two SXOs.
1. If the plasmid were to integrate at spoVFA, the cassette would displace the last ⅓ of
spoVFA and all of spoVFB.
2. A crossover at spoVFB would disrupt the last 16 of 202 residues.






















Figure 3.1: Map of the pDBT21s plasmid, used to disrupt the spoVF operon in B. megaterium by allelic
exchange. The insert contains the two homologous regions for the spoVF operon, and the following antibiotic
resistance cassettes: bla for carbenicillinr; tet for tetracycliner; spc for spectinomycinr. The temperature sensitive
origin of replication, oriT, functions at 30℃ but not at 42℃, so at that latter temperature only a cell which
integrates the plasmid into its chromosome will survive on media containing spectinomycin or tetracycline. The
length of the insert (∼1800 bp) is known from the verification PCR.
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Table 3.1: B. megaterium strains, used in this chapter. Genes tet, spc and kan confer tetracycline,
spectinomycin and kanamycin resistance, respectively. Abbreviations: WT (wild type), SXO (single
crossover), DXO (double crossover).
Strain Genotype Description
QM B1551 WT WT
1551∷21s+ spoVF∷tet∷spc SXO DPA synthetase mutant
PS1462 sleB∷kan SleB CLE (cortex lytic enzyme) mutant
1462∷21s sleB∷kan spoVF∷spc DXO double mutant
The crossover event at spoVFA would knock out the whole operon (which is termed
spoVF, after its B. subtilis homologue).
Figure 3.2 shows how these mutants (thus termed ∆spoVF) sporulated, in standard SNB
(supplemented nutrient broth) or SNB containing 1.1 mM DPA. The bright phase signal
from WT spores in figure 3.2a indicates the high refractive index of the core, associated
with the reduced water content. WT spores turn phase dark in a 30 s transformation shortly
after commitment to germination (figure 3.2b). Within a WT sample, some spores
spontaneously turn phase dark; this is termed autogermination. Such WT spores immediately
proceed with germination.
Strains, for which pDBT21s had integrated at spoVFA, produced phase dark spores. Whereas
in standard medium QM B1551 (WT) spores appeared phase bright, 1551∷21s+ spores
appeared phase dark. The latter had thus autogerminated, yet the next germination phase,
outgrowth, did not begin. The 1551∷21s+ spores in figure 3.2c were viable, and germinated
readily on rich medium. By contrast, strains for which pDBT21s had integrated at spoVFB
produced phase bright spores. The mutant strain 1551:21s-, containing an insertion of
pDBT21s at the downstream region of homology, produced spores which appeared no
different from wild type (images not shown).
In standard medium, ∆sleB ∆spoVFA double mutant 1462∷21s spores appeared phase grey
(figure 3.2d). Additionally, with brighter illumination, these could appear phase bright, just
as WT spores.
The spores shown in figures 3.2e, 3.2f were grown in media supplemented with DPA.
These spores, termed DPA-replete, were mostly phase bright. This indicates (as per Balassa
et al., 1979) that the sporulating cells scavenged the DPA from the sporulation medium and
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Figure 3.2: Phase contrast micrographs of B. megaterium spores, from strains with spoVF deletions. (a) shows phase
bright WT spores; (b) shows germinated spores (phase dark, even with the bright illumination); (c) shows ΔspoVF
mutants 1551∷21s+, grown in SNB (phase dark); (d) shows ΔsleB ΔspoVF double mutants 1462∷21s grown in SNB
(phase grey); (e) shows 1551∷21s+ spores grown with DPA in the medium (mostly phase bright — with some phase
dark); (f) shows 1462∷21s spores grown with DPA in the medium (phase bright). Results are categorical: the intensity
values of phase contrast images do not correspond straightforwardly to any measurable parameter of objects in the field.
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sequestered it in the forespore. The behaviour was bimodal, as reported for B. subtilis, in that
spores either showed phase bright or phase dark spores, corresponding respectively to WT
core hydration, or hydration like that in germinated spores.
Many of the observations recorded for B. megaterium DPA mutants matched those reported
for B. subtilis (Balassa et al., 1979; Magge et al., 2008). The behaviour of the 1462∷21s double
mutants, though, departed slightly. When grown with no exogenous DPA, these spores
were not phase white but phase grey (figure 3.2d); they were noticeably different from WT
spores. (Magge et al., 2008, describe the equivalent B. subtilis mutants as “phase bright”.) This
indicates a higher water content of the core compared with spores containing DPA, and
supports the model in which DPA is required for spores to maximally exclude water. The
DPA-replete variant did still look like WT spores (figure 3.2f).
The DPA mutants may be useful in probing the missing details of mechanisms through
which CLEs operate. Without SleB, the ∆spoVF spores do not autogerminate. It would
appear that this enzyme has a key role in such autogermination. It is likely that DPA
prevents it from degrading the cortex, thereby in the absence of SleB the high osmotic
pressure, and thus reduced core water content, is maintained. Researchers interested in the
dormancy of SleB may therefore have use for these ∆spoVF spores; if one could produce a
strain bearing a ∆spoVF mutation and a functioning SleB, yet which results in stable spores,
it may be possible to infer the factors preventing SleB activation.
DPA assay
The colorimetric DPA assay (section 2.8.1) confirmed that B. megaterium spores with the
∆spoVF mutation were DPA-deficient (figure 3.3). The strains bearing WT spoVF genes,
QM B1551 and PS1462, contained more DPA than their respective ∆spoVF mutant
progeny: 1551∷21s+ and 1462∷21s. A paired comparisons test (table A1.1), using the method
of unweighted means (Montgomery, 2012), estimated that the differences between the
strains with spoVF (86±13% of QM B1551) and those with the ∆spoVF mutation (12±9%)
were statistically significant (t = 20.4, p = 0.016).
Strains 1551∷21s+ and 1462∷21s differ in more than just their background; the former
includes the whole pDBT21s vector as an insertion, disrupting the original operon (i.e. it’s an
SXO, single crossover). For the latter, a DXO (double crossover), the vector has re-ligated,
deleting the original operon. Section 2.3.6 describes the mechanism; the relevant aspect is
that only the latter 1462∷21s lacks the spoVF genes fully. The SXO strain (and other SXOs
such as 1462∷21s+ — results not shown) showed non-zero DPA concentrations for spores


























Exogenous DPA ✗ ✓
Figure 3.3: Results of the DPA assays, for B. megaterium spores. These show the effects of the ΔspoVF mutation and
sporulation in exogenous DPA. Strains with WT spoVF gave higher absorption readings at 440 nm than those without,
corresponding to higher DPA concentrations (QM B1551 and PS1462 versus 1551∷21s+ and 1462∷21s). Spores
grown with 1 mM exogenous DPA read higher for absorption at 440 nm, thus containing more DPA (the three within-
strain comparisons). The PS1462 reading with exogenous DPA is not presented. Results have been combined across
multiple batches (see table A1.3). Concentration values are normalized to the level of WT (QM B1551) spores within
each batch. Errors correspond to standard deviations from multiple batches. Spores were produced via nutrient exhaustion
in SNB; media contained no or 1 mM DPA.
grown without exogenous DPA; the DXO gave a repeatable zero result. This zero error
does not affect the outcome. The DPA assay results showed that B. megaterium strains with
spoVF deletions did not produce DPA.
The assay was subsequently used to compare levels of DPA among spores grown in different
media. Spores of ∆spoVF mutants, grown in the presence of DPA, recovered the WT DPA
level (figure 3.3). A paired comparisons test (table A1.2) showed that the differences between
the strains grown in standard SNB (40±20% of QM B1551 grown in standard SNB) and
those grown in DPA-supplemented medium (115±15%) were statistically significant
(t = 5.95, p = 9.6×10⁻⁴). Again, this matched behaviour seen in B. subtilis (Magge et al., 2008).
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Balassa et al. (1979) reported that the increase in DPA levels shown by spores produced in
DPA-supplemented medium was not seen for WT spores. (None of Li et al., 2012; Magge et
al., 2008; Paidhungat et al., 2000 commented on this). By contrast, results here show that
supplementing the sporulation media of a WT strain too leads to spores with elevated DPA
levels.
Spores with WT spoVF, grown in the presence of DPA, showed elevated DPA levels,
compared with that of spores in standard SNB (figure 3.3). Confirmation of this result itself
in subsequent experiments was precluded by the failure to sporulate at 1 mM exogenous
DPA (section 3.2.3), though other researchers have used the techniques to probe spores’
magnetic abilities (for example Xu Zhou et al., 2018). The finding presents opportunities for
a novel way to investigate the role of DPA in spores, by considering its elevation rather than
its absence. It is not clear to what extent an enhancement of DPA level within the core is
possible.
The increase in measurements is almost certainly due to differences in the quantity of DPA
extracted from cores, as the washing steps remove any DPA from the sporulation medium
(as confirmed by the low readings for DPA-depleted spores). The cause is also more likely
due to differences in the mass of DPA per spore than the extraction efficiency — i.e. a real
difference in spore behaviour.
From an evolutionary perspective, one might expect that spores selected for their resistance
to wet heat might already produce sufficient DPA to reach the upper limit within the
forespore — but this does not seem to be the case. It raises a question: why don’t spores
saturate their cores with DPA? Perhaps higher levels of DPA confer marginal or no
advantage and so were not positively selected; perhaps they confer a disadvantage — such as
reduced flexibility due to DPA being present near its solubility limit — and so were
negatively selected. For the former, it may be relevant here that spore populations across the
genera do demonstrate heterogeneity of dormancy as a collective survival strategy; perhaps
flexibility in DPA level is a part of that. It is possible that higher concentrations might be
difficult for cells to process, and thus cause sporulation to arrest.
Scavenging of DPA during sporulation3.2.2
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Exogenous DPA at 1.4 mM prevented sporulation in B. megaterium (figure 3.4). By contrast,
at 1.1 mM, spores looked phase bright. In a separate laboratory, however, this limit could not
be reproduced: spores grown at 1.0 mM did not sporulate (and appeared like the
aforementioned 1.4 mM sample), yet with 0.5 mM DPA cultures sporulated without
impediment.
There has been no toxic concentration reported for B. subtilis in the relevant literature,
where concentrations up to 2 mM have been used with success (Magge et al., 2008, for
example). In B. megaterium, here, such a threshold was seen. Researchers with access to the
corresponding strain of B. subtilis may wish to investigate this.
Inhibition of sporulation by DPA3.2.3
Figure 3.4: Micrographs of (WT) B. megaterium QM B1551, sporulated in SNB with exogenous DPA.
(a) shows sporulating cells after 18 h with 1.1 mM DPA; (b) shows spores, fully released from sporangia, after
40 h with 1.1 mM DPA; (c) shows (not quite) sporulating cells after 18 h with 1.4 mM DPA; (d) shows cells
that appeared to have stopped growing, after 40 h with 1.4 mM DPA Over time (left to right) cells above the
DPA concentration threshold (bottom row, versus top) began to sporulate, produced a variety of small phase
bright structures (but no forespores) and then arrested. Spores were grown using nutrient exhaustion; a time of
0 h corresponds to inoculation. Scale bars are 5 µm × 1 µm.
a b
c d
3 · The effects of dipicolinic acid on spores Spore-forming bacteria as pharmaceutical factories
130
It has been suggested that the fault here is pH: that the added DPA is lowering the initial pH
such that the culture pH drops too low for the cells to survive, too soon for them to
sporulate. However, this effect is seen when media are pH adjusted back to pH 7.2. In
addition, no other acid analogue inhibited sporulation in the concentrations used in these
experiments. It is possible that there is an interaction with SNB not seen with the
sporulation medium used for B. subtilis, though given that this effect is not seen with
chemical analogues it seems unlikely. Finally, Balassa et al. (1979) added exogenous DPA
after initiation of sporulation (Magge et al., 2008 were somewhat ambiguous on this); it
could be that supplementing at this point in the sporulation cycle results in viable spores.
Given DPA activates CLEs (cortex lytic enzymess), one might suspect this process is at fault
— though it would be surprising as sporulation arrests before forespores are produced.
Perhaps DPA then inhibits sporulation? DPA may reach sufficient concentration in the
mother cell to stop the sporulation machinery (through reaching solubility limits or
otherwise), and thereby kill the cells.
Most concerning, though, is the lack of reproducibility of the threshold, and this merits
further investigation. Whilst cells grown in one laboratory sporulated reproducibly at
≲1.4 mM exogenous DPA, in a second laboratory cells arrested reproducibly with
exogenous DPA concentrations of just 1.0 mM. Such behaviour has already forestalled
further work, which would otherwise directly follow the experiments presented here:
specifically, a rigorous analysis of wet heat resistance of DPA-enhanced spores.
Spores of the following strains were challenged at 70℃, 80℃ or 90℃ for 20 min, using the
method described in section 2.8.3:
• PS1462 (∆sleB +kan, a negative control);
• 1462∷21s, grown in standard SNB (∆sleB ∆spoVF +kan +spc);
• 1462∷21s, grown in medium, doped with DPA; and
• 1551∷21s+, in doped medium (∆spoVF +spc).
Viabilities of samples were estimated using the Miles et al. (1938) plating technique, and the
Comoglio et al. (2013) analysis (section 2.8.4). Such colony counts were also used to test the
variation among spores, without heat challenge.
Wet heat susceptibility3.2.4
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Strains of B. megaterium, cultured with or without exogenous DPA, produced spores with
the viabilities presented in figure 3.5. The experiment for strain 1551∷21s+ without
exogenous DPA was not included, as this combination resulted in autogerminated spores.
The inferred colony count for QM B1551, (1.11±0.10)×10⁸ cfu ml⁻¹, matches the guideline
spore wet density for that strain, for which an OD₆₀₀ of 1 is considered to correspond to
10⁸ spore ml⁻¹. The corresponding value for the ∆sleB mutant, of (3.3±0.4)×10⁷ cfu ml⁻¹, was
lower, broadly matching published behaviour (Setlow et al., 2009). The spores of strain
1462∷21s, grown in DPA-supplemented media, showed greater viable counts than
matching samples without the supplement: (2.8±0.4)×10⁷ cfu ml⁻¹ and (1.6±0.3)×10⁶ cfu ml⁻¹
respectively. This agrees with reported behaviour in B. subtilis (Balassa et al., 1979). Strain
1552∷21s (grown with the supplement) resulted in a count of (5.5±0.8)×10⁷ cfu ml⁻¹: roughly
half that of WT. Overall, DPA-depleted spores produced fewer colonies than
DPA-producing variants, with ∆sleB mutants showing diminished germination efficiency.
DPA-replete spores showed greatest viability after heat challenge. Figure 3.6 shows
preliminary outcomes (single replicate) of the wet heat susceptibility assay for strains PS1462
and 1462∷21s grown with or without 1 mM exogenous DPA. The 1462∷21s spores grown
with exogenous DPA consistently showed higher viable counts than those grown without.
Results of the assays for 1551∷21s+ are shown too, in figure 3.6. B. megaterium spores, subject
to heat challenge, typically show heat activation at 70℃, resulting in increased
measurements of the viable spore count. At higher temperatures, the heat challenge causes a
decline in measurements, as spores are killed. This has been demonstrated with the presented
results. At moderate heat shock (80℃), the differences between strains, as seen with no heat
shock, had disappeared.
Further heat susceptibility assays were precluded by the inability to reproduce spores with
1mM exogenous DPA. Likewise, the inability to isolate a DXO variant of 1551∷21s+
precluded experiments in the WT background. Notwithstanding this, the preliminary
results regarding heat resistance concur with the behaviour reported for B. subtilis.
The germinated viabilities measured without heat activation for PS1462 were lower than
those for QM B1551; the difference disappeared when spores of PS1462 were heat activated.
Though sleB is semi-redundant, its deletion may change the dynamics of germination
sufficiently that a colony count experiment will underestimate the number of spores present
in the original sample. Indeed, the ∆sleB mutation in B. megaterium has been shown to
reduce viability of spores by up to 50% (Setlow et al., 2009). On heat activation, the PS1462





















Figure 3.5: Probability density plot of viable colony counts for germinated B. megaterium spores, grown with (+ DPA) or
without (no suffix) exogenous DPA. Strains with WT sleB produced higher viable counts than the deletion mutants.
Samples grown with exogenous DPA had higher viable counts than the same strains in standard medium. The curves
show >95% highest density intervals, and peaks indicate the maximum likelihood estimators; the heights are confounded
with width, hence the labels on the abscissa have not been shown. Cultures were induced to sporulate using nutrient
exhaustion in either standard SNB or SNB supplemented with 1.1 mM DPA. Spores were induced to germinate on LB
agar.
strain with cwlJ, alone of the germination receptors, recovered the count of non–heat
activated WT spores; one might hypothesize that the (poorly-understood) heat activation
process somehow activates CwlJ.
⁂
The microscopy, DPA assay and preliminary heat susceptibility results confirm that the
∆spoVF mutation works in B. megaterium just as in B. subtilis, in both the WT and ∆sleB
backgrounds.
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Figure 3.6: Survival plots for B. megaterium spores, grown in standard (circles) or DPA-supplemented (squares)
medium. Spores were subjected to no shock (—) or shocked for 20 min at the temperatures on the ordinate. These
temperatures are categorical; points within each category are horizontally displaced, for clarity (as in the legend). Strains
showed either no change or an increase in the measured viability, after challenge at 70℃; for 80℃ and 90℃, viability
measurements decreased. This decrease was greater for the strains sporulated without exogenous DPA. Error bars
indicate the 95% credible intervals. These data show a single replicate.
The DPA-depleted strains were induced to sporulate in analogue-doped SNB
(section 2.5.1). The analogues replicate specific properties of DPA, differing in single,
specific ways (figure 3.7).
Spores grown in DPA analogue–doped media3.2.5
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Figure 3.7: Chemical structures of DPA (2,6-dipicolinic acid) and some chemical analogues. (a) shows DPA; (b) the
structural isomer 3,5‑pyridinedicarboxylic acid, a.k.a. dinicotinic acid: not tested in this work; (c) the weaker acid IPA
(isophthalic acid); (d) the chelation-incompetent PA (picolinic acid); (e) the amine (not pyridine) IDA (iminodiacetic
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Li et al. (2012) probed the B. subtilis SpoVA channel’s specificity to DPA compared with its
position isomers. They found the gate very specific, but the details of the channel
mechanism remained unclear. Analogues were chosen based on these findings.
• Unless the back end of the pyridine ring is sufficient for interactions within the spore,
the interactions with IPA (isophthalic acid) should be the same as for
3,5‑pyridinedicarboxylic acid, found not to interact specifically with the channel (Li et
al., 2012).
• PA (picolinic acid) does still possess the groups, which Li et al. (2012) suggested would
allow it to interact with SpoVAD, though it has different charge delocalization.
• In addition to lacking the aromatic ring, the IDA (iminodiacetic acid) and NTA
(nitrilotriacetic acid) bond angles are different (as is the delocalization of charge over
the structure) so specific interactions would suggest that only the functional groups or
chelation are important.
Sporulation was evaluated in the first instance with phase contrast microscopy: the
brightness of a phase structure gives a qualitative guide to level of hydration. Additionally,
chemicals may have concentrations above which cells do not sporulate. Therefore spores
were produced in various concentrations of the DPA analogues, in a 96-well plate. Samples,
of volume 20 µl per 200 µl well, were incubated, without shaking, at 30℃.
This screen showed that exogenous analogues present in the medium had no effect on
sporulation (figure 3.8). WT strains produced spores in the same manner as in the standard
medium; likewise strains with the ∆spoVF mutation produced phase dark spores. For the
1551∷21s+ strain, only medium supplemented with DPA led to production of phase bright
spores; only DPA led to the sporulation failure seen in figure 3.4d. Spores grown in larger
volumes of supplemented medium showed the same result. IPA (isophthalic acid) was tested
separately from the screen; the results were equivalent.
Additionally, spores of WT strain QM B1551, grown in media supplemented with these
DPA analogues, did not differ from those grown in native SNB (data not shown).
Spores grew successfully in the 20 µl screening samples. However, the samples dried out,
whereas 40 µl samples did not. The 40 µl samples also showed a higher sporulation efficiency.
Given the uniform physics of the wells, it is likely that the mass of water evaporated was
similar in each case. Therefore the concentrations of analogues in the medium increased
with time — quite significantly so for the 20 µl samples. The reported concentrations might
therefore be considered as initial concentrations, and the resulting data points as
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Figure 3.8: Outcome of sporulation screening, in analogue-supplemented SNB. Cells either failed to sporulate ( ), or
produced phase bright ( ) or phase dark ( ) spores. Results with DPA match those reported already (with a slightly
different sporulation arrest threshold); those with analogues matched the behaviour of the strains with no analogue.
Sporulation media were supplemented with one of DPA (dipicolinic acid), PA (picolinic acid), NTA (nitrilotriacetic
acid) and IDA (iminodiacetic acid). Medium supplemented with 0 mM DPA was standard SNB. Cultures of volume
20 µl were induced to sporulate via nutrient exhaustion in a 96-well plate.
underestimates of the true concentrations. However, the DPA threshold, above which
sporulation did not occur, was reproducible between the 20 µl screen and larger volume
samples.
Screening these spores by phase contrast gives a direct, albeit qualitative, measure of the
hydration of the spore core. There are severe limitations to this screening technique, though
— most importantly that it cannot demonstrate that the specific chemical has been taken into
the spore, and that it gives little information in the case of a negative result. Demonstrating
spores have taken up the relevant chemical is non-trivial, especially as there are few in situ
methods to detect what is in the spore core. Raman microspectroscopy is the most suitable
option (Ichimura et al., 2014; Setlow et al., 2012), and was indeed used by Li et al. (2012) to
test the DPA analogues; NMR (nuclear magnetic resonance) spectroscopy of spore extracts
would be the gold standard for characterising the contents of the spores core. However, it is
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also possible that the DPA assay is unable to discriminate between these analogues, and may
result in formation of the Fe(NH₄)₂(SO₄)₂–analogue complex; this may be worth
investigating.
The best way to ensure spores take up DPA analogues would be engineering the proteins in
the SpoVA channel. Given that a crystal structure has been solved for only one sub-unit of
seven, belonging to one species of about 50, such an endeavour has a low chance of success.
More promising would be to try to supplement a species of Clostridium, which has a simpler,
three sub-unit SpoVA operon (C–E). It may even be possible to replace the A–F operon in a
Bacillus with the simpler Clostridium variant. The combination of a simpler operon and a
convenient species would greatly simplify future attempts to elucidate the channel’s
mechanism.
The microscopy evidence presented here suggests sporulating B. megaterium do not scavenge
these molecules from the medium. Spores grown with up to 4 mM of the analogues looked
the same as those without. These results are weakly negative, and pursuit of stronger
evidence is less valuable than investigating the reproducibility issues with exogenous DPA.
Experimental designs for the work, reported in this chapter, failed to differentiate a number
of factors. Replicating the B. subtilis work in B. megaterium offered a good comparison, but
given differences it would be good to repeat experiments with the relevant B. subtilis strains.
Likewise, work with the analogues would be significantly more valuable in both strains, as
the current results confound the behaviour in the presence of analogues with the behaviour
of the different species.
Separately, two factors arose, during the experimental work, that caused difficulties with this
project: reproducing the toxic DPA threshold, discussed in section 3.2.3; and, discussed here,
isolating a DXO strain. A number of further improvements could be made to the
experimental design.
Experimental design3.2.6
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Isolation of DXO strains
The DXO isolation procedure, with strains 1551∷21s+ and 1462∷21s+, resulted in strain
1462∷21s (∆sleB ∆spoVF). A DXO strain with the ∆spoVF genotype was isolated, but it had
been cured of plasmid pBM700 (∆p7). Indeed, no strain 1551∷21s (∆spoVF DXO), which had
not lost its plasmid 7, was isolated, despite four three-week rounds of attempts (∼600 total
events).
The protocol to isolate a DXO strain thereby resulted in a single candidate for strain
1462∷21s, and no candidate strain for 1551∷21s. As a result, the experiments planned for
1551∷21s were only possible with the SXO strain, 1551∷21s+. Early results with the SXO
strains were disquieting. The DPA assays for the SXO strains grown without exogenous
DPA were close to 25% of the WT levels. By contrast, the DXO gave readings close to zero
(and with low variance, too).
Is it possible that cells revert to WT in the sporulation medium, and thereby the resulting
spore crop is actually a polyclonal sample? Cells with SXOs are genetically unstable: there is
a small probability that each cell will revert to WT (see figure 2.1); strains with a DXO are
genetically stable in this regard.
It is possible to estimate the expected number of revertants in a spore crop. Fabret et al.
(2002) reported an elevated pop-out frequency in B. subtilis of 10⁻⁶ (an overestimate, but
sufficient here). Neglecting cell death, and assuming all cells become spores, this would give
a reversion rate of 10⁻⁶ — well below the sensitivity of the DPA assay. However, the timing
of the event matters; at one extreme, if the initial inoculum contained only one cell — and
that cell reverted — the whole sample would be of the revertant. Assuming a small initial
inoculum (perhaps 10³ cells) and a final culture at sporulation of 10¹¹ cells (10⁸×), this gives
27 generations. Even factoring in cell death, and slightly less than doubling each generation,
the generation number is unlikely to reach triple figures. With 50 generations, and a pop-
out frequency of 10⁻⁶, that gives an expected pop-out proportion of their product: 5×10⁻⁵
(see section A1.4 for the model here). This overestimate is well below the proportion of the
wild type value seen for SXOs in the DPA assays.
There are other possible explanations. B. megaterium may co-opt etfA (BMQ_4730), which
Clostridium perfringens uses instead of spoVF (Orsburn et al., 2010). Such spores would
contain DPA, and a colorimetric assay may be sufficiently sensitive to detect this. There is
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currently no evidence that gene is expressed. However, even if there were, it would still not
explain the differences seen between the SXO and DXO strains. It is possible too that the
results are due to chance.
The corollary of the instability of SXOs is that in order to isolate a DXO, one must rely on
that same stochastic process. What is the probability of isolating a DXO strain? This three
week isolation procedure was performed four times for the 1551∷21s+ SXO mutant, still
with no positive result (and as plating events have errors, there were many false positives).
The overestimate above gives a guide. If independent, the 600 plating events (12 colonies, 4
week-nights, 3 weeks, 4 times, 576 total) would result in an expected 3% probability to
isolate a DXO. In this case the pop-out frequency is slightly underestimated (it is higher at
42℃). Whatever the outcome of such a probability model, the low frequency of events
alone destroys the predictability of the technique.
Overall, it is hard to recommend the allelic exchange approach of pUCTV2. There are many
reported counter-selection techniques, which improve the chances of identifying a pop-out,
and it is worth establishing those before continuing, or attempting to replicate, this work
(Biedendieck et al., 2011).
The inability to isolate a DXO strain (1551∷21s) thereby precluded further research into the
true behaviour of the ∆spoVF mutation, in isolation.
Limitations of protocols
In addition to the above challenges, there are limitations to some published protocols. The
most serious of these concerns the DPA assay. The protocol confounds a number of factors:
growth rate, spore size, spore number and spore dipicolinic acid content. In addition, in its
published laboratory manual form (Nicholson & Setlow, 1990) it mentions nothing about
sporulation times. It would be improved were samples normalized to the same optical
density, rather than taking a fixed volume sample, as these factors could then be separated.
When initially compared with the standard curve, a number of spore extract readings
evaluated to negative concentrations. This is most likely a zero error. Spore extract is a more
complex mixture than the water used for the blank, and may inhibit formation of the
Fe(NH₄)₂(SO₄)₂–DPA complex of the assay. Despite the published protocol, it may be better
to produce the standard curve with cell extract or extract of DPA-depleted spores, rather
than water.
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Another difficulty with analysis of extracted DPA is batch-to-batch variation. Different
batches have different ranges of DPA level, such that the readings are not directly
comparable. To compare, one must normalize the readings based on matched samples;
ideally this should be done with two endpoints (e.g. WT and DPA-less spore samples). Like
the zero error, this is mentioned in neither the reporting publications nor the published
protocol.
Colony counts proved reproducible and benefited from efficient experimental design. Time,
temperature, strain, growth conditions and batch are all important factors which contribute
to the measured counts. It is feasible to run complementary fractional factorial experiments
to efficiently cover the state space of the experimental design. Indeed, such a design was
undertaken, but the inability to reproduce spores with 1 mM exogenous DPA forestalled the
experiment itself.
Finally, given the inference model for colony counts (Clough et al., 2005; Comoglio et al.,
2013), it ought to be possible to identify the optimal number of cells to count in order to
give sufficient confidence that two samples are drawn from different populations. This may
require an initial Miles et al. (1938) plating, followed by biological replicates of full plate
counts. It would then be possible to modify BEST (Bayesian estimation [that] supersedes the
*t*-test) such that the Monte-Carlo model generates gamma distributed test data (Kruschke,
2013). This would ensure that the statistical foundations for discrimination of spore
populations can be justified — in a way that no published research has been able to do.
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The ubiquity of DPA among known sporeformers implies that it confers a selective
advantage. Demonstrating, as here, that different Bacilli lacking DPA behave similarly,
implies that the processing of DPA too is evolutionarily conserved.
Here, the putative spoVF operon in B. megaterium is confirmed, and the behaviour of
B. megaterium strains with the ∆spoVF mutation is shown mostly to match that of B. subtilis,
reported by Magge et al. (2008). Such spores do not contain DPA, as the forming spore
cannot produce it, yet spores of such strains grown in the presence of DPA show near WT
levels.
Unlike as reported for B. subtilis, however, too much DPA in the sporulation medium
caused sporulation to arrest. This arrestation was reproducible, though the associated
exogenous DPA concentration was not, and this precluded confirmatory studies of other
effects and behaviour.
For example, results here reproduce the finding that DPA-deficient spores show diminished
resistance to wet heat (and demonstrate this behaviour for the first time in B. megaterium). It
appears, too, that DPA-replete spores, incapable of producing DPA themselves, do not
scavenge sufficient quantities from their environment to replace all the DPA that is lost, and
consequently appear to have a higher water content and lower resistance to wet heat.
By contrast, it is possible to produce B. megaterium spores with elevated levels of DPA — a
feat others have failed to show for B. subtilis. Such spores have assisted in probing other spore
characteristics (e.g. paramagnetism, Xu Zhou et al., 2018) and could in future help elucidate
the interaction between DPA, water and proteins in the spore core.
From supplementation with DPA analogues, the specificity of the DPA B. megaterium uptake
mechanism appears to match that of B. subtilis. The SpoVA channel interactions reported in
B. subtilis focus on the positive requirement for the two carboxylate groups of DPA (Li et al.,
2012). Results here agree with this, and support the assertion that while these groups may be
necessary, they are not sufficient.
Conclusion3.3
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Despite the co-incident work of Batalha et al. (2017), while one might consider DPA a
candidate pharmaceutical excipient, it is not yet known how it protects proteins. As
repeatedly pointed out in comprehensive reviews by Peter Setlow (2006, 2014), nobody
knows how the forespore is able to reduce its water content to such a degree during
sporulation. The strains, techniques and results presented here may help solve this mystery.
However important for spore microbiology, the results presented here not contributed
directly to the overall goal of producing an improved pharmaceutical formulation. With
guidance from those with such expertise, the second approach was investigated, and the
results are presented in the next chapter. That chapter reports work that, rather than
investigating the behaviour of the spore core in order to mimic it, instead engineers spores
themselves to become the delivery vehicles.
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Therapeutic proteins in sporulating
Bacillus subtilis
Chapter 4
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Bacterial endospores possess many desirable qualities for stable pharmaceutical products.
Bacillus species form spores which protect their crucial components in a shielded core: most
critically, their genomes and proteins. One way to mimic that behaviour would be to
replicate the conditions in the core, perhaps using DPA (2,6-dipicolinic acid) as a stabilizer
(as in chapter 3). An alternative, presented in this chapter, uses spores themselves as the
delivery vehicle. In practice, this means engineering sporeformers to express therapeutic
proteins during sporulation.
Unfortunately, some of the features that protect endospores from environmental challenge
are undesirable in other ways. Spores’ robustness has limited the development of spores
bearing therapeutic proteins.
This chapter presents the first investigation of B. subtilis spores as a platform for delivering
humanized mAbs (monoclonal antibodies). It is not, however, the first research to
implement this approach. In previous work in the Christie laboratory, Mohamed (2015)
established the SASP (small acid-soluble protein) promoter PsspB for production of
heterologous proteins in the core of B. subtilis spores. The work was successful with human
growth hormone and single chain insulin, but required heavy strain engineering to produce
just a single antibody fragment (scFv, single chain variable fragment).
Much of the research presented here involves the mAb (monoclonal antibody) NIP109: a
humanized monoclonal IgG (immunoglobulin G), which binds the hapten, NIP
(4-hydroxy-3-iodo-5-nitrophenylacetic acid). In addition to whole IgGs, various other
configurations of domains are therapeutically useful, notably the scFv: a fusion of light and
heavy chain, comprising only their variable fragments (FV, see figure 1.3).
Antibodies are not limited to conventional IgGs, though; for example, the nanobody, a
fragment comprising the variable domain of a camelid heavy-chain antibody, can be
considered an alternative to an scFv. Nanobodies might be used in the form of a single
protein domain, or conjugated to a fluorescent protein to form a chromobody (useful for
imaging as they are small enough to clear the kidneys, Panza et al., 2015). The platform
developed here is tested with a small range of nanobodies: VHH GFP4, which binds GFP
(green fluorescent protein); BcII10, which binds the B. cereus metallo-β-lactamase; and two
further nanobodies which bind other β-lactamases. The α-GFP nanobodies serve laboratory
Introduction4.1
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purposes; the α–β-lactamase nanobodies might be candidates to combat antibiotic resistance.
Using nanobodies avoids the technical bottleneck of having to demonstrate assembly of a
full IgG — a challenge due to spores’ robustness.
Such robustness poses challenges both for product design and research. Laboratory
techniques to investigate the contents of the spore core fall well short of the standards
required for initial formulation characterization, never mind product approval or cGMP
(current good manufacturing practice). Additionally, no method has yet been established to
ensure the protein payload is released appropriately from the spores. What is needed is a fast,
minimally intensive technique to break spores for the purposes of laboratory measurements,
and a reliable method to ensure spores release their contents correctly in vivo. The challenge
is to disrupt the cortex, without allowing the spore to germinate and potentially degrade the
contents of its core.
In earlier work, Mohamed (2015) engineered a release system, in which the PBSX prophage
caused germinating spores to lyse during outgrowth. Though reasonably successful, the
need for germination causes issues with this approach: specifically, the lag time between
germination and release, and the requirement that the spore is capable of germinating.
Additionally, this mechanism does not address the need to disrupt spores, for laboratory
measurement.
The novel alternative, presented in this chapter, uses a single deletion mutation to achieve
both goals. Spores lacking their outer coats retain most environmental resistance, yet the
cortex becomes susceptible to enzymatic degradation (as described in section 1.3.4).
Deleting cotE results in a lysozyme sensitivity, useful for disruption of spores in the
laboratory. It might also provide a novel, simple way to release encapsulated proteins from
the spore in vivo.
This chapter therefore seeks to evaluate whether bacterial spores are viable carriers for
therapeutic antibodies. The work presented here demonstrates that sporulating cells can
produce these pharmaceutically relevant therapeutic proteins, and shows it is possible to
engineer spores to release such protein in a controlled, scalable manner.
Two undergraduate research students, and one masters student, performed a number of the
experiments in this chapter; these contributions are indicated in descriptions of the methods
and results.
Spore-forming bacteria as pharmaceutical factories Therapeutic proteins in sporulating Bacillus subtilis · 4
147
Results & discussion4.2
In addition to the light and heavy NIP109 chains, three scFvs (single chain variable
fragments) were constructed. One uses an 18-mer amino acid linker, of peptide sequence
G₂S₂RS₄G₄SG₄; the other two use the 7-mer GGSSRSS (see Andris-Widhopf et al., 2011). All
constructs are detailed in table 4.1 (see listing A1.1 for the primary amino acid sequences of
the fusion domains). For production during sporulation of each fragment there were two
variants: the fragment with a C-terminal 6×His tag (0.8 kDa), and the fragment with a C-
terminal GFP (green fluorescent protein) fusion (28.8 kDa — the AL11 linker, Robinson &
Sauer (1998); GFP; and a 6×His tag). A representative ectopic plasmid for integration at the
amyE locus is in figure 4.1.
Antibody expression by sporulating B. subtilis4.2.1
Table 4.1: Fragments of the NIP109 antibody. Of the scFvs, two have the light chain first, then heavy;
one vice versa. The domains are labelled as V, for variable, or C, for constant, with suffixes L for light
chain and H for heavy, and numerals according to their position in the chain. 18-mer linker
G₂S₂RS₄G₄SG₄; 7-mer GGSSRSS (G ∼ glycine; R ∼ arginine; S ∼ serine; subscript suffixes indicate the
chain length of identical repeats). The mass is that of the protein with a 6×His tag. ThermoFisher
produced these ten fragments as GeneArt® Strings™, suitable for overlap assembly.
Code Fragment Domains Mass / kDa
l Light chain V L C L 24.0
h Heavy chain V H C H 1 Hinge C H 2 C H 3 50.0
s scFv V L 7-mer V H 26.0
t scFv V L 18-mer V H 26.7
u scFv V L7-merV H 26.0
WT B. subtilis strains
Aliquots of B. subtilis subsp. subtilis 168 were transformed to Chloramphenicol resistance,
with single pDBT61* plasmids, to give the 168∷61* strains, and then induced to sporulate.
Micrographs of the concentrated spore slurry can be seen in figure 4.2. Spores in the left
column of triples, the non-GFP strains (168∷616?), show some diffuse background
fluorescence. Spores in the right column, the GFP strains (168∷611?), additionally show
strong, localized fluorescence. For most strains, the vegetative cells do not appear in the



































Figure 4.1: Representative pDBT61* plasmid for expressing NIP109 fragments under control of promoter PsspB. Plasmid
pDBT611s carries an ORF (open reading frame) encoding an scFv (VH → VL) with a C-terminal AL11-GFP-6×His
fusion. (Bold type indicates the mnemonic; the pDBT616* plasmids have just the C-terminal 6×His tag.) Other features
are antibiotic cassettes: cat, bla, and spc (conferring resistance to Chloramphenicol, Carbenicillin and Spectinomycin
respectively); the E. coli origin of replication, ori; and two regions of homology matching upstream and downstream of
amyE. KAM (Klenow assembly method) was used for assembly.
fluorescence micrographs; where they do, the corresponding cells in the phase contrast
images appear much as strains which have arrested during sporulation back in chapter 3
(figure 3.4d).
These micrographs offer promising results. In contrast to the experience of Mohamed
(2015), there is evidence that scFvs were produced, in the WT background. From the
localized fluorescence for strains bearing C-terminal GFP fusions, one can infer that GFP
was being produced. In turn, from the presence of a fully formed, functional, C-terminal
GFP fusion, one can infer that the full protein was expressed correctly. Typically, antibodies
are produced in mammalian cells; such cells feature complex protein production
mechanisms, from introns and variant exon splicing, to post-translational modifications.
Transcription is far simpler in bacteria, so many of the techniques that demonstrate the
resulting amino acid sequences are correct (e.g. peptide mapping) are not needed for bacterial
protein production.
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Figure 4.2: Triples of phase contrast (left), composite (centre) and fluorescent (right) micrographs of B. subtilis 168∷61*
crude spore crops, aligned such that rows share a NIP109 fragment and columns share a C-terminal fusion (the GFP
fusion is on the right). (a) shows light chain strain 6l; (b) 1l; (c) shows heavy chain strain 6h; (d) 1h; (e) shows
scFv L→H (7-mer) strain 6s; (f) 1s; (g) shows scFv L→H (18-mer) strain 6t; (h) 1t; (i) shows scFv H→L (7-mer)
strain 6u; (j) 1u; The identifiers refer to the codes which take the place of the asterisk in the strain names. The bright
structures in the phase images are the highly (refractile) spores. Dark signal in the (inverted) fluorescence images
corresponds to fluorescence; the distinct structures, present for the GFP strains only, indicate localized fluorescence.
Strains were induced to sporulate by nutrient exhaustion. Where possible, images were selected to include both cells and






Considering the micrographs in detail, one might notice that there is localized fluorescence
within the spore outlines, for samples 1l, 1h and 1t, corresponding to GFP fusions of the
light chain, heavy chain and scFv (with 18-mer linker) respectively. For the other GFP
fusions, both scFvs with the 7-mer linker, there are many vegetative cells showing intense
fluorescence. Given that PsspB is active in the forespore, it is likely that these cells had
produced fluorescent protein, and subsequently arrested during sporulation. This effect is
probably due to metabolic load; the forespore has a finite incoming energy flux from the
mother cell, and by producing heterologous rather than native proteins it may result in
intense fluorescence rather than a viable spore. Those continuing to research production of
heterologous proteins in the spore core would do well to monitor sporulation yields, to
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investigate this. Comparing single cells would be valuable; it may identify an upper
threshold on the mass of protein per spore. Such a threshold would put a hard limit on the
dose of a therapeutic protein, using this delivery method.
The western blot, figure 4.3, confirms correct expression. All lanes show bands of the
predicted masses; for all but one (6l) there is no band more intense. For 6l, the band at
24 kDa is very faint, and there is an intense band at 27 kDa; subsequent blots, though, show
the 24 kDa band, with similar intensity to predicted bands of other strains. A number of
lanes (6l, 6h, all 1?) show bands at approximately integer multiples of the predicted masses.
The 6h lane shows many additional bands, at smaller masses than the predicted band; at
















6l 6h 6s 6t 6u 1l 1h 1s 1t 1u
Predicted mass / kDa
24 50 26 27 26 52 78 54 55 54
Figure 4.3: Western blot of NIP109 fragments, extracted from B. subtilis 168∷61* spores. Lanes are labelled
for the fusion (6×His tag, AL11-GFP) and variant (letters). All lanes show predicted bands, indicated with
arrows (and the s, t and u bands share an arrow). The left-most lane is the MagicMark™ XP Western
Protein standard ladder. Spores were mechanically disrupted. The total protein fraction was fractionated with
SDS-PAGE and transferred to a PVDF membrane, for single antibody western blot analysis.
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The blot indicates that not only were the antibody fragments produced, they could be
extracted from the spore cores. It is hard to judge the extent to which the differences in
intensity among the lanes correspond to differences in production level, extraction efficiency
and probe affinity. The first seems unlikely, as the pattern of fluorescence intensities in
micrographs does not match the intensities of the bands. Given the relatively low intensities
of the 1l and 1h bands at 120 kDa and 180 kDa, it is unlikely the difference is due to the
His tag affinity (the latter two factors). That leaves the extraction efficiency; the extraction is
not only a bottleneck in throughput for protein analysis, but may well damage the proteins
in the resulting extract, too. Research into superior methods to disrupt the spores would
offer immense value, here.
Figure 4.3 shows bands with masses that are integer multiples of the predicted bands; these
are most likely aggregates. From the bands at integer multiples of the predicted masses, one
might infer that there is some association between proteins, despite the reducing, denaturing
environment. This is typically seen when the standard SDS-PAGE conditions are not
optimized for the samples in use, or the chemical components have degraded. One might
consider adding DTT (dithiothreitol) to samples, or heating at lower temperature. Size
exclusion chromatography might help here, too. As these aggregates have multiple His tags,
they may bind multiple western probes, thereby giving a more intense signal than one
would expect for a single protein of the same prevalence.
∆cotE strains
The coat-deficient strain of Zheng et al. (1988) carries a cotE::cat mutation (indicating the
chloramphenicol acetyltransferase gene, cat, has replaced the cotE). Unfortunately, this is the
same antibiotic resistance cassette as the various pDBT61* plasmids, which had already been
constructed and shown to result in expression of various heterologous proteins in the spore
core (see figures 4.1, 4.3). Furthermore, the progenitor strain was B. subtilis PY-17, rather
than B. subtilis 168. It was therefore preferable to generate a new mutant with the ∆cotE
genotype, but in a background suitable for comparison, and with a different marker.
Furthermore, as subsequent strain engineering would be required, that mutation could be
introduced in a strain suitable for marker cycling and counter-selection. The most suitable
strain is that reported by Shi et al. (2013), B. subtilis BUK, derived from B. subtilis 168. It is
both inducibly supercompetent and a suitable host for 5-FU counter-selection, the ideal
combination for the repeated strain engineering processes required. Though some of the
plasmids of Shi et al. (2013) were available from the Bacillus Genetic Stock Centre, this strain
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itself was not. The strain engineering required to replicate those authors’ work, and generate
the isogenic B. subtilis 168∷690, is described in sections 2.4.4, A1.7. This strain was then
transformed to give the chloramphenicol-sensitive ∆cotE strain: B. subtilis 690∷71e.
The B. subtilis 168∷690 and 690∷71e strains were each transformed to Chloramphenicol
resistance with pDBT611l, pDBT611h and pDBT611s. All sporulated successfully. Clumps were
successfully diminished by ball milling; for example, 71e∷611l spores were not damaged
fluoresced as expected.
The PAGE and western blot data in figure 4.4 show that the 168∷690-derived (inducibly
supercompetent) and 690∷71e (∆cotE) strains can express NIP109 fragments, just as WT
B. subtilis 168. The extracts showed predicted bands, by western blot, with some intense
bands on the matching Coomassie stained polyacrylamide gel. The predicted bands are only
present in their corresponding lanes; this is clearer for the 168∷690-derived samples on the
gel, and clearest on the blot, where only the 611? strains show intense bands. The blot itself
shows the predicted bands, bands at integer multiples, and, for the light chain samples, a
band at around 35 kDa. On the polyacrylamide gel, the 168∷690-derived strains display
more intense bands than the 690∷71e-derived strains, with the exception of bands at
approximately 32 and 41 kDa.
It is illustrative to compare the intensities of the bands in figure 4.4. The predicted bands for
the 168∷690-derived strains are more intense than the equivalent 690∷71e bands. This
indicates that the protein concentration in the 690∷71e lysate was lower than that for
168∷690. A number of factors would lead to such an occurrence; differences in extraction
efficiency and errors in normalizing the optical density of the clumped spores are the most
likely culprits, here. A surfactant would improve this latter factor.
Other bands on the blots merit some discussion. The considerations regarding bands at
integer multiples of predicted lengths match figure 4.3, and shall not be repeated. The bands
at 35 kDa on the light chain samples are most likely C-terminal fragments of the NIP109
light chain AL11-GFP fusion, with the break in the middle of the CH domain. Very faint
bands at this length can be seen on other blots featuring this light chain. It is not clear why
the bands should be so strong on the blot, here. The additional bands seen on the gel from
690∷71e-derived strains may well be coat proteins that, in the absence of CotE, loosely
associate during spore washing, but dissociate during mechanical disruption. Peptide
mapping would be required to identify the constituents of these bands.
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Figure 4.4: Fractionated crude lysates from WT coat and ΔcotE B. subtilis spores containing antibody fragments.
Predicted bands on the SDS-PAGE are indicated with arrows; the corresponding bands are all present on the blot (inset
below each lane). The experimental lanes are grouped by progenitor strain, with fragment labels; the ladder at the left is
the Novex® Sharp Pre-stained protein ladder. Spores were processed and samples treated as previously described. The
right-most lane on this photograph has been truncated to minimize display of interference from its neighbouring lane.
These proteins were extracted through mechanical disruption; this may well be a cause of
the variation in extraction efficiency and the main cause of fragmentation. It is likely that
lysozyme disruption, with its gentler conditions, would cause less variation and
fragmentation, and therefore analysis of spore core extracts would more closely represent the
state of the core.
B. subtilis spores, with either viable outer coats or coat disruptions (based on 168∷690 and
690∷71e strains, respectively), were assayed using the lysozyme susceptibility test (see
section 2.8.2). The specific strains chosen had been transformed, using pDBT611l, and spores
were verified by fluorescence microscopy and western blot to contain NIP109 with C-
terminal GFP fusions (e.g. figure 4.4).
Behaviour of the ∆cotE strain4.2.2
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When viewed with phase contrast, only the coat-deficient strain (71e∷611l), and only when
challenged with lysozyme, showed lysed spores (figure 4.5); for all other conditions the
spores were structurally intact, as can be seen in the other panels. For the ∆cotE strain,
challenged with lysozyme, the localized spots of fluorescence correspond only to spores
which, in phase contrast, remained phase bright — i.e. spores which had not been disrupted.
Figure 4.5: Micrographs (phase contrast, composite, fluorescence) of B. subtilis spores containing fluorescent
antibody fusions, challenged with lysozyme. (a) shows spores with WT coat in buffer; (b) and challenged with
lysozyme; (c) shows coat deficient spores in buffer; (d) and challenged with lysozyme. Only the ΔcotE strain,
and only when challenged with lysozyme, showed disrupted spores (phase dark and lacking distinct
fluorescence). Strains are negative control 690∷611l, with intact cotE, and ΔcotE strain 71e∷611l: transformed
from their base strains using pDBT611l. Spores were produced using nutrient exhaustion and challenged on a
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One should infer from this assay that ∆cotE spores, challenged with lysozyme, released their
contents; this matches the behaviour described by Zheng et al. (1988). The fluorescence
micrographs show that non-disrupted spores contained the fluorescent, antibody-fusion
proteins. These two properties of ∆cotE spores make them suitable as a platform with which
researchers might produce sufficient heterologous spore core protein for analysis of protein
quality, using the techniques of formulation science (section 1.2.5).
From a laboratory perspective, the ability to operate the spore extraction process at larger
scale, thanks to lysozyme sensitivity, would certainly be valuable. It may be valuable, too, for
release of a therapeutic payload from the spore core, in a pharmaceutical formulation. Even
if the coat-disrupted spores were susceptible to gastric fluid, it may be possible to protect
them during transit through the stomach. Perhaps a lyophilized pellet of lysozyme and
spores could be covered in an enteric coating; the pellet would hydrate on reaching the
intestine and lysozyme would disrupt the spores, releasing their payload. There are options
to further engineer the outer layers of the spore to induce sensitivity to antagonists, present
at delivery locations in vivo. One option might be to harness a CLE (cortex lytic enzyme)
stored natively as a zymogen, such as SleC from Clostridium, present as ProSleC in dormant
spores. A formulation could be designed such that these spores lyse at the correct part of the
gut.
A more straightforward option would be available were intestinal fluid shown to disrupt
∆cotE spores — wherein lysozyme would be redundant. Ideally, ∆cotE mutant spores would
lose their (intestinal) pepsinogen resistance but retain their resistance to the stomach
enzyme, pepsin; this is indeed possible. There is value in ascertaining whether this
hypothesis is correct. The spores shown in figure 4.5 would make for a suitable test strain;
indeed other than the test fluids (gastric and intestinal), the experiment would look much
the same as that shown here. In addition to the microscopy tests, one could track the change
in OD₆₀₀ over time, for spores exposed to such challenges, for both lysozyme and simulated
gastric and intestinal fluids. Preliminary work, here, did not reach a stage at which it could
produce results; indeed, the kinetics of the disruption are important for detailed design of a
suitable laboratory protocol.
One must have confidence that coat-deficient spores retain the aforementioned desirable
properties for a pharmaceutical formulation. The B. subtilis 168∷690 spores produced here
were indistinguishable from wild type B. subtilis 168 under microscopy. The sporulation
efficiency and yield appeared unchanged — there was no noticeable difference between
plates of either strain. Spores germinated to produce vegetative cells, which themselves
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sporulated and responded to arabinose just as cells which had not undertaken such a
sporulation-germination cycle. Resistance to wet heat remains to be tested, both for the
supercompetent strain and its ∆cotE derivative; this is an important proxy measurement for
ensuring the protection of proteins in the spore core.
During washing, water formed beads on the B. subtilis 690∷71e spore-covered plate’s
surface. These spores, unlike their parent strain with a full copy of cotE, clumped during
subsequent processing. They floated on the top of the System W mixture used to isolate
them from vegetative cells. Despite this, neither cells nor sporangia were carried over into
the final, washed spore suspension. Ball milling diminished the clumps such that optical
density measurements could be taken.
From the high surface tension of water on ∆cotE, one might infer that clumping of the
washed spores is due to hydrophobicity. The high hydrophobicity of the B. subtilis ∆cotE
mutants is consistent with the loss of their hydrophilic outer coat and crusts. Surfactants,
such as Tween-20, are typically used in cleaning hydrophobic strains such as B. cereus. It is
likely that such surfactants would reduce clumping for this strain. However, when testing
the spores’ resistance to enzymatic challenge, it would be good to find a non-chemical
methods to reduce aggregation; otherwise one ought to investigate interference of
surfactants with the enzyme behaviour. In the long term, it may be worth engineering the
∆cotE strains to display a more hydrophilic surface, not least to simplify industrial processing.
Sporulation yields were informed by the visual thickness of the growth on plates and the size
of the recovered pellet. An approximate estimate of relative yields was calculated from
equivalent optical densities (OD₆₀₀) of resuspended pellets. These were analysed using a
paired comparisons model (Montgomery, 2012). Base strains were paired; strains
transformed with the same plasmid were paired, too.
The ∆cotE variant showed a mean 59±7% decrease in the resulting optical density
measurements, quoted as equivalent OD₆₀₀ per millilitre (i.e. the volume in millilitres if the
sample were diluted to an OD₆₀₀ of 1). The paired comparison test (table A1.5) showed that
the differences between the 168∷690-derived strains (630±50 OD ml⁻¹) and the
690∷71e-derived strains (270±60 OD ml⁻¹) were statistically significant (t = -15.4,
p = 5.9×10⁻⁴).
From these optical density measurements, one can infer a ⅗ drop in sporulation yield. The
paired comparisons test suggests that this measurement is reliable across batches, for given
sporulation conditions. It is likely that much of this effect was due to differences in the
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number of spores produced, and a little was due to the aggregation. Spores with a ∆cotE
mutation fail to produce a complete coat; mother cells are more likely to stop the process, as
a result. However, the spore samples did not show excessive vegetative cells, as would be
expected in that scenario. It is possible that the 690∷71e-derived strains sporulated at a lower
cell density. Some of the difference in optical density will be due to aggregation, though
while the aggregates were larger than individual spores, they remained in the same
scattering regime. This difference could be resolved by measuring the viable colony count,
but that assumes there is no difference in germination efficiency due to the ∆cotE mutation
— which would run counter to the evidence of Zheng et al. (1988).
While this ∆cotE mutant strain enables the rigorous analysis of heterologous proteins, there
remain other laboratory challenges. For example, the first candidate ∆cotE strain
(spectinomycinr 5-FUs ∷ ∆cotE +spc +upp) was notably slow growing, compared with
B. subtilis 168∷690. While there are anecdotal reports of ∆cotE mutant strains growing
slowly (G. Christie, personal communications, 2013–2019), it was not clear why this should
be so. It was only when this first candidate displayed other undesirable behaviour (a visibly
poor sporulation yield, close to 50% of the 168∷690 strain, and loss of the inducible
competence phenotype) that it became evident that the strain had a problem. None of these
behaviours was seen for the second candidate; it is therefore likely that there had been a
genome rearrangement, of some description. Despite that, the B. subtilis genome is usually
stable, in that allelic exchange will usually cause genome changes at only the one locus. As
whole genome sequencing becomes routine, any genome loss, or rearrangements, will be
apparent during colony screening. Meanwhile, before characterization of proteins produced
at scale by ∆cotE strains, it would be worth sequencing the full 690∷71e strain genome, to
identify any such changes. It would also be valuable to complement the strain with a
functional cotE to confirm that the WT phenotype results.
The ∆cotE strains here were based on inducibly competent B. subtilis, designed for marker
cycling with counter-selection. Improvements to cloning velocity were invaluable, despite
some technical issues.
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Inducibly competent cells proved to be as useful as suspected, and made simultaneous
transformation of multiple candidate strains feasible. However, there are a number of
ambiguities in the transformation protocol of Shi et al. (2013); in attempting to replicate
their work many were identified and resolved.
The gene upp, commonly used in Gram-negative bacteria, confers sensitivity to 5-FU
(fluorouracil). B. subtilis contains such a gene, natively; Fabret et al. (2002) reported how
knocking out upp allows use of 5-FU as a counter-selection marker. When the authors
flanked the cassette with 30 bp repeats, they saw spontaneous pop-out of the cassette at an
elevated frequency of 1 in 10⁶; homologous recombination with the chromosome more
generally requires repeats of 400–500 bp. Taken together, this allows for marker cycling
with an efficient marker regeneration step. This research was further developed into the
protocol of Shi et al. (2013).
This protocol states that the culture is induced to competence at OD₆₀₀ 1, yet gives no idea
of precision. In the standard arabinose induction protocols, Para is only induced during linear
growth. In the standard chemical competence protocols, B. subtilis cells are only incubated
with CaCl once they reach stationary phase. Presumably, the authors’ intention here was
that cells should be at the end of exponential growth, and are in their linear growth phase
when induction takes place. Attempts to induce overnight cultures, which had passed into
stationary phase, did result in some colonies, though far fewer than those induced at the
suggested point of growth, and only visible after 24 h rather than 16 h. In all other cases,
cultures were induced when OD₆₀₀ were measured to be between 0.8 and 1.2, and there was
no evidence of a relationship between OD₆₀₀ and transformation success.
Induced competent cells also lack the immediacy of a stock stored in a -80℃ freezer. In
order to freeze bacterial cells in this manner, they typically require a cryoprotectant. Shi et al.
(2013) did not report details of such treatment for their strain. Freshly prepared competent
cells could in fact be supplemented to 7% v/v DMSO, then flash frozen and stored at -80℃;
these cells retained their competence, and could be transformed just as their freshly prepared
counterparts.
Attempts to delete the native upp from B. subtilis 168 in the manner of Shi et al. (2013) failed,
with all colonies showing the wild type locus. Transformation of B. subtilis 168 with the
4527 bp linear fragment, corresponding to the replacement upp operon, resulted in ∼600
Inducible competence and counter-selection4.2.3
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colonies, none of the 2% screened had the desired mutation: indeed, all were false positives.
This trade-off is as described by You et al. (2012). A transformation protocol producing
fewer false positives is more desirable; this is the case even though there are fewer true
positives. Even for the supercompetent strains, transformation using plasmids offers exactly
that trade-off, and so plasmids were used for all subsequent cloning in this chapter.
Eventually, a more conventional transformation with pDBT69d, selecting on
Chloramphenicol, was successful (see sections 2.4.4, A1.7).
Counter-selection with 5-FU proved disappointing. From the gradient plate analysis
(figure 4.6), selection with 5-FU appeared to be somewhat reliable, in that there were lawns
for the strain with the resistant genotype, yet that with the sensitive variant showed only
sporadic colonies. However, those sporadic colonies appeared across the entire plates. A
concentration of ∼40 µM retarded growth of the 5-FUs lawn, but permitted growth of the
resistant strain, and so a concentration of 37.5 µM (corresponding to 0.075% v/v) was picked
for subsequent selection. The sporadic, 5-FU–sensitive colonies were more prevalent on
sample 10 µM plates, matching the Fabret et al. (2002) and Shi et al. (2013) protocols, than on
the 37.5 µM plates. Even with selection at a variety of 5-FU concentrations, it was not
possible to isolate a 5-FUs strain from transformation with pDBT690: a plasmid equivalent to
pSS (that used by Shi et al., 2013). Given that a strain with the desired genotype was
eventually isolated, this appears to be a consequence of transformation efficiency —
specifically, selection on 5-FU. It was the ability to validate the selection process, using the
chloramphenicolr 5-FUs strain 168∷69c, that proved invaluable; perhaps Shi et al. (2013) had
other strains suitable for this, though they gave no mention in their publication. As a
consequence, marker cycling for B. subtilis 690∷71e was unsuccessful.
The value of 5-FU was not diminished by the initial failure of direct selection. Rather, its
critical deficiency was failure to select strains following digestion with I-SceI, i.e. a)
stationary phase recombinant strains (rather than recovered chemically competent cells), b)
following a single homologous recombination event (more probable than a double
crossover), for which c) there is a double strand break in the genome (enhancing the chance
of homologous recombination). These factors make viable colony formation far more likely;
failure here thus greatly reduced the value of the technique.
Perhaps upp counter-selection is not such a great idea after all, though some form of
counter-selection would still be useful in this system. Based on this experience with upp and
5-FU, the most promising alternative might be the pheS system, selecting on
para-chlorophenylalanine. In that system, the presence of the mutant pheS cassette confers
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Figure 4.6: Gradient plates (⌀ 90 mm) of 5-FU (fluorouracil), spread with B. subtilis. (a) shows Δupp strain 168∷69c;
(b) shows WT. A smooth, near-confluent lawn of growth can be seen for the nominally 5-FU–resistant strain
(168∷69c) at concentrations ≲ 40 µM. By contrast, the WT strain (168) produced sporadic colonies, some of which are
indicated on the image with arrows; the inset is a magnified region including the colony just to its right. Concentration
gradients were linear, increasing 0–50 µM from right to left, as indicated by the triangular bars; the regions of the plate
beyond these bars were at the minimum or maximum concentration.
a b
sensitivity, even in the presence of native pheS. This dominant phenotype means that unlike
with upp, counter-selection is feasible in strains with an existing copy of pheS (which
includes all strains reported here). Furthermore it should be straightforward to determine
whether B. subtilis strains without the mutant pheS allele are reliably resistant as on
chloramphenicol, and as opposed to their behaviour on 5-FU. Finally, Carr et al. (2015)
reported two tips for generating a suitable pheS for a strain: that the cassette works better (at
least in T. thermophilus) when the protein is native but the nucleotide sequence shares
minimal homology with the native DNA, and para-chlorophenylalanine can be added to
agar before autoclaving (and in fact it was necessary as its water solubility is poor). The
former tip may have precluded use of such a system, until the recently widened availability
of gene synthesis; the latter indicates another advantage of para-chlorophenylalanine over
5-FU, in preparing working solutions.
Difficulties, experienced with 5-FU, themselves demonstrate the benefits of counter-
selection. Such benefits will be invaluable as use of a spore platform becomes routine, and
the research focus shifts to functionality of the therapeutic proteins.
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There is a major obstacle in verifying the functionality of NIP109 fragments, produced in
the forespore core. Conventionally-produced NIP109 is only available in its full IgG form.
Given ∆cotE strains can produce heterologous proteins and be disrupted by lysozyme, it may
now be possible to verify assembly, within the spore core, of full IgGs. This is not yet
possible; the failure of 5-FU counter-selection impeded the relevant experiments.
Thankfully it is also not necessary for testing functionality; an alternative without a complex
quaternary structure, such as a nanobody, might be more amenable to a functional assay.
B. subtilis subsp. subtilis 168 aliquots were transformed to Chloramphenicol resistance with
pDBT65* plasmids, containing coding sequences for the nanobodies in table 4.2 (see
listing A1.2 for the sequences). The resulting strains 168∷65* were induced to sporulate and
examined in a similar manner to section 4.2.1. Most microbiological work with nanobodies
was performed by undergraduate research students Joshua Cozens and Luke Vinter, or by
masters student Tayla Gordon.
Just as for antibody fragments, sporulating cells deposited nanobodies in their cores. Both
the BcII10 and VHHGFP4 nanobodies were produced (strains 168∷6510 and 168∷6540
respectively), and shown to migrate to the predicted bands under PAGE (figure 4.7 shows a
Nanobodies expressed by sporulating B. subtilis4.2.4
Table 4.2: Nanobodies, used in this chapter. In all cases the authors of the nanobody sequence demonstrated
binding of the nanobodies to their target. The code is the plasmid/strain suffix; the masses include the
nanobody and C-terminal 6×His tag. The β-lactamase sequences were located by undergraduate research
students Luke Vinter and Joshua Cozens.
Code Nanobody Target Source
Mass /
kDa
1 BcII10 Bacillus metallo-β-lactamase Conrath et al.
(2001)
14.7
2 TEM02 TEM-1 β-lactamase Conrath et al.
(2001)
14.2
3 TEM13 TEM-1 β-lactamase Conrath et al.
(2001)
14.0
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corresponding western blot). The only discernible bands were at the predicted masses for
each protein. In addition, masters research student Tayla Gordon was able to demonstrate

























Figure 4.7: Western blot of B. subtilis 168∷6510 (BcII10, 12.8 kDa) and 168∷6540 (VHHGFP4,
14.7 kDa) spore core extracts. Bands are present at the predicted sizes. Spores extracts were fractionated and
















Figure 4.8: Western blot of extract from strain 168∷651m (BcII10-mCherry chromobody). The predicted
band at 42.5 kDa, indicated with the arrow, is present. Spores extracts were fractionated and blotted as
previously described. The blot was produced by masters student Tayla Gordon.
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Fractionated, purified, extracted cores of strain 168∷6510 (engineered to express BcII10
nanobodies) showed predicted bands on a polyacrylamide gel (figure 4.9). The HisTrap-
purified extract shows a band at the predicted mass of the BcII10 nanobody (14.8 kDa, see
table 4.2). There is also a band at 60 kDa, and a faint band around 48 kDa, which most likely
correspond to aggregates. The His tag would still be present on aggregates, which would
then bind along with the desired monomer and elute into the purified sample. Insufficient
quantities of TEM02 and TEM13 were isolated to detect.
Compared with the antibody results, those for the nanobodies were a little more mixed.
While the VHHGFP4 and BcII10 nanobodies were produced, the same could not be said for
the TEM02 and TEM13 variants. Indeed, as the extraction and purification protocol gave a
positive result for the BcII10 nanobodies, it is likely these TEM variants were not expressed.
It is not clear at which point the process failed; it could have been poor codon optimization,
instability of the final protein (perhaps related to missing disulphide bridges) or problem
inherent to the sequences. More positively, despite sporulation failures seen with the
VHHGFP4-mCherry chromobody, the BcII10-mCherry chromobody was successfully
expressed. Taken together, this is good evidence that sporulating B. subtilis are capable of



















Figure 4.9: Fractionated, purified extracts of B. subtilis 168∷6510 spores (BcII10 nanobodies). The band at
the predicted mass, 14.8 kDa, is indicated by the arrow. The crude extract was purified using a HisTrap
column. Eluents were concentrated from 5 ml to 500 µl using 3 kDa columns. Samples were otherwise
extracted and fractionated as described previously, alongside a Novex® Sharp ladder. All this nanobody work
was performed by undergraduate research students Joshua Cozens and Luke Vinter.
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Path to a commercially viable product4.2.5
Do expressed proteins function?
While these results demonstrate that antibody fragments and nanobodies can be produced
by sporulating cells, they provide no further evidence that those proteins function correctly.
Assaying function is tricky; in previous, related work, Mohamed (2015) performed a
binding assay on the anti-lysozyme scFv produced in his optimized strain, though the assay,
using spore lysate, was difficult to validate (and gave slightly nonsensical results: no signal
for some positive controls). The proteins chosen for use in this chapter offer the promise of
robust functional assays, in the future.
While useful as a model IgG and therapeutically relevant humanized antibody, NIP109 is at
a disadvantage when it comes to a functional assay. NIP109 is a hapten binder; that means it
binds the small hapten molecule, NIP (4-hydroxy-3-iodo-5-nitrophenylacetic acid), for
which it is named. The resulting antibody-hapten complex will generate a measurable
immune response. For the NIP109 functional assay, one must measure this response. There
are two difficulties with this approach: the antibody configuration, and isolating sufficient
quantities.
MedImmune use NIP109 in the form of a whole IgG, and do not even have standard scFv
constructs (C. F. van der Walle, personal communications, 2016). There is neither specific
evidence that these particular antibody fusions demonstrate hapten-binding, nor that the
resulting complexes generate an immune response. One may therefore wish to use this spore
expression system to produce full IgGs rather than individual chains, or fusion fragments;
indeed there was some progress made in developing plasmids to construct such strains.
However, this is far from straightforward. One must match expression ratios of the light
chain and heavy chain; work by Guiziou et al. (2016) indicated potential promoter
mutations to help with this challenge.
There is also no established technique (such as BiFC, bimolecular fluorescence
complementation) for assessing protein interactions in vivo in the spore core. It would be
worth validating BiFC (bimolecular fluorescence complementation) within the spore core;
this would then help indicate the nature of interactions within the spore core itself, both in
the context of therapeutic proteins and basic microbiology of spores — in particular, how
proteins are stably maintained. Without such a technique, assessing IgG assembly would
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involve native PAGE, which would enable direct comparison of spore and CHO sourced
antibodies. However, with mechanical disruption one cannot be confident that the
condition of antibodies in the lysate reflects their state in the spore core.
That last point touches on the second difficulty: that of isolating sufficient quantities of
protein for an immunoassay. A rigorous set of assays requires reliable production of
milligram levels of protein. Scaling up the spore batches to produce such quantities is
relatively straightforward; growth of spores on plates scales linearly in the number of spores
required, using a CSTR (continuous stirred tank reactor) would make this growth sublinear
and much of the subsequent processing benefits from economies of scale. However,
mechanical disruption is a major bottleneck. A new technique to disrupt spores in the
laboratory is a requirement for producing protein of sufficient quantity, never mind quality.
To this end, the nanobodies may prove useful. They do not require inter-domain
association to effect their functions, though the issues of spore disruption remain. For the
anti-GFP nanobody VHHGFP4, a binding assay would test the nanobodies’ ability to attach
specifically to GFP and a functional assay that such complexes show diminished
fluorescence. In a binding assay, the anti–β-lactamase nanobodies would need to
demonstrate that they form complexes with their corresponding β-lactamase. In a functional
assay, working nanobodies would re-sensitize β-lactam resistant bacteria. There is another
functional assay, which measures β-lactamase activity via colour change of the
cephalosporin nitrocephin. Though nitrocephin degradation is only one example of β-
lactamase degradation, and that itself is only a proxy for antibiotic resistance, the
mechanisms are generally well understood and the colour change makes for a robust
screening assay. Indeed, preliminary work on the nitrocephin assay, by masters student
Tayla Gordon, suggests that the BcII10 nanobodies can inhibit the β-lactamase induced
colour change, meaning it is a promising avenue for the future.
Finally, in producing spores which carry a therapeutic protein payload, it does not matter
whether these proteins are functional in the core; it only matters that they do not degrade
there, and are functional when released. Characterising this must be a goal of future
research.
Expression levels
It is not enough that spores bear functional therapeutic proteins; if the level within a spore is
too low, the spore dose would be infeasible — as would research into protein quality. The
B. subtilis spore preparations on 90 mm 2×SG plates typically yield a quantity of spores which
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if suspended at OD₆₀₀ of 1 would take a volume of 150 ml; this is hereafter described as
equivalent to an OD₆₀₀ of 150, even though the linear relationship between OD₆₀₀ and
particle density is only valid for OD₆₀₀ ≲ 1. Mohamed (2015) supplies the figures for yield in
terms of this equivalent OD₆₀₀ of a spore suspension, based on OD₆₀₀ 1 corresponding to
0.1 mg spores. According to this conversion rate, one 90 mm plate yields 150 times this, i.e.
15 mg spores. At least 10 plates of spores would be needed to produce a single, daily dose of
single chain insulin, and the daily dose of full IgG would need perhaps 40 000. In practice,
producing such quantities is far beyond the scope of this project. However, the full battery
of protein characterisation tests used by formulation scientists requires 250 mg protein per
variant (see section 1.2.5). With the productivity presented by Mohamed (2015), this
corresponds to 300 g spores, i.e. 20 000 plates.
One might no doubt propose changing the method by which spores are grown, and
harvested, perhaps taking advantage of the recent developments in cGMP (current good
manufacturing practice) manufacture of spores. Unfortunately, there is one step for which
such an improved process does not exist, and that is extraction of the contents of spores. The
use of ∆cotE mutants, as explored in this chapter, may help, here.
Analysing the spore core in vivo
Indeed it is problematic that the core proteins must be extracted, for analysis. The properties
of proteins within the spore core are important, and the dearth of techniques for probing
such a location is problematic. The standard biophysical techniques for ex vivo analysis of
proteins are impossible here; one could not, for example, perform dynamic light scattering
on a spore core. What remains are inference techniques, relying on extensively controlled
interaction experiments; none has yet been implemented for the spore core.
The most immediately implementable of these is BiFC (bimolecular fluorescence
complementation), in which a pair of non-fluorescent, weakly interacting domains of YFP
(yellow fluorescent protein) are fused to the target proteins; if the target proteins interact,
only the correctly paired fusions will fluoresce. (One might consider the system of Trauth &
Bischofs, 2014, to reduce background noise.) BiFC requires positive controls with two
proteins known to interact (Kudla & Bock, 2016), and given the state of the dormant spore
core it is not clear which proteins do interact there. It is possible that IgG chains turn out to
be suitable here, as positive controls.
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A compromise approach may be hydrogen-deuterium-exchanged mass spectrometry
(Dobson et al., 2016). The spore core does exchange ions with its environment. The
hydrogen atoms on these proteins could therefore be exchanged with deuterium. Minuscule
quantities of these protein would be required for subsequent analysis. Protected proteins
within the core are likely to resist the hydrogen-deuterium exchange; a comparison with
exchange beyond the core, perhaps in other pharmaceutical formulations, would give a
good indication of the relative degree of protection the spore affords.
With such techniques, one would have a suitable platform for screening protein interactions
within the spore core, without needing to produce large spore batches. This would be a
useful addition to a spore formulation tool-kit, and could well lead to an improved
understanding of the spore core.
Many of these remain an open research problems: both in order to develop a potential
formulation, and as a prerequisite for conducting the necessary plethora of formulation
experiments on spore proteins, before spores bearing therapeutic proteins can become a
viable commercial offering.
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The research presented in this chapter seeks to evaluate whether bacterial spores are viable
carriers for therapeutic antibodies. Results demonstrate that sporulating B. subtilis cells can
produce a variety of therapeutic proteins. These proteins — IgG fragments (NIP109) and
nanobodies — have the correct masses, and are highly likely to have folded correctly, too.
Spores bearing the cotE mutation demonstrated sensitivity to lysozyme, and the same
capability to produce heterologous proteins WT backgrounds. These spores form a proof-
of-principle bacterial spore formulation.
The nanobodies show mixed results; both the VHH GFP4 and BcII10 nanobodies were
produced successfully, though corresponding chromobodies followed only in the latter case.
Though these fragments have been produced in the core, it may also be possible to use these
configurable binding proteins to decorate the spore (Lin, 2017), perhaps as sensors, or for
environmental clean-up. There is a straightforward functional assay for β-lactamase activity,
and when the strains of spores which produce the relevant nanobodies can themselves be
produced and disrupted at scale, it will be possible to evaluate whether these nanobodies do
indeed function.
There is a different story for NIP109, the IgG from MedImmune. A variety of fragments —
individual chains and scFvs — were produced. The next steps would be to produce both
chains in the same spore, and attempt to assemble a full IgG. However, the necessary
technology does not yet exist, to allow for satisfactory evaluation of the result. There is
neither technology to characterize interactions between the chains, within the core, nor to
disrupt the spores at scale and in a minimally damaging manner so that proteins can be
analysed in vitro. Although NIP109 is a standard model antibody, its scFv is not; it is best
evaluated in its full IgG form. With work on such techniques in future, B. subtilis spores
might become useful for delivering therapeutic proteins. The benefits of such a protein
platform might be greatest for non-IgG therapeutic proteins, however.
The single, simple ∆cotE mutation may resolve both the laboratory and formulation core-
release problems. It appears that spores bearing this coat deficiency correctly produce
heterologous proteins in their cores, too. These spores must, however, retain their other
resistances: the properties which make them desirable as a pharmaceutical formulation. In
particular, it is highly desirable that these spores maintain their resistance to wet heat, as it is
this challenge which primarily damages spore core proteins. Were the stability conferred on
Conclusions4.3
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proteins packaged in the core found to suffer, formulating with such spores would no longer
be a viable approach. This is unlikely; the coat deficiency was first reported thirty years ago,
with no reported loss of heat resistance since. It is the use, here, that is novel.
It remains to be seen what sensitivity these spores have to gastric and intestinal fluid, and to
that end, experiments in which these spores were challenged with those fluids will be
worthwhile. This system might yet provide a novel, simple way to release encapsulated
proteins from the spore in vivo.
Despite the advances presented here, many challenges with packaging therapeutic proteins
in the spore core remain. It may be possible to use a completely different sporulation system
to produce therapeutic proteins, thereby obviating the requirement to disrupt spores to
release the active ingredient; this forms the topic of the next chapter.
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One difficulty with producing therapeutic proteins in the sporulating B. subtilis forespore is
described in detail in section 1.4.3: heterologous protein comprises a low proportion of the
resulting spore. By contrast, there is one sporulation system notable for the scale of its
protein production: the Cry machinery of B. thuringiensis. In a review, Agaisse & Lereclus
(1995) asked “How does Bacillus thuringiensis produce so much insecticidal crystal protein?”
— and mercifully they answered, too (see section 1.3.3). Can this system be engineered to
produce heterologous fusions of therapeutic proteins?
Despite a great deal of research into Cry proteins over the past century, focus has fallen
mostly on the toxins, which form but one part. Few publications considered affordances of a
robust crystallization process, already operating at scale (Nair et al., 2015; Roh et al., 2004;
Sawaya et al., 2014). Others have considered these same proteins for surface display instead
(Du et al., 2005; Shao et al., 2009). These researchers all produced single fusions to full length
Cry proteins, or single subdomains (for Cry1Ac). This chapter presents a systematic
approach.
Cry1Ac, native to B. thuringiensis subsp. kurstaki HD-73, is fused in combinations of its sub-
domains, the fluorescent protein mCherry, and antibody fragments. The expression operons
are tested in B. thuringiensis, B. cereus and B. subtilis. B. thuringiensis HD-73 produces native
Cry1Ac crystals; the other strains do not. Triple fusions of a Cry domain, mCherry
fluorophore and antibody fragment are a prerequisite for a Cry-protein antibody platform.
The TEMs (transmission electron micrographs) in this chapter were prepared by fellow PhD
candidate Sina Schack, whose own project builds on this work.
Introduction5.1
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Results & discussion5.2
The region which confers on the full Cry1Ac protein the ability to form crystals,
corresponding to domains IV–VII at the C-terminus, is known as the protoxin domain, and
the three N-terminal domains, I–III, as the toxic core (see figures 1.9, 5.1).
By breaking the cry1Ac coding sequence into leader, protoxin and toxic core, there are 21
different mCherry fusions it is possible to make.
• Each of the three native regions can be present or absent.
• Each of these (2³ = 8) can take an N-terminal, C-terminal or no mCherry (×3 = 24).
• However, there is only one option with none of the three native elements (-2 = 22).
• Additionally, both N- and C-terminal fusions are identical when only the leader and
mCherry are present (-1 = 21).
Of those 21 fusions, eight are indicated in table 5.1. Coding sequences were assembled into
pDBT30 (see table 2.2, figure 2.2), a general purpose vector for B. thuringiensis derived from
the high copy number E. coli—Bacillus shuttle vector, pHT315, for expression, in Bacillus
species, of the Cry fusions. The coding sequences are flanked by the B. thuringiensis HD-73
native cry1Ac promoter and terminator regions. Plasmid pDBT310 is shown in figure 5.2.
Further vectors in the pDBT31* family feature the domains listed in table 5.1, in place of the
native cry1Ac.
Aliquots of B. thuringiensis HD-73 were transformed to Erythromycin resistance with one of
these pDBT31* plasmids to give the corresponding HD-73∷31* strains, induced to sporulate
and pelleted to concentrate the resulting spore-crystal slurries. Slurries were analyzed by
microscopy and PAGE.
Cry1Ac subdomain fusions5.2.1
I IIIII VIIV VIIV
Toxic core ProtoxinLeader
Figure 5.1: The domains of the Cry1Ac protein (arranged as primary structure). The native operon comprises
(from N- to C-terminus) the leader, the toxic core, and the protoxin domains. The seven subunits of the
protein make up the toxic core (I–III) and protoxin (IV–VII) domains.
Spore-forming bacteria as pharmaceutical factories Cry protein fusions · 5
173
Table 5.1: Schematic representation of mutant cry1Ac fusion operons. The element names give rise to the mnemonic for
identifying the variants. For example, the construct LTPm comprises the leader, toxic core, protoxin and mCherry
sequences: in that order when tracing the primary amino acid structure from N- to C-terminus. The 6×His tag allows




LTP 0 Toxic core ProtoxinLeader 6×His 133.6
Lm 10 mCherryLeader 6×His  31.5
LmP 20 ProtoxinmCherryLeader 6×His  96.6
LPm 30 Protoxin mCherryLeader 6×His  96.6
LTm 40 Toxic core mCherryLeader 6×His  95.8
LTPm 50 Toxic core Protoxin mCherryLeader 6×His 160.9
m 710 mCherry 6×His  27.7





































Figure 5.2: Plasmid pDBT310, for expression of (His-tagged) Cry1Ac, from its native operon. Antibiotic cassettes are
erm (erythromycin) and bla (carbenicillin); the E. coli and Bacillus origins are ori and ori1030’ respectively.
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Figure 5.3 shows the outcome of fractionating the solubilized spore-crystal slurries, using
PAGE. The Coomassie-stained gel shows bands of varying intensity present at all of the
predicted positions, and at many other positions, too. Likewise, the western blots shows
bands with a variety of intensities at all the predicted positions; there were also distinct bands
present at various other positions, notably at 20 kDa for the LTPm and LPm variants (less
intense bands can be seen at that position on the m and LTm lanes). The constructs in these
lanes all feature C-terminal mCherry fusions. These bands are not seen on any lane without
a C-terminal mCherry fusion. They are most likely C-terminal fragments of mCherry and
its His-tag. (The His-tagged mCherry itself produced neither fluorescent bodies nor a
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Figure 5.3: Analysis by PAGE of spore slurries for B. thuringiensis subsp. kurstaki HD-73–derived strains
expressing Cry1Ac-mCherry fusions. All strains with Cry1Ac fusion (L, T, P) showed bands at predicted
sizes on the associated blots (lower); bands are also visible on the (upper) gel. Arrows on the Coomassie-
stained polyacrylamide gel indicate positions of the predicted bands (using the Novex® Sharp Pre-stained
protein ladders). Snippets below cover the predicted band positions (and two 20 kDa regions) from
corresponding western blots; ticks indicate presence of a detectable band, the tilde indicates possible presence,
and no symbol indicates no band. Lane labels: WT (wild type), empty vector (∅) pDBT30 strain, HD-73∷3*
strains. Spore slurries were produced by nutrient exhaustion, pelleted and resuspended in water at 10×
concentration, and solubilized in LDS at the modified conditions.
Spore-forming bacteria as pharmaceutical factories Cry protein fusions · 5
175
The fluorescence phenotypes of the B. thuringiensis HD-73∷31* slurries are summarized in
table 5.2; micrographs follow. The WT strain, the background strain for all the
transformations, produces the native Cry1Ac protein. All strains produced crystals; these are
the phase dark, (typically) diamond-shaped structures in the phase contrast micrographs.
Some micrographs show sporulating cells, bearing both forespore and crystal. All strains
bearing mCherry fusions fluoresced distinctly; none did without. This was as expected, and
all fluorescence can be attributed to mCherry.
Micrographs of strains which lack fluorescent fusions are displayed in figure 5.4. Strains
shown in figures 5.4a, 5.4b, 5.4c do not bear plasmids encoding fluorescent fusions; the
negative control strain for fluorescent structures in figure 5.4d bears the gene for a His-
tagged mCherry only. There is only limited, diffuse background fluorescence for these
strains.
By contrast, the remaining strains have been transformed with plasmids encoding
fluorescent fusions; all showed distinct (and often very bright) fluorescence. For the strains
in figure 5.5, bright fluorescence associated with the crystals and vegetative cells, not spores.
Table 5.2: Fluorescence phenotypes of B. thuringiensis HD-73 strains bearing cry1Ac
fusion operons. All strains with an mCherry (m) fusion showed distinct fluorescence. This
was associated with the crystals for all strains with the protoxin (P) too. The ∅ variant
indicates the strain transformed with the empty vector. The columns indicate the quality
(distinct) or location (crystal, spore, shells) of the fluorescence. Missing entries indicate
unsatisfied dependencies (e.g. no distinct fluorescence means no location would be
meaningful).





LTPm HD-73∷3150 ✓ ✓ ―
LmP HD-73∷3120 ✓ ✓ ―
LPm HD-73∷3130 ✓ ✓ ―
mP HD-73∷31720 ✓ ✓ ―
Lm HD-73∷3110 ✓ ― ✓ ―
LTm HD-73∷3140 ✓ ― ✓ ✓
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Figure 5.4: Micrographs (phase, composite, fluorescence) of B. thuringiensis HD-73 negative control spores, i.e. not
engineered to encode fluorescent fusions of Cry1Ac. (a) shows WT HD-73; (b) shows HD-73∷30, the empty vector
strain (∅); (c) shows LTP strain HD-73∷310; (d) shows m strain HD-73∷31710. Cells, spores and crystals do not
differ from WT; differences in relative proportion are an artefact. There is only limited, diffuse background fluorescence.





The largest construct fluoresced (160.9 kDa, in the crystal–positive control strain
HD-73∷13150, see figure 5.5a), indicating that the Cry1Ac expression pathway is not
unduly taxed by the extra fluorophore. No variation in fluorescence was seen with age, over
a two month period. Indeed, samples stored at 4℃ still fluoresced after twelve months.
The brightest and most uniformly distributed fluorescence was seen in samples of
HD-73∷3120 and HD-73∷3130 (LmP and LPm respectively, in figures 5.5c, 5.5b). These
variants lack the toxic core, having an mCherry fusion (respectively in its place, and
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Figure 5.5: Micrographs (phase, composite, fluorescence) of B. thuringiensis HD-73 spores bearing pDBT31* vectors
encoding fluorescent fusions of Cry1Ac. (a) shows LTPm strain HD-73∷3150; (b) shows LPm strain HD-73∷3130;
(c) shows LmP strain HD-73∷3120; (d) shows mP strain HD-73∷31720. Almost all crystals fluoresced, with near-
uniform high intensity for the L variants. Spores did not fluoresce; some cells did. In phase contrast, cells, spores and





between the protoxin domain and C-terminal 6×His tag). This fluorescence was localized to
the crystals, not spores (though some cells fluoresce brightly, too). These are minimal
fusions, to which additional sub-units of interest might be added, and are thus candidates for
the base of a therapeutic protein platform.
The transformed strains contain both the native and the heterologous operons. Where any
crystals fluoresced, nearly all did; it is most likely the crystals were heterogeneous: well
documented behaviour for these crystal proteins. It is possible that the heterologous gene
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was reducing or preventing transcription or translation of the native cry1Ac, perhaps due to
copy number effects. However the plasmid, from which pDBT31* were derived, has been
shown to display saturation kinetics with B. thuringiensis cry1Ac (Agaisse & Lereclus, 1995),
making this unlikely.
Since the completion of the bulk of the work presented here, PhD student Sina Schack has
used the techniques and results to design and construct further fusions. Transmission
electron microscopy of a number of fluorescent fusions of Cry1Ac revealed no differences
from native crystals. Micrographs of the native Cry1Ac and a fusion with mCherry and the
exosporium basal protein ExsFA (Stewart, 2015), are in figure 5.6. Crystals showed the same
bipyramidal structure, with some patches of low electron density, and edges with regular
order at the 500 nm scale, but great irregularity at the 50 nm scale.
Whereas HD-73∷3120 (LmP) showed near uniform, distinct, bright fluorescence across all
crystals, the leaderless mP variant (HD-73∷31720) showed greater variation (figure 5.5d). A
more extreme version of this leader effect can be seen comparing the negative control strain
HD-73∷31710 (m) to the Lm variant (HD-73∷3110, in figure 5.7), i.e. with the leader. In the
former case once can see no fluorescence; for the latter, cells and spores, but not crystals,
fluoresce.
Comparing outcomes for all four (LmP, mP, Lm, m), one can infer that the protoxin domain is
necessary for the fusion protein to embed into the heterogeneous crystals. One might
hypothesize that the leader is involved in crystallisation, despite not appearing in diffraction
patterns (Evdokimov et al., 2014, not that an amorphous sequence would appear). This does
not explain why the Lm variant’s fluorescence demarcates spores, but not crystals.
A more likely explanation is that the leader prevents export of the associated peptide from
the mother cell, or perhaps prevents its degradation during sporulation, and thus the LPm
variant can embed in the crystal, and the Lm associate with the spore. This by itself would
Figure 5.7: Micrographs (phase, composite, fluorescence) of B. thuringiensis Lm variant (HD-73∷3110). The
bipyramidal structures did not fluoresce, whereas cells and spores did. Spore slurries were produced as
previously described. Scale bars are 5 µm × 1 µm.
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Figure 5.6: TEMs of Cry1Ac crystals. (a) shows the native crystal; (b) shows the fluorescent fusion with ExsFA and
mCherry. Both variants form typical crystals (the large, electron dense structures); on 5.6b, near-vertical lines can be
seen. The thin strands are fragments of exosporium. The objects at the top right and right of 5.6b are spores. It is not
clear what the electron density at the lower left of 5.6b represents. Samples were prepared by Sina Schack; images were
taken at CAIC (Cambridge Advanced Imaging Centre) with assistance of Dr. Katrin Mueller and Lyn Carter. Scale
bars are 500 × 50 nm.
a
b
not explain why no spore of the LPm variant showed more than background fluorescence;
there are however two factors that can explain this. Firstly, unlike for the LPm fusion none of
the Lm protein is incorporated into crystals, meaning there is more available to attach to the
spores. Secondly, this experiment could not control for total protein expression: if the total
protein expressed in each sample had the same mass, the mass of mCherry produced would
be greater in the Lm than the LPm variant, and thus there would be more fluorophore and
more leader in the former case, leading to a greater fluorescence signal. The total protein
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expressed is likely to be similar, given similar conditions. These two factors would explain
the difference in background fluorescence, supporting the model that the leader prevents
protein export or degradation.
The most surprising result corresponds to strain HD-73∷3140 (LTm, figure 5.8). Distinct
rings are visible at locations corresponding to the spores’ outer layers. The rings are not
uniform; they appear thickest at the spore equator. There is some diffuse fluorescence
corresponding to the vegetative cells, too. However, the vast majority of the crystals, seen
on phase contrast, did not fluoresce. Some structures, faint on phase contrast, fluoresced
brightly; indeed in phase contrast there is no signal at the corresponding locations. This
evidence strongly suggests the heterologous protein is not integrating into the crystal; rather
it is deposited into one of the outer layers of the spore: the coat, interspace, or exosporium.
It is unusual that fluorescence appears to concentrate at the spore equator. More typical is
pooling at the poles, as that is where the coat is normally thickest (Manetsberger et al., 2015).
The effect here might be seen were the protein to embed in the coat, where the coat is
already otherwise thinnest. Considering Cry1Ac, Du & Nickerson (1996) postulated that
Figure 5.8: Micrographs (phase, composite, fluorescence) of B. thuringiensis HD-73∷3140 spores, bearing the
LTm fusion variant. Most of the fluorescent objects are spores, for which the shells show distinct fluorescence.
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“the N-terminal ‘business end’ of the protoxin is exposed on the spore surface and the C-
terminal region anchors the protoxin inside the spore coat”. The result demonstrated here is
perhaps inconsistent with this model, as here the entire C-terminus of the protein has been
replaced. It is still possible that wild-type Cry1Ac is embedding in the coat and the
heterologous protein is attaching through complementary interactions; such an occurrence
would be quite surprising as the toxic cores are not thought to interact until the protoxin is
cleaved, and crystallographic studies demonstrate minimal interaction between toxic cores
(Evdokimov et al., 2014). The postulated model is most likely wrong, and in fact Cry1Ac
embeds in the coat in some other way. This plausibly relates to the leader sequence itself, as
discussed above. ELM (Ellipsoid Localization Microscopy) may help identify what is
happening here, though it has yet to be tested in B. thuringiensis (Ghosh et al., 2018;
Manetsberger et al., 2015).
Whether or not some of the heterologous protein is embedded in the spore coat, it is likely
that some is located in the interspace. Even if every molecule partially embedded in the coat,
the rest of the structure would be in in the interspace. From the non-uniform distribution of
fluorescence around the shell of the spore, it is likely that there would still be a specific
interaction with the coat.
One might note that it is only strain HD-73∷3140, for which the micrographs show these
fluorescent shells. This suggests that it is the absence of an inhibitory factor (the protoxin
domain) rather than the presence of the leader, 6×His tag, or mCherry, causing the protein
to deposit in this manner — though the earlier comments on mass of protein produced apply
here (albeit as a lesser consideration).
There was also fluorescence beyond the shells. Careful inspection of slides revealed some
localised fluorescence at positions corresponding to some crystals and mother cells in phase
contrast. It is not clear to what these spots correspond. From their brightness on the
fluorescence micrographs, it is likely that these are aggregates of fluorescent protein. These
perhaps comprise the native domain, with which the toxic cores of the fluorescent fusion
interact, though there is not enough information in these images to be certain. The larger
objects could be partially crystalline aggregates of Cry1Ac, with fusions embedded therein.
⁂
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The Cry1Ac subdomain fusions display the desired properties: most importantly, expression
of heterologous protein at high yield. Thus these proteins might therefore serve as a
platform, in which the gene for a protein of interest is cloned into the mutant cry1Ac genes
in pDBT3120 or pDBT3130, following (C-terminal to) and preceding (N-terminal) the
protoxin domain, respectively.
What if an antibody fragment were cloned into these Cry1Ac fusions?
Table 5.3 lists the B. thuringiensis vectors, for expression of Cry1Ac–NIP109 fusions. The
source plasmid for the entries with an N-terminal antibody fragment and C-terminal
mCherry is pDBT3130; pDBT3120 provides for an N-terminal mCherry and C-terminal
antibody fragment (see table 5.1).
Phase contrast and fluorescence micrographs of spore-crystal mixtures, for B. thuringiensis
HD-73, engineered to produce Cry–antibody fusions, are shown in figure 5.9. Fluorescent,
bipyramidal crystals can be seen for all samples, though there is visible heterogeneity. The
signal is strongest for LlPm (HD-73∷313l) and LmPs (HD-73∷312s). The latter is uniformly
strong; by itself it is not clear whether the full protein has been expressed, as the fluorescent
fusion is near the C-terminus. The phase contrast and fluorescence micrographs clearly
show that something fluorescent was being produced, which mostly aligned with the
positions of crystals visible under phase contrast.
Cry1Ac–antibody fusions5.2.2
Table 5.3: Schematic representation of Cry1Ac–NIP109 fusion operons. The extended mnemonic includes l for
light chain, h for heavy chain and s for scFv. For example, pDBT312s comprises (in order from the N-terminus) the





LlPm 3l Protoxin mCherryLeader 6×Hislight 119.8
LhPm 3h Protoxin mCherryLeader 6×Hisheavy 145.8
LsPm 3s Protoxin mCherryLeader 6×HisscFv 121.8
LmPh 2h heavyProtoxinmCherryLeader 6×His 145.8
LmPs 2s ProtoxinmCherryLeader 6×HisscFv 121.8
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Figure 5.9: Micrographs (phase, composite, fluorescence) of cells, spores and NIP109 fusion crystals in B. thuringiensis
HD-73 spore cultures. (a) shows LlPm strain (HD-73∷313l); (b) shows LhPm strain (HD-73∷313h); (c) shows LmPh
strain (HD-73∷312h); (d) shows LsPm strain (HD-73∷313s); (e) shows LmPs strain (HD-73∷312s). All strains
showed fluorescence corresponding to the locations of crystals on phase contrast; the fluorescence is particularly distinct
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A representative outcome of fractionating solubilized slurries of the Cry1Ac-NIP109 fusions
can be seen in figure 5.10. As for the Cry1Ac-mCherry fusions in figure 5.3, from
figure 5.10 it appears these triple fusion crystals had not been solubilized correctly, and there
are few distinct bands. No western blot band corresponded to the predicted mass of a
NIP109 fusion, nor did any band correspond to a C-terminal domain fragment (i.e. a
fragment bearing the His tag). On the gel, predicted bands are visible for the LsPm, LmPh and
LmPs variants. This result was seen across multiple gels and blots.
For the strains with C-terminal mCherry fusions (figures 5.9a, 5.9b, 5.9d), one can be almost
certain that the correct primary sequence was expressed, and that the mCherry folded
correctly; for the C-terminal mCherry fusions to express, cells must translate the whole
protein (the unlikely possibility of internal ribosomal entry sites notwithstanding). Further
supporting evidence is provided by the appearance of the 20 kDa mCherry degradation
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120 146 122 146 122
Bands at 20 kDa on blot
Figure 5.10: Analysis by PAGE of spore slurries, for strains expressing Cry1Ac-mCherry-NIP109 fusions.
No strain showed bands at predicted sizes on the associated blots, but the C-terminal mCherry fusions
showed bands at 20 kDa. On the gel, bands are visible at predicted positions for LsPm, LmPh and LmPs variants
(at arrows, inferred from the Novex® Sharp Pre-stained protein ladder). Lane labels are for HD-73∷3*
strains. The spore slurries were solubilized in LDS at the modified conditions.
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It is possible that for the variants with the N-terminal mCherry fusion (figures 5.9c, 5.9e),
expression arrested after producing the fluorophore but before the antibody fragment.
Direct analysis of the relevant proteins ought to help eliminate that possibility; the lack of
bands on the western blots provide weak evidence in favour of elimination. One should
infer that the successful expression of the C-terminal mCherry fusions makes it unlikely that
the N-terminal variants failed to express. However, current evidence cannot confirm the
contrary.
These triple antibody fusions form heterogeneous crystals, in the presence of the WT
Cry1Ac. Is it possible to produce crystals of these fusions in the absence of the native
protein? This could be answered by transforming an acrystalliferous strain of B. thuringiensis,
using the pDBT31* plasmids.
Phase contrast and fluorescence micrographs of various strains, transformed with the
pDBT3130 and pDBT3140, are displayed in figures 5.11–5.13. These plasmids feature variants
LPm and LTm of the cry1Ac operon with mCherry at the 5’ end, which lack the toxic core and
protoxin domain coding sequences, respectively. No sample showed fluorescent crystals.
Surely another species of B. thuringiensis would produce protein crystals? B. thuringiensis
subsp. finitimus YBT-020 produces Cry4A crystals within its exosporium (i.e. spore-crystal
association). Micrographs of that strain, transformed with the aforementioned plasmids,
showed background fluorescence only (figure 5.11). Indeed, while the YBT-020–native
Cry4A crystals were present, there seemed to be no production, or no interaction, with the
Cry1Ac fusions. It is strange that the promoter from one B. thuringiensis would not appear to
be active in another; it seems likely that there are other factors, present in B. thuringiensis
HD-73 alone. For comparison, one might clone the cry1Ac fusions into vectors driven by
σK from B. thuringiensis YBT-020, or clone both the native cry1Ac variant and a fusion into
that strain.
The difference between B. thuringiensis and B. cereus is the former’s cry- or cyt-bearing
plasmids (Agaisse et al., 1999). One might expect expression in B. cereus to be similar to that
in B. thuringiensis; however, this was not the case. Figure 5.12 shows B. cereus transformed as
B. thuringiensis YBT-020, above.
Expression in other Bacilli5.2.3
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Figure 5.11: Micrographs (phase, composite, fluorescence) of B. thuringiensis subsp. finitimus YBT-020 spore slurries.
(a) shows LPm strain YBT-020∷3130; (b) shows LTm strain YBT-020∷3140. The resulting cultures appeared like WT
(not shown): crystals were exclusively associated with the spores, and no structure fluoresced distinctly. Spore slurries
were produced as described previously for B. thuringiensis HD-73 strains. Scale bars are 5 µm × 1 µm.
a
b
The spores of strains bearing the LPm variant showed fluorescent inclusions within cells, but
no other fluorescence of cells nor spores beyond that seen for the WT strain. The
fluorescent shape at the top of figure 5.12b appears like neither cell nor spore. By contrast,
the LTm variant showed a mixture of fluorescent inclusions and fluorescent shells around
some spores (figure 5.12d). As seen in that figure, the fluorescence was most intense at the
poles.
For B. cereus ATCC 14579, at least, there was discernible fluorescence corresponding to both
fusions, and possibly crystals, seen in figure 5.12b, whereas the other LPm image (more
representative of that strain) and that for LTm both show fluorescent inclusions of some kind.
The LTm strain showed shells very similar to that for B. thuringiensis HD-73. However, the
level of production of what might be crystals was nowhere near that seen in B. thuringiensis;
the Cry fusions alone thus appear unable to form extracellular crystals.
It would seem unlikely that B. subtilis spore crops would fluoresce. Within the Bacilli,
B. thuringiensis and B. subtilis share a relatively distant phylogenetic relationship. In addition,
as B. subtilis does not feature an exosporium there can be no interspace. Despite this,
figure 5.13 shows faint shells of fluorescence for both the LPm and LTm variants. For the LTm
variant fluorescence was greatest at the poles. This seems like evidence for the various cry
fusions embedding in the coat.
Spore-forming bacteria as pharmaceutical factories Cry protein fusions · 5
187
Figure 5.12: Micrographs (phase, composite, fluorescence) of B. cereus ATCC 14579 spore slurries. (a) shows WT
B. cereus; (b) shows LPm strain 14579∷3130; (c) likewise; (d) shows LTm strain 14579∷3140. There were no
bipyramidal structures, though small fluorescent inclusions can be seen — in both experimental strains. For LTm variant,
shells fluoresced with very bright poles (compared with the distinct but less bright fluorescence for the WT strain). Spore





Finally, the work in chapter 4 considered expression in the forespore of sporulating
B. subtilis. Such expression relied on the PsspB promoter, under control of σG, which drives
transcription in the late forespore. As it is desirable to increase this protein expression, the
cry1Ac machinery appeals: a cry1Ac operon, for which the aforementioned promoter PsspB
would replace Pcry1Ac, might be a useful tool. With it, one could investigate the extent to
which this B. thuringiensis cry1Ac machinery can boost protein expression in the B. subtilis
forespore.
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Figure 5.13: Micrographs (phase, composite, fluorescence) of B. subtilis 168∷690 progeny, for expression of the modified
cry1Ac operon. (a) shows LPm strain 690∷3130; (b) shows LTm strain 690∷3140. There were no bipyramidal structures,
although shells showed distinct fluorescence, in particular at poles. Spore slurries were produced using nutrient
exhaustion, then processed as described previously. Scale bars are 5 µm × 1 µm.
a
b
Micrographs of such a B. subtilis strain 690∷31610, engineered to express 6×His-tagged
mCherry in the forespore, can be seen in figure 5.14. Fluorescence can be seen over the
whole of each spore, though intensity is greater at the shell (especially at the poles),
indicating that mCherry is indeed produced from such an operon. It is possible that this
corresponds to diffuse mCherry, over the whole spore core; ELM would help clarify this. A
variant based on the mother cell promoter, such as one driven by σK, might make a
worthwhile comparison.
⁂
Figure 5.14: Micrographs (phase, composite, fluorescence) of B. subtilis 690∷31610 progeny, for expression of
His-tagged mCherry. Shells showed distinct fluorescence, particularly at poles. There are also small, faint,
phase dark structures, which also appear in the fluorescence micrograph; These are indicated on the composite
with white arrows. Spore slurries were produced as described previously. Scale bars are 5 µm × 1 µm.
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It does appear that none of these strains produces crystals. It is plausible that there are
additional factors required for crystallization of these fusions. It may be worth investigating
the capacity of these strains to produce the native crystal or (fluorescent) LTPm variant.
Likewise, testing with an acrystalliferous variant of B. thuringiensis subsp. kurstaki HD-73
would be worthwhile — however, it should ideally lack only the native cry1Ac operon.
Despite this, some strains did produce fluorescent protein. As it turns out, such strains were
not limited to Bacilli.
During cloning of E. coli bearing the desired plasmids, a number of strains showed
fluorescence. Samples of these cultures, when examined under optical microscopy, were
found to fluoresce. Some LmP (pDBT3120) cells contained large, phase-bright inclusions,
which fluoresced with great intensity under UV illumination: indeed, an intensity often
visible even while the sample was illuminated for phase contrast. Representative micrographs
can be seen in figure 5.15.
Expression of the cry1Ac operon in E. coli5.2.4
Figure 5.15: Micrographs (phase, composite, fluorescence) of E. coli Turbo cells used to assemble pDBT31*
vectors. (a) shows LTP variant (0 suffix); (b) shows m (710); (c) shows LTPm (50); (d) shows LmP (20);
(e) shows LPm (30); (f) shows mP (720); (g) shows Lm (10); (h) shows LTm (40). All strains bearing
mCherry-encoding plasmids showed fluorescence. Samples were taken from cultures grown for Miniprep.
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All strains but that in figure 5.15a contained plasmids encoding fluorescent fusions; all
samples but that in figure 5.15a fluoresced. Unlike for B. thuringiensis spores (in figure 5.4d)
the m variant fluoresced, too (figure 5.15b). The localization and heterogeneity of the
fluorescence varied. While strains showed diffuse fluorescence if and only if they carried the
mCherry variants, some strains showed highly localized fluorescence, within the structures of
the cells. The plasmids in these latter strains all contained the protoxin domain; indeed only
the strains with a protoxin domain and mCherry fusion showed such localized fluorescence
figures 5.15c, 5.15d, 5.15e, 5.15f. Within the micrographs of strains which fluoresced, one
can also see cells which do not — there was heterogeneity of fluorescence. Older cultures
showed more uniform fluorescence.
Phase contrast microscopy of samples revealed what appeared to be large inclusions within
the E. coli cells. These are not as clearly visible on images, recorded by the CCD, as they
were through the eyepiece of the microscope. The inclusions were also present in samples of
the strain containing pDBT310, encoding the LTP variant.
Fluorescence was not limited to microscopy. Routinely, cultures were pelleted for miniprep
after 8 h growth; for three of these cultures (LPm: Turbo∷3110, Lm: Turbo∷3120 and m:
Turbo∷31710) the pellets would appear red. Indeed, old liquid culture turned red, too. This
red colour could be seen on plates. Day old colonies on plates would turn red, even if
refrigerated. The change in colour began at the centre of the colony and spread from there.
Figure 5.16 shows an example of this. N-terminal mCherry fusions in particular showed a
striking red colour, with the greatest intensity corresponding to mCherry (with or without
the leader sequence). This latter detail supports the hypothesis that more mCherry was
present for the Lm than LmP variant in B. thuringiensis (postulated in section 5.2.1).
To identify a cause of such protein expression, NNPP was performed, as described in
section 2.2.3, with the region of the cry1Ac operon just upstream of the RBS. The target: the
E. coli σs (aka σ38) consensus sequence, is TTGACA N₁₅ KC TATACT TWWWW R (Becker &
Hengge-Aronis, 2001). This revealed four matches for the E. coli σs promoter with scores
≥0.99 just upstream of the cry1Ac RBS (ribosome binding site). This sigma factor is not only
the main stationary phase transcription factor, it is also involved in stress response (Becker &
Hengge-Aronis, 2001). The presence of these matches suggests transcription of the crystal
proteins is likely during stationary phase growth; this is what was seen experimentally. The
diffuse fluorescence seen from all the samples whose plasmids encode fluorescent proteins
supports this σs hypothesis. Beyond that, the variation in localized fluorescence seen among






Figure 5.16: Streaks of E. coli Turbo cells, bearing pDBT31* plasmids for expression, in Bacillus, of Cry fusions, from
their native promoter. The top half and lower right sector showed a red colour, which on the agar plate itself (as opposed
to a photograph) was quite distinctive and clearly visible to the naked eye. The colour saturation was strongest for the
top and top-right sectors, corresponding to mCherry (alone or with the leader). This red hue was quite stable; it was still
visible after storage for two months at 4℃. Cultures were streaked onto a 90 mm LB-agar plate.
the fusions matches what has been shown for expression in B. thuringiensis: that the protoxin
domains enhance stability. However, the causes of the heterogeneity within each sample are
less clear. The σs story is not complete, though it would explain some cloning difficulties.
Isolation of gDNA corresponding to the cry1Ac operon was straightforward, as was cloning
into library vectors. This was also the case for cry4A, from B. thuringiensis YBT-020.
However, cloning the full cry1Ac gene (or any of the operons from YBT-020) into pHT315
proved challenging; often transformations would result in single digits of transformants, and
colony PCRs indicated the resulting constructs had mis-assembled, sometimes in interesting
and unpredictable ways. Overlap assembly methods have their limitations, and so plasmid
pDBT30 was designed and constructed as a Golden Gate recipient vector, using standard parts
(Patron et al., 2015). Golden gate cloning, too, proved unsuccessful; colony PCR of
transformants identified either religations or no PCR product. Plasmid pDBT30 proved as
susceptible to these issues as pHT315.
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Eventually, using a batch of freshly prepared E. coli Turbo competent cells, a correct clone
containing pDBT310 was produced (from the single colony to result from the
transformation). By contrast, transformations with the fusions produced numbers of colonies
(20–100 per 90 mm plate) more typical of successful ligations. Having successfully identified
a clone containing pDBT310, it became most likely that these difficulties related to the operon
sequence itself. From the low number of colonies (and low likelihood that they comprised
correct clones) one should infer that the correct ligation is a toxic sequence and only
incorrect ligations resulted in viable colonies. Transcription from the backbone vector, and
concomitant leaky translation, seemed unlikely; whilst there was a lac operon present, from
the lack of reports of cloning difficulties with pHT315, one might infer this is not the fault of
the vector.
Unintended expression from the cry1Ac operon explains the difficulties in cloning the full
length cry1Ac gene. Protein expression causes metabolic load which can greatly reduce
growth rates (Glick, 1995). It is possible that during cloning, expression of Cry proteins
shortly after the start of recovery reduced growth rates to such an extent that visible colonies
were not formed. By contrast, transformants with mis-assembled cry1Ac operons would
grow at the expected rate. Researchers working with this operon should bear this in mind
for future work, and consider mutating these consensus sequences.
There is precedent for production of Cry proteins in E. coli. Of note here, E. coli has been
engineered to express Cry proteins from the tac promoter before, and the resulting inclusion
bodies were found to be amorphous if grown at 37℃, yet crystalline if grown at 30℃
(Oeda et al., 1989). One might grow these strains at 30℃ to test whether that observation
holds in this case, too.
While this operon has presented cloning difficulties, this autoinduced expression of
fluorescent proteins presents an opportunity. Given that cells assembling a coding sequence
featuring mCherry turn red, one might identify correct clones with high likelihood before
colony PCR, digest or sequencing. Whilst the coding sequences of all picked colonies that
turned red were subsequently verified successfully by Sanger sequencing, the numbers
sequenced were too small to judge the sensitivity or specificity of this test.
Cloning was not the only process to show unexpected fluorescence; crystals in denaturing
conditions maintained their fluorescence, too.
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Many researchers have analysed crystal proteins, and there are a number of methods used to
solubilize them for different purposes (Bulla et al., 1977; Huber et al., 1981; Pearson & Ward,
1987; Schnepf & Whiteley, 1981; Thomas & Ellar, 1983). For the work here, the approach
of Thomas & Ellar (1983) was selected, as it involved minimal modification to the existing
PAGE protocol. Importantly, this protocol can be used without needing to purify the
crystals, making it suitable for screening.
It was tested on B. thuringiensis subsp. kurstaki HD-73 bearing pDBT3130 (with the standard
PAGE technique as a negative control), and then performed on all strains (including the
antibody fusions).
Phase contrast and fluorescence micrographs of spore-crystal slurries following the
solubilization process can be seen in figure 5.17. The direct solubilization process of Thomas
& Ellar (1983) resulted in complete loss of fluorescence, and no phase-dark bipyramidal
structures could be seen on the phase contrast micrographs (figure 5.17b)
Thus boiling the slurry dissolved the crystals, as there was no longer visible fluorescence.
However, the PAGE and western blot results show that the process also resulted in
significant degradation of the proteins. The crystal proteins — which from microscopy were
clearly present as a major component — barely appeared on gels (though they did on blots).
Many lanes showed strong bands at 20 kDa; all these lanes corresponded to fusion variants
with the Pm C-terminus: the protoxin domain, mCherry, then the His-tag. There were
20 kDa bands, though fainter, for other variants with just a C-terminal mCherry (and His-
tag). This must surely indicate that the fusion, specifically the mCherry tag, had been
degraded (as seen, for example, in Beilharz et al., 2015). In addition to confirming that the
whole protein was produced, this may explain some of the other bands that could be seen on
the gels and blots. It is worth optimizing the solubilization protocol, for further work on
these proteins.
Under standard PAGE conditions, however, the crystals appeared to grow. The crystals
were barely visible when viewed using phase contrast; indeed, at first glance it had appeared
they had dissolved. When illuminated with UV, however, fluorescent bodies were clearly
visible (figure 5.17c). These structures featured the distinctive, bipyramidal shape of Cry1A
crystals. They were, however significantly larger than those in untreated samples (see
figure 5.17a).
Solubilization of crystal proteins5.2.5
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Figure 5.17: Micrographs (phase, composite, fluorescence) of B. thuringiensis HD-73, following attempts to dissolve
crystal proteins. (a) shows LPm strain (HD-73∷3130) without treatment; (b) shows the modified treatment; (c) shows
standard PAGE conditions After application of the modified protocol (boiling for 5 min), no crystal remained;
furthermore boiling can destroy spores, meaning the smaller number of spores is most likely not an artefact. Following
the modified protocol (incubation at 70℃ for 10 min), the fluorescent structures appeared larger and more diffuse: the
matching objects in the phase contrast micrographs likewise. Spore slurries were produced as described previously, then




There are a number of possible explanations. It is unlikely that this was an example of
selection bias: that there was no difference between the samples but smaller crystals appeared
in the untreated slurries and larger in those treated. Likewise, it is unlikely to have been be
an artefact: the fluorescence of the larger crystals was significant when compared with the
spores in the same field.
The most likely reason is also the most interesting: that the crystals begin to dissolve, yet not
fully, and when cooled the remaining crystals act as seeds around which the protein in
solution aggregates (and possibly crystallizes). Further evidence for this mechanism is that
there were still cells in the sample, which fluoresced with the same magnitude of brightness
as the untreated samples; these proteins had not been dissolved and can be treated as a
control. It is not clear whether the resulting bodies were crystalline, although the shape
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suggests this may have been the case. Likewise it is not clear whether the resulting bodies
were the same material as the originals. The original crystals were heterogeneous: composed
of native and fluorescent protein. It is clear these extended crystals all contained the latter,
and they are likely to have contained the former too. There may also have been lithium ions
or dodecyl sulphate present within the crystals, though. A protocol for analysis of such
structures would require careful design, though to start it would be worthwhile to screen a
variety of similar conditions for this crystal growth phenomenon.
This effect may provide a way to combine separately produced subdomains into a single,
heterogeneous crystal, which could greatly simplify the challenge of producing antibody-
fused Cry crystals.
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The research presented in this chapter confirms the utility of Cry as a fusion protein
platform for antibody fragments. Triple fusions of a Cry domain, mCherry fluorophore and
antibody fragment have been produced. For most of these fragments, results confirm they
have been produced at the correct sizes; the same limitations as chapter 4 apply, concerning
function. Such fusion crystals may indeed prove suitable for oral or subcutaneous
formulation, subject to acceptable release profile or bioavailability. Additionally, a variant of
the cry1Ac operon, adjusted to use the late forespore promoter σG, may help increase the
mass of protein produced per spore using the B. subtilis spore core expression system of
chapter 4.
This result for triple-fusions builds on the systematic approach taken to analysing
Cry1Ac-mCherry fusions. It extends results presented in the academic and patent literature,
demonstrating for example that the in vitro work of Nair et al. (2015) is applicable to Cry1Ac
(a variant missing from the list of Cry proteins in the patent application of Chan et al., 2010).
The fluorescence demonstrated by mCherry fusions was bright and resisted photobleaching,
meaning such crystals could provide suitable labels for samples at risk of that damage. This is
consistent with understanding of the native crystals (Agaisse & Lereclus, 1995). Other results
were surprising: from the operation of the native B. thuringiensis promoter in E. coli to the
apparent recrystallization in lithium dodecyl sulphate. Results contradict the model in which
Cry1Ac embeds in the spore coat (Du & Nickerson, 1996), as the phenotype is shown in the
absence of the apparently necessary domain.
While Cry protein research will continue to focus on the toxic core, and the use of
B. thuringiensis spores as a pesticide, it is likely that researchers will be drawn to the novel
applications in crystallogenesis. New imaging techniques increase the value of these crystals:
still simple to produce, no longer computationally intractable to analyse. A platform
comprising a fluorescent reporter protein and crystallizable domain may have value in
screening candidate crystals.
Crystallogenesis notwithstanding, the main outcome here concerns formulation of
therapeutic proteins. This chapter reports — for the first time — production during
sporulation of antibody fragment fusions to a Cry protein. It contains the first report of
triple fusions of target protein, crystallization domain and fluorescent protein, too.
Together, these provide the ground onto which it may be possible to build a novel platform
for antibody delivery.
Conclusions5.3
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The introduction to this dissertation listed a trio of goals for this project:
1. an investigation of the mechanisms that enhance protein stability in spores,
2. the design and optimisation of protein expression systems in spores, and
3. the production, as a proof-of-principle, of a deliverable formulation which allows a
controlled dose of proteins to be released in its environment.
These are intended to help answer the question: is it possible to use bacterial spores as
vehicles for drug delivery? The answer is certainly yes. It is possible to produce large
quantities of spore protein (chapter 5), including various antibody fragments, and it is
possible to release antibody fragments from the spore core (chapter 4). For the goal (beyond
this thesis) of actually producing such a product, many significant challenges remain — both
for the biology and the process engineering. This chapter shall review the progress made in
evaluating these new technologies.
Bacterial spores as a commercially
viable therapeutic product
Chapter 6
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The work reported here improves the prospects for spores as a means to formulate
therapeutic proteins. Many challenges around commercial viability remain: choice of
biologic and delivery location, fabrication and validation concerns (including scale-up and
cGMP, current good manufacturing practice), environmental and commercial proliferation
requirements, and the organizational difficulties of adding an entirely new product line. As a
result of the work in this dissertation, these challenges have become worthwhile topics for
future research.
Chapter 3 reported a somewhat standalone investigation of the role of DPA (dipicolinic
acid) in the stability of spores. Previous research has been unable to separate the absence of
DPA from presence of water, and therefore has struggled to investigate whether DPA plays
a role by itself or whether it simply allows the spore to maintain or generate a low water
content. Here the work in B. subtilis of Paidhungat et al. (2000) and Magge et al. (2008) on
spores that cannot produce DPA was successfully replicated in B. megaterium, a species with
more complicated germination machinery. Like Li et al. (2012), attempts to replace DPA
with other, similar chemicals, were not successful. However, in doing so chapter 3
demonstrated a new tool, with which to investigate the effects of DPA alone: spores with an
enhanced DPA level. The research proved sufficiently promising that a new research project
was begun, resulting in a publication by Batalha et al. (2017) (and an unsuccessful patent
application) on DPA as a pharmaceutical excipient.
However, from the perspective of the goals of this thesis, the work on the effects of DPA
proved disappointing. The screening of DPA analogues revealed no suitable candidate. The
protocol of analysis of spores by phase contrast was appropriate for screening, but would
have been unsuitable for confirming a positive result. It may have be possible to adapt the
DPA assay to work with these analogues, but this was beyond the scope of the investigation.
Likewise, the use of Raman microscopy and NMR (nuclear magnetic resonance) were
deemed not worthwhile, given the negative result in the screen. With such guidance from
collaborators, with expertise in formulating biopharmaceuticals, the focus shifted to the
second approach: investigating the protein-producing capabilities of sporulating bacteria
themselves.
The effects of DPA6.1
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The question of whether sporulating cells can produce therapeutic proteins, such as
antibodies, inspired the remainder of this thesis. Building on the work of Mohamed (2015),
the work in chapter 4 demonstrated that B. subtilis can produce a variety of antibody
fragments; the specific fragments were the light chain, heavy chain and three different scFvs
(single chain variable fragments) of an IgG (immunoglobulin G), and camelid VHH
nanobodies. The strain that was engineered to produce these fragments had not been
optimized for protein production; indeed, this work demonstrated for the first time that
sporulating B. subtilis subsp. subtilis 168 is capable of producing an scFv in the spore core,
without such optimizations.
The antibody fragments were demonstrated to run at their predicted masses on SDS-PAGE,
and fluorescent fusions shown to fluoresce. However, it has not been demonstrated whether
such antibodies are functional. The lack of a simple assay for NIP109 means that
optimization cycles take far longer than they might otherwise do. The work with the
camelid antibody fragments was designed to make such a functional assay feasible; this is
now the case. The BcII10 nanobodies, targeting B. cereus metallo-β-lactamase, may be used
in the colorimetric nitrocephin assay as an indirect test. Directly testing the effect on
antibiotic resistance in culture would then be valuable.
The challenge of producing a full, assembled IgG inside the spore core remains. There is a
straightforward route to producing both chains in the core, using a two-promoter system.
However, there exists no suitable technique to analyse such co-expression in vivo, in the
spore core. Analysis ex vivo presents another form of the challenge addressed by the
following chapter.
In chapter 4, production of antibody fragments has only been demonstrated in B. subtilis
subsp. subtilis 168. Other sporeformers — notably the large B. megaterium or a strain like
B. thuringiensis subsp. finitimus YBT-020, for which there is a crystal and spore core together
within the exosporium — may prove a far better host, based on their size. It is not yet clear
which location (core, coat or interspace) in a spore may prove the best. It may be possible to
use multiple locations to combine targeting and payload functionality.
Therapeutic proteins in the spore core6.2
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Finally, the total mass of protein in each spore is relatively low, as seen in earlier work by
Mohamed (2015). The work in chapter 5 showed some success in adapting the cry1Ac
operon to function in the late forespore; such work may in future help to increase this low
limit.
One bottleneck in much work with spore cores has been extraction of the expressed protein
— leading to an inability to scale the production process. Part of the original aim of this
project was to analyse the structural properties of these proteins from a formulation
perspective. However, having successfully, and for the first time, produced various antibody
fragments, it became clear that there existed no process capable of producing and extracting
enough protein from the cores to perform such analysis.
A potential solution to the bottleneck in extraction of protein from spores, investigated in
chapter 4, is to use spores bearing a ∆cotE mutation. This manifests as a missing outer coat
(and damaged inner coat), thereby rendering the spores sensitive to lysozyme. Though such
a mutation has been known for three decades, it has never been proposed as a technique to
facilitate such analysis of the spore core. Such chemical disruption scales in a way mechanical
disruption does not. With such spores it will now be possible to produce sufficient protein to
run a full set of formulation experiments: work which has never before been reported for a
therapeutic protein produced by sporulating cells.
The chapter reported successful development of a strain with the ∆cotE mutation in a
supercompetent background; it also demonstrated the ease of working with such a strain by
replicating earlier transformations. Coat deficient spores, containing fluorescent antibody
fusions, were disrupted by exposure to lysozyme. This released the fluorescent contents of
the spores.
The spores of these strains, containing a model therapeutic protein that can be released by a
specific chemical mechanism, are a proof-of-principle bacterial spore formulation.
This research ought to move forward in two directions. Firstly, the lysozyme disruption
protocol should be optimized for use in the laboratory; this would enable further
experiments on the proteins produced in the spore cores. Secondly, the spores should be
tested in simulated gastric and intestinal fluids, to investigate whether the coat deficiency
alone will help ensure that a protein payload is released at the GALT (gut associated
lymphatic tissue). Indeed, it may now be possible to produce spores which lyse in the
duodenum, thereby providing one solution to the delivery challenge around commercial
viability.
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Such a solution may be considered an engineering solution to the aforementioned problem.
An alternative way to solve problems is to revisit assumptions and completely revise the
approach. In this case, the problem is the inherently limited productivity of forespores; the
core is already fairly well packed and so there may well be a relatively low upper limit to the
mass fraction of heterologous protein the spore can contain. The assumption to revisit is
that, in order to benefit from spores’ ability to stabilize proteins, the protein must be in the
spore core.
B. thuringiensis is well known for its large crystalline inclusions, which typically reach the
same size as the spore. Chapter 5 demonstrated the successful production of various
fluorescent fusions of Cry1Ac as inclusions in E. coli and as heterologous crystals with native
Cry1Ac in the mother cells of sporulating B. thuringiensis subsp. kurstaki HD-73.
Furthermore, it demonstrated that sporulating B. thuringiensis subsp. kurstaki HD-73 can
produce fluorescent Cry1Ac fusions of antibody fragments: light-chain, heavy-chain and
scFv.
There were difficulties in analysing such crystals, however. Attempts to solubilize crystal
fusions for SDS-PAGE resulted in widespread fragmentation. In a few cases, this has made it
difficult to be certain whether the full length crystal has been produced; in others, by
contrast, it helped confirm it.
The fabrication system developed here offers the possibility to produce robust therapeutic
crystals, suitable for delivery to patients in crystalline form. Even conventional formulations
may benefit from such a bacterial production system. The productivity improvements of a
greater titre are an advantage over CHO (Chinese hamster ovary)–produced antibodies; that
and the reduced requirements for downstream processing offer an advantage over E. coli. If
encapsulated within the spore exosporium, in the same manner as B. thuringiensis YBT-020,
crystal protein fusions offer an alternative to the core protein model presented in chapter 4
— another fully self-contained delivery system.
Perhaps the most significant unexpected outcome, with its own promising line of further
research, concerns the utility of Cry fusion proteins in enabling structural studies of proteins
that have proved impervious to crystallization, and one can hope there are opportunities to
Crystal protein fusions6.3
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investigate such possibilities. At the time of this work, nobody had yet proposed Cry fusions
as a tool with which to produce crystals from recalcitrant proteins; indeed, the use of fusions
in crystallogenesis is itself very recent.
The crystals produced by B. thuringiensis are too small for conventional X-ray diffraction and
though they may suit Cryo-EM, it may also be possible to recrystallize these fusions. For
recrystallization, Evdokimov et al. (2014) claimed it was necessary to substitute fourteen
cysteine residues within the protoxin domain of native Cry1Ac. Here, for the first time, it
has been demonstrated that heating crystals to 70℃ for 10 min in LDS sample buffer (for
PAGE analysis) resulted in crystals that did not appear on phase contrast, yet still fluoresced,
and were measurably larger than the source culture, or those not heated. While it is not yet
fully clear what mechanism lies behind such a serendipitous observation, nor the factors
affecting such behaviour, it may offer an alternative method of growing crystals to a size
suitable for structural studies.
The work on Cry1Ac protein fusions has resulted in a platform for producing fusion
crystals, at scale. There is now a project investigating such a possibility. Additionally, while
inclusions have previously been reported in E. coli, this dissertation has demonstrated for the
first time that in E. coli the Pcry1Ac from the aforementioned B. thuringiensis strain appears to
be constitutively active. Such constructs might be used when assembling plasmids encoding
crystal fusions, so that colonies can be screened for correct DNA assembly and protein
folding.
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In sum, this dissertation reports a number of novel findings concerning the heterologous
production capabilities of sporulating cells, and highlights significant leads for future
research.
The investigation of the mechanism by which DPA acts in spores has led directly to others
demonstrating that DPA enhances protein stability in vitro. It is not clear how relevant this is
to in vivo stabilization of proteins; however thanks to the work presented here, a new
technique — that of producing DPA-enhanced spores — is now available to researchers.
The engineering of B. subtilis to produce therapeutic proteins, while sporulating, was a
success. However the spore is able to keep proteins in its core stable, it may be possible to
confer that stability on heterologous proteins, too. The antibody chains and scFvs have been
produced with the predicted masses, and fluorescent fusions gave a positive signal (and vice
versa for non-fluorescent variants). Likewise, various nanobodies and nanobody fusions
produced correct outputs. Furthermore, by genetically removing the spore outer coat (and
perturbing the inner coat), this work has resulted in a proof-of-principle B. subtilis strain
capable of releasing antibody fragments on demand.
There is an alternative model, too, using the Cry1Ac production mechanism of
B. thuringiensis, to produce antibody fusions. The resulting crystals may be useful as part of
pharmaceutical formulations, and beyond, in crystallogenesis for structural study.
Taken together, the core and crystal expression systems show, as proof of principle, that
bacterial spores are feasible vehicles for delivery of therapeutic proteins. There is, however,
much work needed to develop that possibility into a commercial product.
The great variety of healthcare challenges demands a variety of formulation approaches.
Bacterial endospores offer a new possibility.
Final conclusions6.4
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Figure A1.1 shows the standard curve for DPA assays. Table A1.1 shows the details of the
paired comparisons calculation in section 3.2.1. Table A1.2 shows the details of the second
paired comparisons calculation in section 3.2.2. Table A1.3 shows the data used to plot
figure 3.3.
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Figure A1.1: Calibration curve for DPA assay. Values are jittered so coincident points can be resolved. Data
are from multiple batches of standard solution.
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Table A1.1: Paired comparisons test, of differences in DPA content with or without
ΔspoVF mutation. Values presented are averages of the readings in each category: with (+)
or without (-) spoVF or sleB. The resulting test statistic, t₀, is 20.4 (mean difference
divided by error in mean), giving a p-value of 0.016.
Normalized DPA concentration +spoVF -spoVF Difference
+sleB 0.986 0.212 0.775
-sleB 0.729 0.026 0.702
Mean 0.858 0.119 0.738
Sum of error squares 1.093
Standard deviation 0.182 0.131 0.051
Error in mean 0.129 0.093 0.036
Table A1.2: Paired comparisons test of differences in DPA content with (✓) or without (✗)
exogenous DPA. The resulting test statistic, t₀, is 5.95 (mean difference divided by error in mean),
giving a p-value of 9.6×10⁻⁴.
Normalized DPA concentration Batch ✓ ✗ Difference
QM B1551 1 1.174 1.000 0.174
QM B1551 2 1.862 1.000 0.862
1462∷21s 1 0.941 0.008 0.933
1462∷21s 2 0.949 0.000 0.949
1551∷21s+ 1 0.888 0.277 0.611
1551∷21s+ 2 1.076 0.155 0.921
Mean 1.148 0.407 0.742
Sum of error squares 3.765
Standard deviation 0.365 0.471 0.305
Error in mean 0.149 0.192 0.125
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SXO Batch Coded Normalized
Concentration /
µgml⁻¹
QM B1551 ✗ ✗ 1 0.1203 1     85.9
QM B1551 ✗ ✗ 2 0.1065 1.03  76.1
QM B1551 ✗ ✗ 2 0.1007 0.97  71.9
QM B1551 ✗ ✗ 3 0.1385 1     98.9
QM B1551 ✓ ✗ 1 0.1412 1.17 100.9
QM B1551 ✓ ✗ 3 0.2579 1.86 184.2
PS1462 ✗ ✗ 2 0.0867 0.84  61.9
PS1462 ✗ ✗ 2 0.0685 0.66  48.9
1551∷21s+ ✗ ✓ 1 0.0333 0.28  23.8
1551∷21s+ ✗ ✓ 2 0.0189 0.18  13.5
1551∷21s+ ✗ ✓ 2 0.0253 0.24  18.1
1551∷21s+ ✗ ✓ 3 0.0215 0.16  15.4
1551∷21s+ ✓ ✓ 1 0.1068 0.89  76.3
1551∷21s+ ✓ ✓ 3 0.1490 1.08 106.4
1462∷21s ✗ ✗ 1 0.0010 0.01   0.7
1462∷21s ✗ ✗ 2 0      0      0  
1462∷21s ✗ ✗ 2 0      0      0  
1462∷21s ✗ ✗ 3 0      0      0  
1462∷21s ✓ ✗ 1 0.1132 0.94  80.9
1462∷21s ✓ ✗ 3 0.1315 0.95  93.9
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Table A1.4 shows colony count data for figures 3.5, 3.6. The PS1462 value for the former is
based on slightly different raw data to that corresponding to no shock for the latter.
B. megaterium colony countsA1.2
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1462∷21s ✓ none 185 6.66×10-6 2.76×107
QM B1551 ✗ none 442 3.99×10-6 1.11×108
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Figure A1.2 shows micrographs of ∆spoVF mutant spores grown with various DPA
anaolgues. They appear just as the spores grown with no supplement.
Spores grown with DPA analoguesA1.3
Figure A1.2: Micrographs of B. megaterium 1551∷21s+, sporulated in DPA analogue–supplemented SNB.
(a) shows the culture supplemented with IPA; (b) PA; (c) IDA; (d) NTA. Spores grown in these media
looked no different to those grown in standard medium. Strain 1551∷21s has the ΔspoVF mutation. Cultures
were induced to sporulate via nutrient exhaustion. Scale bars are 5 µm × 1 µm.
a b
c d
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To estimate the pop-out proportion from the pop-out frequency, one need only consider
the cells which do not revert.
Let f denote the pop-out frequency (i.e. the probability that any one cell division results in
excision of the plasmid); assume this is small (∼10⁻⁶). Let g denote the number of
generations. Let ai denote the proportional growth of the culture in generation i. Let n
denote the number of cells in the culture. Let N denote the number of cells in the initial
inoculum; assume this is large (≳10³).
The inoculum contains N cells, initially. After 1 generation, the expectation of n is a0 N;
after 2, a0 a1 N; etc. After g generations, this is N Π_i_ai, where the product runs from a0 to
a(g-1).
The inoculum contains N non-revertants, initially. After 1 generation, the expected number
of non-revertants is a0 (1-f) N; after 2, a0 a1 (1-f) ²N; etc. After g generations, this is
(1-f) g N Π_i_ai, where the product runs as above.
Thus the expected proportion of non-revertants, after g generations, is the quotient: (1-f) g.
The expected proportion of revertants, after g generations, is 1 - (1-f) g ≃ f g.
This Poisson process corresponds to a Gamma distribution, with shape parameter g and scale
parameter f. The mean is f g; the variance is f ² g. Distributions are plotted in figure A1.3.
Spore crops in SNB have number densities of the order of 10⁹ spore ml⁻¹. A 200 ml culture,
resuspended in 4 ml, gives an OD₆₀₀ of 1 when diluted 500×. This means if diluted to
500 × 4ml = 2000 ml the whole sample would have an OD₆₀₀ of 1, corresponding to
10⁸ spore ml⁻¹. As that is 10× the original volume, the original culture must have had 10× the
number density, i.e. 10⁹ cfu ml⁻¹. The 200 ml culture would contain 10¹¹ spores.
Pop-out calculationA1.4























Figure A1.3: Probability density distributions, for fraction of cells undergoing pop-out. The mean (and maximum
likelihood estimator) grows linearly with the number of generations, and linearly with the pop-out frequency. The pop-
out frequency used here is 10⁻⁶.
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Listing A1.1 shows amino acid sequences of fusion domains.
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Listing A1.2 shows amino acid sequences of nanobodies. These use using single letter
notation.
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Multiple methods were used to attempt to transform B. subtilis 168 to the desired genotype.
• Plasmid pDBT690 was used to transform wild type chemically competent Bacillus
subtilis 168 to 5-fluorouracilr.
• A 200 µl aliquot of chemically competent B. subtilis 168 was transformed to
chloramphenicol resistance with 230 ng of a 4527 bp PCR fragment corresponding to
the operon shown in figure A1.6, otherwise according to the standard protocol from
section 2.3.5.
• B. subtilis 168 was transformed to chloramphenicolr with pDBT69d, and selected on LB
plates containing chloramphenicol, as described in section 2.4.
Plasmid pDBT690 matches pST, used by Shi et al. (2013) with the purpose of converting
B. subtilis subsp. subtilis 168 to B. subtilis BUK (figure A1.4). The construct replicated here
uses their same homologous regions, but a backbone from pDG1662.
Strain 168∷69c lacks upp, and can therefore be a positive control for upp counter-selection.
Thanks to its cat cassette, it can also be isolated using chloramphenicol selection. Like
pDBT690, pDBT69c has homology with regions at the upp locus. When integrated by double-
crossover, it would also knock out upp. Rather than introducing the aforementioned comK
machinery to induce competence, though, it simply adds a chloramphenicol resistance
cassette.
Inducibly (super-)competent B. subtilisA1.7
Figure A1.4: The upp locus, following a successful indel mutation. This mutation would generate an
inducibly (super‑)competent strain of B. subtilis. The locus corresponds to a double crossover integration of
plasmid pDBT690 into the B. subtilis 168 genome. The uppF(orward) and uppR(everse) elements correspond
to loci just 5’ and 3’ of the wild type upp respectively. The comK gene and terminator, which encode the
competence master regulator, are assembled facing upstream. The araR gene, terminator and the Para
(arabinose inducible) promoter at its 5’ are assembled downstream of that. Thus Para drives comK, and
arabinose induces competence.
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Plasmid pDBT69d introduces the comK machinery and a chloramphenicol cassette, at the upp
locus (figures A1.5, A1.6). The upstream region of homology, like in pDBT690, matches the
region just upstream of upp. Here, however, the downstream region of homology matches a
region that is also upstream of upp — as opposed to a region downstream of upp. The
plasmid would thereby insert its payload immediately upstream of upp, with minimal
deletion. At this point, there would now be two 30 bp regions of homology: one from the
insert, one in the region just downstream of upp. The chloramphenicol resistance gene, cat,
and upp are now located between these two 30 bp repeats. An I-SceI restriction site is
situated such that recombination at these two repeating regions, following I-SceI digestion,
will excise the marker (cat, from pDBT69d) and the counter-selection marker (upp, already
present in the genome).
Following transformation of B. subtilis 168 with pDBT69d, two of the twelve screened
colonies showed bands, consistent with those predicted at 898 bp and 1261 bp. Strain
168∷69d was then transformed with pEBS-cop1, and eight of the resulting colonies were
screened for marker excision, by multiplex PCR. The subsequent phenotypic screen






















Figure A1.5: Plasmid pDBT69d for construction of 168∷690 via dual cassette strain 168∷69d. Labels indicate:
araR, arabinose repressor; comK, master competence regulator; upp, uracil phosphoribyl-transferase; bla, β-
lactamase (carbenicillin resistance); spc, spectinomycin adenyltransferase; cat, chloramphenicol acetyltransferase;
ori, E. coli origin of replication; Para, arabinose-inducible promoter; I-SceI, restriction site.
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Figure A1.6: The upp locus following, a successful double crossover integration of plasmid pDBT69d into the
B. subtilis 168 genome. The native elements (in black) are disrupted by a) the comK–araR cassette and 30 bp of the upp
terminator region from pDBT690, b) the I-SceI recognition site TAGGG|ATAA_CAGGGTAAT, and c) the cat cassette
(chloramphenicol resistance). The aforementioned 30 bp region is present twice; flanking the recombinant cat and native
upp. Following I-SceI digestion, recombination between these regions excises the full selection-counter-selection cassette.
associated with having lost the plasmid pEBS-cop1 — this before having cultured the strain at
50℃. Colony 4, when cultured at 50℃, resulted in colony a, chosen as 168∷690; colony
PCR verification of strain 168∷690 was performed using multiplexed and simple PCR.
Additionally, a 2138 bp fragment was amplified from gDNA using primers y188 and y192
(table 2.31); this region was designed to cross the region from which the marker had been
excised. Sanger sequencing was used to confirm the fragment had the correct sequence.
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Table A1.5 shows the details of the paired comparisons calculation in section 4.2.2.
∆cotE mutantsA1.8
Table A1.5: Paired comparisons test, of differences in OD₆₀₀ in ΔcotE strains. The
resulting test statistic, t₀, is 15.4 (mean difference divided by error in mean), giving a
p-value of 5.9×10⁻⁴.
Equivalent OD₆₀₀ 690∷_ 71e∷_ Difference
— 784  415  369   47%
611l 554  152  402   73%
611h 571  176  395   69%
611s 622  324  298   48%
Mean 633  267  366   59%
Sum of error squares 542594  
Standard deviation 105  125  47.5
Error in mean 52.4 62.4 23.8
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